<SEC-DOCUMENT>0001437749-23-014359.txt : 20230515
<SEC-HEADER>0001437749-23-014359.hdr.sgml : 20230515
<ACCEPTANCE-DATETIME>20230515082223
ACCESSION NUMBER:		0001437749-23-014359
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230515
DATE AS OF CHANGE:		20230515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		23918589

	BUSINESS ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>dffn20230331_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dffn="http://www.diffusionpharma.com/20230331" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21"><head>
	<title>dffn20230331_10q.htm</title>


	<!-- Generated by ThunderDome Portal - 5/14/2023 1:52:33 PM -->
<meta http-equiv="Content-Type" content="text/html" /></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityCentralIndexKey">0001053691</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
<ix:nonFraction id="c220" contextRef="d_2023-01-01_2023-03-31_CounterpartyNameAxis-BtigLlcMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="dffn-20230331.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2023-01-01_2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2022-01-01_2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="i_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2023-01-01_2023-03-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_PlanNameAxis-EquityIncentivePlan2015Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-01-01_PlanNameAxis-EquityIncentivePlan2015Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_PlanNameAxis-EquityIncentivePlan2015Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020InvestorWarrantExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020OfferingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_CashAndCashEquivalentsAxis-BankTimeDepositsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_CashAndCashEquivalentsAxis-BankTimeDepositsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dffn:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dffn:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_CounterpartyNameAxis-BtigLlcMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dffn:BtigLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_CounterpartyNameAxis-BtigLlcMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dffn:BtigLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-05-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-11</xbrli:instant></xbrli:period></xbrli:context>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fe94240fc-b4f2-44ab-a6ef-b62420724a17" fromRefs="c606 c605"></ix:relationship></ix:resources>
</ix:header></div>
<div>&#xa0;</div>

<div class="null">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Washington, D.C.</b>&#xa0;&#xa0;<b>20549</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>FORM <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:DocumentType" id="c2">10-Q</ix:nonNumeric></b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">(Mark one)</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:DocumentQuarterlyReport" id="c3" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:top;width:91.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>For the quarterly period ended </b><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:DocumentPeriodEndDate" id="c4" format="ixt:datemonthdayyearen">March 31, 2023</ix:nonNumeric><b> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
			<td style="vertical-align:top;width:5.5%;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:DocumentTransitionReport" id="c5" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:top;width:91.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">For the transition period from ___________ to ___________.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Commission file number: <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityFileNumber" id="c6">001-37942</ix:nonNumeric> </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="dffn20230331_10qimg001.jpg" src="dffn20230331_10qimg001.jpg" style="width:163;height:50;" /></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityRegistrantName" id="c7">DIFFUSION PHARMACEUTICALS INC.</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityIncorporationStateCountryCode" id="c8" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></b></p>
			</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityTaxIdentificationNumber" id="c9">30-0645032</ix:nonNumeric></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State of other jurisdiction of incorporation or organization)</p>
			</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification Number)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityAddressAddressLine1" id="c10">300 East Main Street, Suite 201</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityAddressCityOrTown" id="c11">Charlottesville</ix:nonNumeric>, <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityAddressStateOrProvince" id="c12">VA</ix:nonNumeric> <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityAddressPostalZipCode" id="c13">22902</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">(Address of principal executive offices, including zip code)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>(<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:CityAreaCode" id="c14">434</ix:nonNumeric>) <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:LocalPhoneNumber" id="c15">220-0718</ix:nonNumeric></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">(Registrant&#x2019;s telephone number including area code)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Title of Each Class</span></b></p>
			</td>
			<td style="vertical-align: bottom; width: 20%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Trading Symbol</span></b></p>
			</td>
			<td style="vertical-align: bottom; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Name of Each Exchange on Which Registered</span></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:Security12bTitle" id="c16">Common Stock, par value $0.001 per share</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 20%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:TradingSymbol" id="c17">DFFN</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:SecurityExchangeName" id="c18" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">Securities registered pursuant to Section 12(g) of the Act:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>None</b>&#xa0;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityCurrentReportingStatus" id="c19">Yes</ix:nonNumeric> &#x2612; No &#x2610;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#xa7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityInteractiveDataCurrent" id="c20">Yes</ix:nonNumeric> &#x2612; No &#x2610;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:middle;width:74.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Large&#xa0;accelerated&#xa0;filer &#x2610;</p>
			</td>
			<td style="vertical-align:middle;width:25.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Accelerated&#xa0;filer&#xa0;&#x2610;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:74.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityFilerCategory" id="c21" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric>&#xa0;&#x2612;</p>
			</td>
			<td style="vertical-align:middle;width:25.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Smaller&#xa0;reporting&#xa0;company <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntitySmallBusiness" id="c22" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:74.8%;">&#xa0;</td>
			<td style="vertical-align:middle;width:25.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">Emerging growth&#xa0;company <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityEmergingGrowthCompany" id="c23" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#xa0;12b-2 of the Act).Yes&#xa0;<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dei:EntityShellCompany" id="c24" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;No&#xa0;&#x2612;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">The number of shares of common stock outstanding at May 11, 2023 was <ix:nonFraction id="c25" contextRef="i_2023-05-11" unitRef="Share" name="dei:EntityCommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,040,025</ix:nonFraction> shares.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">&#xa0;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#xa0;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
</div>

<div>&#xa0;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC. </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM 10-Q</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MARCH</b>&#xa0;<b>31, 2023 </b></p>

<div>&#xa0;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>INDEX</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;text-indent:9pt;"><span style="text-decoration: underline; ">Page</span></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART I &#x2013;&#xa0;FINANCIAL INFORMATION</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;">ITEM 1.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;FINANCIAL STATEMENTS&#xa0;</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;">ITEM 2.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS&#xa0;</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">15</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;">ITEM 3.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK&#xa0;</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">20</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;">ITEM 4.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;CONTROLS AND PROCEDURES&#xa0;</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">20</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART II &#x2013;&#xa0;OTHER INFORMATION&#xa0;</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">21</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;">ITEM 1.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;LEGAL PROCEEDINGS&#xa0;&#xa0;</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">21</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;">ITEM 1A.&#xa0;&#xa0;RISK FACTORS&#xa0;</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">21</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;">ITEM 2.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS&#xa0;</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">21</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;">ITEM 3.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;DEFAULTS UPON SENIOR SECURITIES&#xa0;</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">21</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;">ITEM 4.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;MINE SAFETY DISCLOSURES</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">21</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;">ITEM 5.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;OTHER INFORMATION&#xa0;</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">21</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
			<td style="vertical-align:top;width:19.5%;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:80.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;">ITEM 6.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;EXHIBITS</p>
			</td>
			<td style="vertical-align:top;width:19.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">21</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">i</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Note Regarding Company References and Other Defined Terms</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Unless the context otherwise requires, in this Quarterly Report, (i) references to "Diffusion," "the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us&#x201d; refer to Diffusion Pharmaceuticals Inc. and its subsidiaries and (ii) references to &#x201c;common stock&#x201d; refer to the common stock, par value $0.001 per share, of the Company, and (iii) all share and per share amounts related to our common stock give effect to our 1-for-50 reverse stock split effected April 18, 2022. We have also used several other defined terms in this Quarterly Report, many of which are explained or defined below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Term</b></p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Definition</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2015 Equity Plan</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan, as amended</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">401(k) Plan</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion Pharmaceuticals Inc. 401(k) Defined Contribution Plan</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Annual Report</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 24, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASC</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounting Standard Codification of the FASB</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Canaccord</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Canaccord Genuity LLC, our financial advisor</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CRO</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">contract research organization</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EIP</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EIP Pharma, Inc., a Delaware corporation</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exchange Act</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities Exchange Act of 1934, as amended</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FASB</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial Accounting Standards Board</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FDA</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Food and Drug Administration</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">G&amp;A</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">general and administrative</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GAAP</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. generally accepted accounting principles</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GBM</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">glioblastoma multiforme brain cancer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Merger</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the proposed merger of Merger Sub with and into EIP, with EIP surviving as a wholly-owned subsidiary of the Company, upon the terms and subject to the conditions set forth in the Merger Agreement</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Merger Agreement</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the Agreement and Plan of Merger, dated as of March 30, 2023, by and among the Company, Merger Sub, and EIP</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Merger Sub</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Dawn Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of the Company</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Nasdaq</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Nasdaq Stock Market, LLC</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NOL</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">net operating loss</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Preliminary Merger Proxy Statement</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">our preliminary proxy statement/prospectus/information statement related to a special meeting of our stockholders related to the transactions contemplated by the Merger Agreement, filed with the SEC on May 11, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Quarterly Report</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">this Quarterly Report on Form 10-Q</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">R&amp;D</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">research and development</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Regulation S-K</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Regulation S-K promulgated under the Securities Act of 1933, as amended</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reverse Stock Split</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the reclassification and combination of all shares of our common stock outstanding at a ratio of one-for-50 approved by our stockholders at the Special Meeting and effective April 18, 2022</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEC</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Securities and Exchange Commission</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Series C Preferred Stock</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">the Company's previously outstanding Series C Convertible Preferred Stock, par value $0.001 per share</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TSC</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">trans sodium crocetinate</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 25%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S.</p>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">United States</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">ii</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Quarterly Report (including, for purposes of this Note Regarding Forward-Looking Statements, any information or documents incorporated herein by reference) includes express and implied forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, liquidity, and prospects may differ materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial condition, liquidity, and prospects are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of actual results or reflect unanticipated developments in future periods.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Forward-looking statements appear in a number of places throughout this Quarterly Report . We may, in some cases, use terms such as &#x201c;believes,&#x201d; &#x201c;estimates,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;expects,&#x201d; &#x201c;plans,&#x201d; &#x201c;intends,&#x201d; &#x201c;may,&#x201d; &#x201c;could,&#x201d; &#x201c;might,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;approximately,&#x201d; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements also include statements regarding our intentions, beliefs, projections, outlook, analyses or expectations concerning, among other things:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#xa0;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the approval by our stockholders of the issuance of our common stock in connection with, and the change of control that would be occasioned by, the Merger, the closing of the Merger, including the timing of the Merger,&#xa0;&#xa0;and the approval of the proposal regarding a potential reverse stock split of our common stock as described in the Preliminary Merger Proxy Statement, the likelihood of the satisfaction of the minimum net cash condition as well as the other conditions to the closing of the Merger, the Exchange Ratio (as defined in the Merger Agreement) and relative ownership levels as of the closing of the Merger, including any adjustments thereto related to Diffusion&#x2019;s net cash balance at closing of the Merger, the expected benefits of and potential value created by the Merger for the stockholders of Diffusion and EIP, and Diffusion&#x2019;s ability to control and correctly estimate its operating expenses and its expenses associated with the Merger;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our cash balances following the closing of the Merger, if any;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to obtain additional financing in the future and continue as a going concern ;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the plans, strategies and objectives of management for future operations, including the execution of integration plans and the anticipated timing of filings;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the success and timing of our clinical and preclinical studies, including our ability to enroll subjects in our future clinical studies at anticipated rates and our ability to manufacture an adequate amount of drug supply for our studies&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">obtaining and maintaining intellectual property protection for our current or future product candidates and our proprietary technology&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the performance of third parties, including contract research organizations, manufacturers, suppliers, and outside consultants, to whom we outsource certain operational, staff and other functions&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to obtain and maintain regulatory approval of our current or future product candidates and, if approved, our products, including the labeling under any approval we may obtain&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our plans and ability to develop and commercialize our current or future product candidates and the outcomes of our research and development activities&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our estimates regarding expenses, future revenues, capital requirements, and needs for additional financing&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our failure to recruit or retain key scientific or management personnel or to retain our executive officers&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the accuracy of our estimates of the size and characteristics of the potential markets for our current or future product candidates, the rate and degree of market acceptance of any of our current or future product candidates that may be approved in the future, and our ability to serve those markets&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the success of products that are or may become available which also target the potential markets for our current or future product candidates&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to operate our business without infringing the intellectual property rights of others and the potential for others to infringe upon our intellectual property rights&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any significant breakdown, infiltration, or interruption of our information technology systems and infrastructure&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">recently enacted and future legislation related to the healthcare system&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">other regulatory developments in the U.S., E.U., and other foreign jurisdictions&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#xa0;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to satisfy the continued listing requirements of the Nasdaq Capital Market or any other exchange on which our securities may trade in the future&#x37e;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">uncertainties related to general economic, political, business, industry, and market conditions&#x37e;&#xa0;and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">other risks and uncertainties, including those discussed under the heading "Risk Factors" in our Annual Report and elsewhere in our other public filings.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">iii</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">As a result of these and other factors, known and unknown, actual results could differ materially from our intentions, beliefs, projections, outlook, analyses, or expectations expressed in any forward-looking statements in this Quarterly Report. Accordingly, we cannot assure you that the forward-looking statements contained or incorporated by reference in this Quarterly Report will prove to be accurate or that any such inaccuracy will not be material. You should also understand that it is not possible to predict or identify all such factors, and you should not consider any such list to be a complete set of all potential risks or uncertainties. In light of the foregoing and the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">Any forward-looking statements that we make in this Quarterly Report speak only as of the date of such statement, and, except as required by applicable law or by the rules and regulations of the SEC, we undertake no obligation to update such statements to reflect events or circumstances after the date of this Quarterly Report or to reflect the occurrence of unanticipated events. Comparisons of current and any prior period results are not intended to express any ongoing or future trends or indications of future performance, unless explicitly expressed as such, and should only be viewed as historical data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Trademarks, Trade Names and Service Marks</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">This Quarterly Report contains certain trademarks, trade names, and service marks of ours, including &#x201c;DIFFUSIO<sub>2</sub>N.&#x201d; All other trade names, trademarks, and service marks appearing in this Quarterly Report are, to the knowledge of Diffusion, the property of their respective owners. To the extent any such terms appear without the trade name, trademark, or service mark notice, such presentation is for convenience only and should not be construed as being used in a descriptive or generic sense.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">iv</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<div>&#xa0;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>PART I </b>&#x2013;<b> FINANCIAL INFORMATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:12.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ITEM 1.</b></p>
			</td>
			<td style="vertical-align:top;width:88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>FINANCIAL STATEMENTS</b></p>
			</td>
		</tr>

</tbody></table>

<div>&#xa0;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Consolidated Balance Sheets</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>(unaudited)</b></p>

<div>&#xa0;</div>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31, 2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">Assets</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Current assets:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c30" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="0">14,645,586</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c31" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="0">10,113,706</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Marketable securities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c32" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:MarketableSecuritiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">2,991,770</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c33" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:MarketableSecuritiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">12,408,940</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses, deposits and other current assets</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c34" contextRef="i_2023-03-31" unitRef="USD" name="dffn:PrepaidExpensesDepositsAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="0">767,530</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c35" contextRef="i_2022-12-31" unitRef="USD" name="dffn:PrepaidExpensesDepositsAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="0">112,406</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current assets</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c36" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">18,404,886</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c37" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">22,635,052</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>Liabilities and Stockholders&#x2019; Equity</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Current liabilities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Accounts payable</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c40" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">971,455</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c41" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">1,127,782</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Accrued expenses and other current liabilities</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c42" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">1,154,475</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c43" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">1,289,554</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total liabilities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c44" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="0">2,125,931</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c45" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="0">2,417,336</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Commitments and Contingencies (Note 9)</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<ix:nonFraction id="c47" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<ix:nonFraction id="c48" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Stockholders&#x2019; Equity:</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Common stock, $<ix:nonFraction id="c50" contextRef="i_2023-03-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF"><ix:nonFraction id="c51" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction id="c52" contextRef="i_2023-03-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF"><ix:nonFraction id="c53" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized: <ix:nonFraction id="c54" contextRef="i_2023-03-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF"><ix:nonFraction id="c55" contextRef="i_2023-03-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">2,040,025</ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="c56" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF"><ix:nonFraction id="c57" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">2,039,557</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c58" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="0">2,040</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c59" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="0">2,040</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additional paid-in capital</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c60" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="0">165,968,961</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c61" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:numdotdecimal" decimals="0">165,847,590</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated other comprehensive loss</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c62" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">3,123</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c63" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">35,375</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated deficit</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c64" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">149,688,923</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c65" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">145,596,539</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total stockholders' equity</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c66" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="0">16,278,955</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c67" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="0">20,217,716</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total liabilities and stockholders' equity</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c68" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="0">18,404,886</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c69" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="0">22,635,052</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">See accompanying notes to unaudited interim consolidated financial statements.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Consolidated Statements of Operations and Comprehensive Loss</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>(unaudited)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&#xa0;</p>

<div>
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended March 31,</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c73" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="0">1,308,589</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c74" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="0">2,425,898</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c75" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="0">2,957,691</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c76" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="0">2,128,552</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Loss from operations</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c77" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,266,281</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c78" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,554,450</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest income</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c79" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" format="ixt:numdotdecimal" decimals="0">173,897</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c80" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" format="ixt:numdotdecimal" decimals="0">27,809</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,092,384</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c82" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,526,641</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Per share information:</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share of common stock, basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c84" contextRef="d_2023-01-01_2023-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1.95</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c85" contextRef="d_2022-01-01_2022-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2.22</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding, basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c86" contextRef="d_2023-01-01_2023-03-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">2,039,737</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c87" contextRef="d_2022-01-01_2022-03-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:numdotdecimal" decimals="INF">2,038,323</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Comprehensive loss:</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c89" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,092,384</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c90" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,526,641</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Unrealized gain (loss) on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c91" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:numdotdecimal" decimals="0">32,252</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c92" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">49,658</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Comprehensive loss</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c93" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,060,132</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c94" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,576,299</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">See accompanying notes to unaudited interim consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<div>&#xa0;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Consolidated Statements of Stockholders' Equity</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Three Months Ended March 31, 2021 and 2023</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>(unaudited)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&#xa0;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Series C Convertible Preferred Stock</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Common Stock</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Additional</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Paid-in</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated Other Comprehensive </b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stockholders'</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Shares</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Amount</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Capital</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Loss</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Deficit </b></td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Equity</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 28%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at January 1, 2022</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c97" contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c98" contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c99" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,038,185</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c100" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">2,038</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c101" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">164,914,540</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c102" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c103" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">130,005,111</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c104" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">34,911,467</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Sale of series C preferred stock to related parties</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c105" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c106" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="0">5,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c108" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c109" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c110" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c111" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c112" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="0">5,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation expense and vesting of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c113" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c114" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c115" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:numdotdecimal" decimals="INF">207</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c116" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c117" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:numdotdecimal" decimals="0">278,131</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c118" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c119" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c120" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:numdotdecimal" decimals="0">278,131</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Unrealized loss on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c122" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c124" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c125" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c126" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">49,658</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c127" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c128" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">49,658</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c130" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c132" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c133" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c135" contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,526,641</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c136" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,526,641</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at March 31, 2022</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c137" contextRef="i_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c138" contextRef="i_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">5,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c139" contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,038,392</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c140" contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">2,038</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c141" contextRef="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">165,192,671</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c142" contextRef="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">49,658</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c143" contextRef="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">134,531,752</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c144" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">30,618,299</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Common Stock</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Additional</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Paid-in</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated Other Comprehensive </b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Total</b></b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Stockholders'</b></b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Capital</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Loss</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Deficit</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b>Equity </b></b></td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 46%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at January 1, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c147" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,039,557</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c148" contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">2,040</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c149" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">165,847,590</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c150" contextRef="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">35,375</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c151" contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">145,596,539</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c152" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">20,217,716</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation expense and vesting of restricted stock units</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c153" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:numdotdecimal" decimals="INF">468</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c154" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c155" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:numdotdecimal" decimals="0">121,371</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c156" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c157" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c158" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:numdotdecimal" decimals="0">121,371</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Unrealized gain on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c160" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c161" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c162" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:numdotdecimal" decimals="0">32,252</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c163" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c164" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:numdotdecimal" decimals="0">32,252</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c166" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c167" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c168" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c169" contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,092,384</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c170" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,092,384</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c171" contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,040,025</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c172" contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">2,040</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c173" contextRef="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">165,968,961</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c174" contextRef="i_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">3,123</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c175" contextRef="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">149,688,923</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c176" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="0">16,278,955</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">See accompanying notes to unaudited interim consolidated financial statements.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<div>&#xa0;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Diffusion Pharmaceuticals Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Consolidated Statements of Cash Flows</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>(unaudited)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended March 31,</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">Operating activities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c180" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,092,384</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c181" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,526,641</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c183" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="0">121,371</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c184" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="0">278,131</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Amortization of premium and discount on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c185" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="0" format="ixt:numdotdecimal" decimals="0">50,578</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c186" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="0" format="ixt:numdotdecimal" decimals="0">13,546</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Changes in operating assets and liabilities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses, deposits and other assets</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c188" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="0">655,124</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c189" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="0">495,903</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable, accrued expenses and other liabilities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c190" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">291,405</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c191" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="0">28,146</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in operating activities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c192" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,968,120</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c193" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">4,729,813</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Cash flows used in investing activities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Purchases of marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c195" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c196" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">22,716,415</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-left: 9pt;">Maturities of marketable securities</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c197" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">9,500,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c198" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by (used in) investing activities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c199" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="0">9,500,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c200" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">22,716,415</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Cash flows provided by financing activities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceeds from the sale of series C preferred stock to related parties</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c202" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c203" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="0" format="ixt:numdotdecimal" decimals="0">5,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Net cash provided by financing activities</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c204" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c205" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="0">5,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net increase (decrease) in cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c206" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="0">4,531,880</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c207" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">27,441,228</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at beginning of period</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c208" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" format="ixt:numdotdecimal" decimals="0">10,113,706</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c209" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" format="ixt:numdotdecimal" decimals="0">37,313,558</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at end of period</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c210" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" format="ixt:numdotdecimal" decimals="0">14,645,586</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c211" contextRef="i_2022-03-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" format="ixt:numdotdecimal" decimals="0">9,872,330</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Supplemental disclosure of non-cash financing activities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Unrealized gain (loss) on marketable securities</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c213" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="0" format="ixt:numdotdecimal" decimals="0" sign="-">32,252</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c214" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="0" format="ixt:numdotdecimal" decimals="0">49,658</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div>&#xa0;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">See accompanying notes to unaudited interim consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">DIFFUSION PHARMACEUTICALS INC.</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<div>&#xa0;</div>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:NatureOfOperations" id="c215" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Organization and Description of Business</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Diffusion Pharmaceuticals Inc., a Delaware corporation, is a biopharmaceutical company that has historically focused on developing novel therapies that may enhance the body&#x2019;s ability to deliver oxygen to areas where it is needed most. The Company&#x2019;s most advanced product candidate, TSC, has been investigated and developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#x2019;s most intractable and difficult-to-treat conditions, including GBM.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div>&#xa0;</div>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="dffn:LiquidityDisclosureTextBlock" id="c217" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Liquidity</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has not generated any revenues from product sales and has historically funded operations primarily from the proceeds of public and private offerings of equity, convertible debt, and convertible preferred stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In July 2022, the Company entered into an at-the-market sales agreement (the "2022 Sales Agreement") with BTIG pursuant to which the Company may, from time to time and through BTIG as its agent, sell up to an aggregate of $<ix:nonFraction id="c219" contextRef="i_2023-03-31_CounterpartyNameAxis-BtigLlcMember" unitRef="USD" name="us-gaap:CommonStockSharesSubscriptions" scale="6" format="ixt:numdotdecimal" decimals="-7">20.0</ix:nonFraction> million in shares of the Company&#x2019;s common stock by any method permitted that is deemed an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) under the Securities Act. To date, the Company has <span style="-sec-ix-hidden:c220">not</span> sold any shares pursuant to the 2022 Sales Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On October 25, 2022, the Company announced that its Board authorized a thorough review and evaluation of a range of potential strategic opportunities in the interest of enhancing stockholder value, including transactional opportunities such as a merger, joint venture, licensing, sale, or divestiture of assets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the first quarter of 2023, in connection with the ongoing strategic review process and efforts to utilize and preserve assets in a manner that maximizes value for its stockholders, the Company committed to a reduction in force that impacted seven of the Company&#x2019;s thirteen employees. The reduction was a cash preservation measure and impacted employees primarily in the Company&#x2019;s clinical operations function. In connection with the strategic review process and pending its conclusion, the Company has paused significant portions of its TSC development activities, including initiation of the Company&#x2019;s previously announced Phase 2 study of TSC in newly diagnosed GBM patients.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On March 30, 2023, the Company entered into the Merger Agreement with EIP and Merger Sub, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into EIP at the effective time of the Merger, with EIP continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of the Company. The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. As of the date of this Quarterly Report, the Merger remains pending and subject to, among other closing conditions, certain approvals by the Company&#x2019;s stockholders, &#xa0;and there is no assurance in the Merger or any other transaction will be consummated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Substantial additional financing will be required by the Company to fund any research and development activities related to the Company's existing or future product candidates, including EIP's product candidates if the Merger is closed. The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties, and other strategic alliances and business transactions. However, as of the date of this Quarterly Report, the Company does not have any commitments to obtain additional funds and no assurance can be given that any such financing will be available in the future &#x2014; when needed, in sufficient amounts, on acceptable terms, or at all. If the Company cannot obtain the necessary funding, it may need to, among other things, delay, continue to scale back or eliminate research and development programs, modify its overall development strategy for one or more product candidates (or the Company as a whole) in a manner it would not if sufficient cash resources were available, or cease operations altogether.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">DIFFUSION PHARMACEUTICALS INC.</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Operations of the Company are subject to certain additional risks and uncertainties as well, and any one or more of these factors could materially affect the Company&#x2019;s financial condition, future operations and liquidity needs. Many of these risks and uncertainties are outside of the Company&#x2019;s control, including the outcome of its ongoing strategic review process and various internal and external factors that may affect the success or failure of the Company's research and development efforts, the length of time and cost of developing and commercializing the Company's current or future product candidates, whether and when any such product candidates become approved drugs, and how significant a drug's market share will be, if approved, among others.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Subject to the outcome and timing of its ongoing strategic review process, and without giving effect to the consummation of the proposed Merger with EIP, the Company currently expect that its existing cash, cash equivalents and marketable securities as of March 31, 2023 are sufficient to fund current operations for at least 12 months following the date of this Quarterly Report.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div>&#xa0;</div>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c221" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Basis of Presentation and Summary of Significant Accounting Policies</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of the date of this Quarterly Report, the Summary of Significant Accounting Policies included in the Company's Annual Report have not materially changed, except as set forth below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c37038561439571" escape="true" continuedAt="c37038561439571_1"><i>Basis of Presentation</i></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><ix:continuation id="c37038561439571_1">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information as found in the ASC and ASUs of the FASB, and with the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the SEC. In the opinion of management, the accompanying unaudited interim consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of March 31, 2023, and its results of operations and cash flows for the three months ended March 31, 2023 and 2022. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The unaudited interim consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2022 filed with the SEC as part of the Annual Report.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:UseOfEstimates" id="c260953453310560" escape="true" continuedAt="c260953453310560_1"><i>Use of Estimates</i></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><ix:continuation id="c260953453310560_1" continuedAt="c260953453310560_2">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c260953453310560_2">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c496653349819554" escape="true" continuedAt="c496653349819554_1"><i>Fair Value of Financial Instruments</i></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c496653349819554_1">The carrying amounts of the Company&#x2019;s financial instruments, including cash, cash equivalents, and accounts payable approximate fair value due to the short-term nature of those instruments.</ix:continuation></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">DIFFUSION PHARMACEUTICALS INC.</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:ConcentrationRiskCreditRisk" id="c1451237916133946" escape="true" continuedAt="c1451237916133946_1"><i>Concentration of Credit Risk</i></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c1451237916133946_1">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c127951372828067" escape="true" continuedAt="c127951372828067_1"><i>Cash and Cash Equivalents</i></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c127951372828067_1">The Company considers any highly-liquid investments, such as money market funds, with an original maturity of three months or less to be cash equivalents.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:MarketableSecuritiesPolicy" id="c1163347336978062" escape="true" continuedAt="c1163347336978062_1"><i>Marketable securities</i></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c1163347336978062_1" continuedAt="c1163347336978062_2">The Company classifies its marketable securities as available-for-sale, which include commercial paper and U.S. government debt securities with original maturities of greater than three months from date of purchase. The Company considers its marketable securities as available for use in current operations, and therefore classifies these securities as current assets on the consolidated balance sheet. These securities are carried at fair value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive loss within stockholders&#x2019; equity. Gains or losses on marketable securities sold will be based on the specific identification method.</ix:continuation></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c1163347336978062_2">The Company routinely monitors the difference between cost and the estimated fair value of its investments. Each reporting period, securities with unrealized losses are reviewed to determine whether the decline in fair value requires the recognition of an allowance for credit losses. Factors considered in the review include (i) current market interest rates, (ii) general financial condition of the issuer, (iii) issuer's industry and future business prospects, (iv) issuer's past defaults in principal and interest payments, and (v) the payment structure of the investment and the issuer's ability to make contractual payments on the investment.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c227282049721951" escape="true" continuedAt="c227282049721951_1"><i>Research and Development</i></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c227282049721951_1" continuedAt="c227282049721951_2">Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&#x2019;s behalf). Costs incurred for research and development are expensed as incurred.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c227282049721951_2">Upfront payments made to third parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">DIFFUSION PHARMACEUTICALS INC.</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:LegalCostsPolicyTextBlock" id="c816531795414716" escape="true" continuedAt="c816531795414716_1"><i>Patent Costs</i></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><ix:continuation id="c816531795414716_1">Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations and comprehensive loss.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c1032028848819100" escape="true" continuedAt="c1032028848819100_1"><i>Stock-based Compensation</i></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c1032028848819100_1" continuedAt="c1032028848819100_2">The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the expected dividend yield and the fair value of the Company&#x2019;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c1032028848819100_2" continuedAt="c1032028848819100_3">For certain stock option grants, the expected term was estimated using the &#x201c;simplified method&#x201d; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The Company uses the simplified method to estimate the expected term.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c1032028848819100_3">For stock price volatility, the Company uses a combination of its own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes no dividend yield because dividends are not expected to be paid in the near future, which is consistent with the Company&#x2019;s history of not paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the option. The Company accounts for forfeitures in the periods they occur.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c713833990570218" escape="true" continuedAt="c713833990570218_1"><i>Net Loss Per Common Share</i></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c713833990570218_1" continuedAt="c713833990570218_2">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><ix:continuation id="c713833990570218_2" continuedAt="c713833990570218_3">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</ix:continuation></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c263" escape="true"><ix:continuation id="c713833990570218_3">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c265" contextRef="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">88,252</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c266" contextRef="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">111,891</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c267" contextRef="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">104,047</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c268" contextRef="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">116,564</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested restricted stock awards</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c269" contextRef="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">2,910</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c270" contextRef="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">5,182</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c271" contextRef="d_2023-01-01_2023-03-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">195,209</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c272" contextRef="d_2022-01-01_2022-03-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">233,637</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
		</tr>

</tbody></table>
</ix:continuation></ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c1331704437450428" escape="true" continuedAt="c1331704437450428_1"><b><i>Recently Adopted Accounting Pronouncements</i></b></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c1331704437450428_1" continuedAt="c1331704437450428_2">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments</i>&#x2014;<i>Credit Losses, Measurement of Credit Losses on Financial Instruments</i> (Topic 326). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. The Company adopted the guidance using a modified retrospective approach as of January 1, 2023 which resulted in no cumulative-effect adjustment to retained earnings.</ix:continuation></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><ix:continuation id="c1331704437450428_2" continuedAt="c1331704437450428_3">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">DIFFUSION PHARMACEUTICALS INC.</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
</div>
</div>
</ix:continuation></div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><ix:continuation id="c1331704437450428_3">The updated guidance in ASU 2016-13 also amended the previous other-than-temporary impairment (&#x201c;OTTI&#x201d;) model for available-for-sale fixed income securities by requiring the recognition of impairments relating to credit losses through an allowance account and limits the amount of credit loss to the difference between a security&#x2019;s amortized cost basis and its fair value. In addition, the length of time a security has been in an unrealized loss position will no longer impact the determination of whether a credit loss exists. The Company adopted the guidance related to available-for-sale fixed income securities on January 1, 2023 using a prospective transition approach for available-for-sale fixed income securities that were purchased with credit deterioration or had recognized an OTTI write-down prior to the effective date. The effect of the prospective transition approach was to maintain the same amortized cost basis before and after the effective date.</ix:continuation></p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div>&#xa0;</div>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="c273" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>4. </b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Cash, cash equivalents and marketable securities </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following is a summary of the Company's cash and cash equivalents as of the date indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="c316" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2022</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash in banking institutions</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c318" contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-BankTimeDepositsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="0">631,002</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c319" contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-BankTimeDepositsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="0">1,586,920</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c320" contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="0">14,014,584</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c321" contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="0">8,526,786</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c322" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="0">14,645,586</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c323" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="0">10,113,706</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following is a summary of the Company's marketable securities as of as of the date indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="c324" escape="true">
<table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amortized cost</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized gains</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized losses</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fair Value</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"><b>March 31, 2023</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c327" contextRef="i_2023-03-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:numdotdecimal" decimals="0">1,995,318</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c328" contextRef="i_2023-03-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="0">210</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c329" contextRef="i_2023-03-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="0">1,437</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c330" contextRef="i_2023-03-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">1,994,091</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c331" contextRef="i_2023-03-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:numdotdecimal" decimals="0">999,575</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c332" contextRef="i_2023-03-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c333" contextRef="i_2023-03-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="0">1,896</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c334" contextRef="i_2023-03-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">997,679</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c335" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:numdotdecimal" decimals="0">2,994,893</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c336" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="0">210</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c337" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="0">3,333</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c338" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">2,991,770</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">&#xa0;</td>
			<td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#xa0;</td>
			<td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"><b>December 31, 2022</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c340" contextRef="i_2022-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:numdotdecimal" decimals="0">9,445,220</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c341" contextRef="i_2022-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="0">263</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c342" contextRef="i_2022-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="0">21,313</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c343" contextRef="i_2022-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">9,424,170</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c344" contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:numdotdecimal" decimals="0">2,999,095</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c345" contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c346" contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="0">14,325</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c347" contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">2,984,770</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c348" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:numdotdecimal" decimals="0">12,444,315</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c349" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="0">263</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c350" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:numdotdecimal" decimals="0">35,638</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c351" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">12,408,940</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company's marketable securities generally have contractual maturity dates between <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31_RangeAxis-MinimumMember" name="dffn:MarketableSecuritiesContractualMaturity" id="c307" format="ixt-sec:durmonth">7</ix:nonNumeric> and <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31_RangeAxis-MaximumMember" name="dffn:MarketableSecuritiesContractualMaturity" id="c308" format="ixt-sec:durmonth">30</ix:nonNumeric> months.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of March 31, 2023, $<ix:nonFraction id="c311" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="0" format="ixt:numdotdecimal" decimals="0">1,991,770</ix:nonFraction> of the marketable securities held were in an unrealized loss position, all of which have been in an unrealized loss position for less than twelve months. The Company determined that unrealized losses on marketable securities were primarily due to market conditions, including changes in the U.S. Federal Reserve interest rate, and not credit losses. The Company does not intend to sell the investments and it is not more likely than not that that the Company will be required to sell the investments before the recovery of the amortized cost basis. No allowance for credit losses related to any of these securities was recorded for the three months ended March 31, 2023.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">DIFFUSION PHARMACEUTICALS INC.</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
</ix:nonNumeric>

<div>&#xa0;</div>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:FairValueDisclosuresTextBlock" id="c352" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>5. </b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Fair Value of Financial Instruments </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <i>Fair Value Measurement</i>, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table presents the Company&#x2019;s assets that are measured at fair value on a recurring basis (amounts in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="c402" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair value measurement at reporting date</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted prices in </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>active markets for </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>identical assets </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level <b>1)</b></b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant other </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>observable inputs</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level <b>2)</b></b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>unobservable inputs </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level <b>3)</b></b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 55%;">March 31, 2023</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Cash equivalents:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money market funds</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c406" contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="0">14,014,584</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c407" contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#x2014;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c409" contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c410" contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c412" contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="0">14,014,584</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c413" contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Marketable securities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c416" contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c417" contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">1,994,090</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c419" contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c420" contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">997,680</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c422" contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c423" contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">2,991,770</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total financial assets</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c425" contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="0">14,014,584</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c426" contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="0">2,991,770</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>December 31, 2022:</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Cash equivalents:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money market funds</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c430" contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="0">8,526,786</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c431" contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#x2014;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c433" contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c434" contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c436" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="0">8,526,786</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c437" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
			<td>&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Marketable securities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c440" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c441" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">9,424,170</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c443" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c444" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">2,984,770</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c446" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c447" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:numdotdecimal" decimals="0">12,408,940</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total financial assets</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c449" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="0">8,526,786</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c450" contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="0" format="ixt:numdotdecimal" decimals="0">12,408,940</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#x2014;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair values of the Company&#x2019;s Level 2 marketable securities are estimated primarily based on benchmark yields, reported trades, market-based quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications, which represent a market approach. In general, a market approach is utilized if there is readily available and relevant market activity for an individual security. This valuation technique may change from period to period, based on the relevance and availability of market data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">DIFFUSION PHARMACEUTICALS INC.</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
</ix:nonNumeric>

<div>&#xa0;</div>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="c452" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Accrued Expenses and Other Current Liabilities</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Accrued expenses and other current liabilities consisted of the following as of the dates indicated below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="c464" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31, </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued payroll and payroll related expenses</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c466" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:AccruedSalariesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">302,085</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c467" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccruedSalariesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">131,777</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued professional fees</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c468" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">734,371</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c469" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">552,785</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued clinical studies expenses</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c470" contextRef="i_2023-03-31" unitRef="USD" name="dffn:AccruedClinicalStudiesExpensesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">16,745</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c471" contextRef="i_2022-12-31" unitRef="USD" name="dffn:AccruedClinicalStudiesExpensesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">475,141</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c472" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">101,274</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c473" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">129,851</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c474" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">1,154,475</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c475" contextRef="i_2022-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="0">1,289,554</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
</ix:nonNumeric>

<div>&#xa0;</div>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c476" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>7.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Stockholders' Equity and Common Stock Warrants</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Common Stock Warrants</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of March 31, 2023, the Company had the following warrants outstanding to acquire shares of its common stock:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c503" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Outstanding</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Range of exercise </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price per share</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration dates</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the May 2019 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c505" contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">27,648</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">$<ix:nonFraction id="c506" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">250.09</ix:nonFraction></td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c508" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">306.04</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">May and December 2024</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the November 2019 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c510" contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">4,269</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#xa0;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$<ix:nonFraction id="c511" contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">17.51</ix:nonFraction></td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">May 2024</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the December 2019 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c513" contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">6,264</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">$<ix:nonFraction id="c514" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">21.68</ix:nonFraction></td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">-</p>
			</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$<ix:nonFraction id="c516" contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">34.92</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">December 2024 and June 2025</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the May 2020 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c518" contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">11,424</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$<ix:nonFraction id="c519" contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">65.65</ix:nonFraction></td>
			<td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">March 2025</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the May 2020 investor warrant exercise</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c521" contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">4,998</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$<ix:nonFraction id="c522" contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">29.7</ix:nonFraction></td>
			<td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">November 2025</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the February 2021 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c524" contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">33,649</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$<ix:nonFraction id="c525" contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">64.08</ix:nonFraction></td>
			<td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">February 2026</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c527" contextRef="i_2023-03-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">88,252</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 5%;">&#xa0;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;">&#xa0;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 18%;">&#xa0;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">During the three months ended March 31, 2023, <ix:nonFraction id="c501" contextRef="d_2023-01-01_2023-03-31" unitRef="Share" name="dffn:ClassOfWarrantOrRightsExpired" scale="0" format="ixt:numdotdecimal" decimals="INF">23,639</ix:nonFraction> warrants expired.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div>&#xa0;</div>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c528" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>8.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Stock-Based Compensation</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>2015 Equity Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The 2015 Equity Plan provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to <ix:nonFraction id="c530" contextRef="d_2023-01-01_2023-03-31_PlanNameAxis-EquityIncentivePlan2015Member" unitRef="Pure" name="dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" scale="-2" format="ixt:numdotdecimal" decimals="2">4.0</ix:nonFraction>% of the total shares of the Company&#x2019;s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the Company's board of directors. Accordingly, <ix:nonFraction id="c531" contextRef="d_2023-01-01_2023-01-01_PlanNameAxis-EquityIncentivePlan2015Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">81,582</ix:nonFraction> shares were added to the reserve as of January 1, 2023, which shares may be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the 2015 Equity Plan. As of March 31, 2023, there were <ix:nonFraction id="c532" contextRef="i_2023-03-31_PlanNameAxis-EquityIncentivePlan2015Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">141,096</ix:nonFraction> shares available for future issuance under the 2015 Equity Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">DIFFUSION PHARMACEUTICALS INC.</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim consolidated statements of operations and comprehensive loss for the periods indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c573" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c575" contextRef="d_2023-01-01_2023-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="0">12,011</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c576" contextRef="d_2022-01-01_2022-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="0">58,892</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c577" contextRef="d_2023-01-01_2023-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="0">109,360</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c578" contextRef="d_2022-01-01_2022-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="0">219,239</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c579" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="0">121,371</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c580" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="0">278,131</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table summarizes the activity related to all stock option grants for the three months ended March 31, 2023:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c581" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise price</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>per share</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>contractual life</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>intrinsic </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>value</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 52%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at January 1, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c583" contextRef="i_2022-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">140,040</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c584" contextRef="i_2022-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">126.75</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c585" contextRef="d_2023-01-01_2023-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c586" contextRef="d_2023-01-01_2023-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cancelled</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c587" contextRef="d_2023-01-01_2023-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">35,993</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c588" contextRef="d_2023-01-01_2023-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">20.13</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c589" contextRef="i_2023-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">104,047</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c590" contextRef="i_2023-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">163.64</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c591" format="ixt-sec:duryear">7.99</ix:nonNumeric></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c592" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c593" contextRef="i_2023-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">78,533</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c594" contextRef="i_2023-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">211.21</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c595" format="ixt-sec:duryear">7.75</ix:nonNumeric></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c596" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested and expected to vest at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c597" contextRef="i_2023-03-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">104,047</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c598" contextRef="i_2023-03-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">163.64</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="c599" format="ixt-sec:duryear">7.99</ix:nonNumeric></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c600" contextRef="i_2023-03-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">There were no options granted during the three months ended March 31, 2023. The total fair value of options vested during the three months ended March 31, 2023 and 2022 was $<ix:nonFraction id="c557" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" format="ixt:numdotdecimal" decimals="-5">0.1</ix:nonFraction> million and $<ix:nonFraction id="c558" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction> million, respectively. No options were exercised during any of the periods presented. At March 31, 2023, there was $<ix:nonFraction id="c559" contextRef="i_2023-03-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction> million of unrecognized compensation expense that will be recognized over a weighted-average period of <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c560" format="ixt-sec:duryear">1.27</ix:nonNumeric> years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Restricted Stock Unit Awards</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company issues restricted stock ("RSU") to newly elected, non-executive members of the board of directors that vest in six, tri-monthly installments beginning <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c561" format="ixt-sec:durmonth">18</ix:nonNumeric> months after the respective grant date. The fair value of an RSU is equal to the fair market value price of the Company&#x2019;s common stock on the date of grant. RSU expense is recorded on a straight-line basis over the service period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table summarizes activity related to RSU awards during the period indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="c601" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Units</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted average grant date fair value</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at January 1, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c603" contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">3,652</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c604" contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">36.49</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested (1)</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c605" contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">742</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c606" contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">33.72</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c607" contextRef="i_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">2,910</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c608" contextRef="i_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">38.28</ix:nonFraction></td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(1) <ix:footnote xml:lang="en-us" id="fe94240fc-b4f2-44ab-a6ef-b62420724a17">The RSUs vested during the three months ended March 31, 2023 were settled on a hybrid basis. The Company withheld <ix:nonFraction id="c568" contextRef="d_2022-01-01_2022-03-31" unitRef="Share" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">274</ix:nonFraction> shares of common stock and, in lieu of delivering such shares, paid the RSU holder an amount in cash equal to the fair market value of such shares on the vesting date, representing the holder's approximate tax liability associated with the vesting.</ix:footnote></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">DIFFUSION PHARMACEUTICALS INC.</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company recognized approximately $<ix:nonFraction id="c569" contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="0">14,000</ix:nonFraction> and $<ix:nonFraction id="c570" contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="0">16,000</ix:nonFraction> in expense related to these awards during the three months ended March 31, 2023 and March 31, 2022, respectively. At March 31, 2023, there was $<ix:nonFraction id="c571" contextRef="i_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:numdotdecimal" decimals="-9">48,000</ix:nonFraction> in unrecognized compensation cost that will be recognized over a weighted average period of <ix:nonNumeric contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c572" format="ixt-sec:duryear">1.04</ix:nonNumeric> years.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div>&#xa0;</div>

<ix:nonNumeric contextRef="d_2023-01-01_2023-03-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c609" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>9.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Commitments and Contingencies</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Office Space Lease Commitment</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has a short term agreement to utilize membership-based co-working space in Charlottesville, Virginia and was previously party to a second, similar agreement for co-working space in Philadelphia, Pennsylvania, which was terminated during the year ended December 31, 2022. Rent expense related to the Company's short-term agreements was approximately $<ix:nonFraction id="c611" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:numdotdecimal" decimals="0">1,000</ix:nonFraction> and $<ix:nonFraction id="c612" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:numdotdecimal" decimals="0">9,000</ix:nonFraction> for the three months ended March 31, 2023 and 2022, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Research and Development Arrangements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Prior to the strategic review process and entry into the Merger Agreement with EIP, in the course of normal business operations, the Company entered into agreements with universities and CROs to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of cash.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Defined Contribution Retirement Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has established its 401(k) Plan, which covers all employees who qualify under the terms of the plan. Eligible employees may elect to contribute to the 401(k) Plan up to <ix:nonFraction id="c613" contextRef="d_2023-01-01_2023-03-31" unitRef="Pure" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" format="ixt:numdotdecimal" decimals="1">90</ix:nonFraction>% of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of <ix:nonFraction id="c614" contextRef="d_2023-01-01_2023-03-31" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" format="ixt:numdotdecimal" decimals="2">4</ix:nonFraction>% of the participant&#x2019;s compensation. The Company made matching contributions under the 401(k) Plan of approximately $<ix:nonFraction id="c615" contextRef="d_2023-01-01_2023-03-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" format="ixt:numdotdecimal" decimals="0">26,000</ix:nonFraction> and $<ix:nonFraction id="c616" contextRef="d_2022-01-01_2022-03-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" format="ixt:numdotdecimal" decimals="0">27,000</ix:nonFraction> for the three months ended March 31, 2023 and 2022, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Legal Proceedings</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company&#x2019;s legal predecessor under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#x2019; fees and costs. On December 30, 2014, the Company filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to the Company&#x2019;s petition to compel arbitration and a motion to stay the action. After a related hearing on April 14, 2015, the court granted the Company&#x2019;s petition to compel arbitration and a motion to stay the action. On January 8, 2016, the plaintiff filed an arbitration demand with the American Arbitration Association. On November 19, 2018 at an Order to Show Cause Re Dismissal Hearing, the court found sufficient grounds not to dismiss the case and an arbitration hearing was scheduled, originally for November 2020 but later postponed due to the COVID-19 pandemic and related restrictions on gatherings in the State of California. In addition, following the November 2018 hearing, an automatic stay was placed on the arbitration in connection with the plaintiff filing for personal bankruptcy protection. On October 22, 2021, following a determination by the bankruptcy trustee not to pursue the claims and release them back to the plaintiff, the parties entered into a stipulation to abandon arbitration and return the matter to state court. A case management conference was held on February 23, 2022 at which an initial trial date of May 24, 2023 was set, following which the parties agreed to stipulate to mediation in advance of the trial. On October 20, 2022, the parties filed a joint stipulation to continue the trial and certain deadlines related to the mediation in order to allow plaintiff's counsel to continue to seek treatment for an ongoing medical issue. On November 1, 2022, based on the parties joint stipulation, the court entered an order continuing the trial date to October 25, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">DIFFUSION PHARMACEUTICALS INC.</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;">&#xa0;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company believes the claims in this matter are without merit and is defending itself vigorously. However, at this stage, the Company is unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on the Company&#x2019;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&#x2019;s consolidated financial position, results of operations and cash flows.</p>
</ix:nonNumeric>

<div>&#xa0;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;</p>

<div>&#xa0;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>MANAGEMENT</b>&#x2019;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">You should read the following discussion of our financial condition and results of operations together with the unaudited interim consolidated financial statements and the notes thereto included elsewhere in this report and other financial information included in this report. The following discussion may contain predictions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under &#x201c;<i>Part I </i>&#x2014;<i> Item 2. Management</i>&#x2019;<i>s Discussion and Analysis of Financial Condition and Results of Operations</i>&#x2014;<i>Special Note Regarding Forward-Looking Statements</i>&#x201d; in this report and under &#x201c;<i>Part I </i>&#x2014;<i> Item 1A. Risk Factors</i>&#x201d; in our Annual Report, as well as the risk factors discussed under the heading "<i>Risk Factors</i>" in the Preliminary Merger Proxy Statement. These risks could cause our actual results to differ materially from any future performance suggested below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><b>Overview</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Diffusion is a biopharmaceutical company that has historically focused on developing novel therapies that may enhance the body&#x2019;s ability to deliver oxygen to the areas where it is needed most. Our most advanced product candidate, TSC, has been investigated and developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#x2019;s most intractable and difficult-to-treat conditions, including hypoxic solid tumors like GBM.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC in March 2022, we identified the pursuit of an opportunistic transaction with the potential to complement and diversify our portfolio of product candidates as one of our key strategic objectives intended to enhance long-term value for our stockholders. In pursuit of this objective, in July 2022, we engaged Canaccord as our financial advisor to support our process and, in October 2022, following further deterioration of the public capital markets throughout 2022 and the corresponding increase in the cost of capital for small biopharmaceutical companies, we publicly announced our board of directors&#x2019; authorization of an expanded evaluation and review of potential strategic transactions, including a joint venture, licensing, merger, reverse merger, sale or divestiture of some of proprietary technologies or a sale of Diffusion, among others.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On March 30, 2023, Diffusion, Merger Sub and EIP entered into the Merger Agreement, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into EIP, with EIP surviving the merger as the wholly-owned subsidiary of the combined company. If consummated, immediately following the effective time of the Merger, former EIP stockholders are expected to own approximately 77.26% of the outstanding shares of our common stock, and stockholders of Diffusion as of immediately prior to the effective time of the Merger are expected to own approximately 22.74% of the outstanding shares of our common stock, in each case, as calculated in the Merger Agreement and assuming &#x201c;Parent Net Cash&#x201d; (as defined in the Merger Agreement, which is attached as an exhibit to this Quarterly Report) at the closing of the Merger is between $13.5 million and $14.5 million. The actual amount of Parent Net Cash &#xa0;delivered at Closing will depend on many factors, including among others, the date of the closing, and no assurance can be given as to the actual amount of Parent Net Cash that will be delivered.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If the Merger is completed, it will result in a combined company primarily focused on the advancement of central nervous system focused therapeutics, including EIP&#x2019;s lead drug candidate neflamapimod, which is currently being developed for the treatment of dementia with Lewy bodies (&#x201c;DLB&#x201d;).&#xa0; Phase 2a clinical trial results with neflamapimod in DLB that showed statistically significant positive effects compared to placebo on dementia severity and walking ability were published in a major scientific journal in September 2022, and in January 2023, EIP was awarded $21.0 million in non-dilutive grant funding from the National Institutes of Health&#x2019;s National Institute on Aging that is expected to fully fund clinical trial costs associated with a planned Phase 2b study evaluating neflamapimod in patients with DLB, a study which EIP anticipates initiating by the end of the second quarter of 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If the Merger is not completed, we will reconsider our strategic alternatives and may pursue one of the following courses of action, which we currently believes are the most likely alternatives if the Merger is not completed:</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Pursue another strategic transaction similar to the Merger. </i>&#xa0;We may resume our process of evaluating other companies interested in pursuing a strategic transaction with us and, if a candidate is identified, focus our attention on negotiating and completing such a transaction with such candidate.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Dissolve and liquidate its assets, </i>If we are unable, or do not believe that we will be able, to find a suitable candidate for another strategic transaction in the best interests of our stockholders, we may dissolve and liquidate its assets. In the event of dissolution, we would be required to pay all its debts and contractual obligations and to set aside certain reserves for potential future claims. If we dissolve and liquidate our assets, there can be no assurance as to the amount or timing of available cash that will remain for distribution to our stockholders after paying our debts and other obligations and setting aside funds for its reserves.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Subject to the availability of additional funding on acceptable terms, we may also consider resuming development of TSC if the Merger is not completed.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><b>Financial Summary</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of March&#xa0;31, 2023, we had cash, cash equivalents, and marketable securities of $17.6 million, in the aggregate. We have incurred operating losses since inception, have not generated any product sales revenue and have not achieved profitable operations. We incurred a net loss of $4.1 million for the three months ended March&#xa0;31, 2023, mostly related to payment of non-recurring severance cost during the period. Our accumulated deficit as of March&#xa0;31, 2023 was $149.6 million, and we expect to continue to incur substantial losses in future periods.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Currently and during the period ended March 31, 2023, the majority of our costs &#xa0;are and were related to our strategic review process and proposed Merger with EIP. We also expect, if we complete the Merger, another strategic transaction, or resume development of TSC, to continue to incur substantial losses in future periods for the foreseeable future, including any costs related to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any additional studies we may undertake to evaluate our current or future product candidates, including other preclinical and clinical studies to support the filing of any NDA with the FDA</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">other research, development, and manufacturing activities designed to develop and optimize formulation, manufacturing processes, dosage, dose forms, and other characteristics prior to regulatory approval;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the maintenance, expansion, and protection our global intellectual property portfolio;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the hiring of additional clinical, manufacturing, scientific, sales, or other personnel</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">research and development related to any other product candidates we may acquire or in-license in the future; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#xa0;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">investments in operational, financial, and management information systems</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Subject to the outcome and timing of our ongoing strategic review process, and without giving effect to the consummation of the proposed Merger with EIP, we currently expect that our existing cash, cash equivalents and marketable securities as of March&#xa0;31, 2023 are sufficient to fund current operations for at least 12 months following the date of this Quarterly Report.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Additionally, if completed, the Merger will result in an ownership change under Section&#xa0;382 of the U.S. tax code for Diffusion, and our pre-merger NOL carryforwards and certain other tax attributes will be subject to limitation.&#xa0;Similar rules may apply under state tax laws. Consequently, even if the combined company achieves profitability, it may not be able to utilize a material portion of Diffusion&#x2019;s, EIP&#x2019;s, and the combined company&#x2019;s NOL carryforwards and other tax attributes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><b>Financial Operations Overview</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Revenues</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We have not yet generated any revenue from product sales. We do not expect to generate revenue from product sales for the foreseeable future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Research and Development Expense</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">R&amp;D expenses include, but are not limited to, third-party CRO arrangements and employee-related expenses, including salaries, benefits, stock-based compensation, and travel expense reimbursement. R&amp;D activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical studies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>General and Administrative Expense</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">G&amp;A expenses consist principally of salaries and related costs for executive and other personnel, including stock-based compensation, other employee benefit costs, expenses associated with investment bank and other financial advisory services, and travel expenses. Other G&amp;A expenses include, facility-related costs, communication expenses and professional fees for legal, patent prosecution and maintenance, consulting, accounting, and other professional services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Interest Income</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Interest income consists of interest earned from our cash, cash equivalents and marketable securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><b>Results of Operations for Three Months Ended March</b>&#xa0;<b>31, 2023 Compared to Three Months Ended March</b>&#xa0;<b>31, 2022 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table sets forth our results of operations for the three months ended March 31, 2023 and 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended March 31,</b></b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;"><b>&#xa0;</b></td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Change</b></b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,308,589</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2,425,898</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,117,309</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,957,691</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,128,552</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">829,139</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Loss from operations</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,266,281</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,554,450</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(288,169</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Interest income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(173,897</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(27,809</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(146,088</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,092,384</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,526,641</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">434,257</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We recognized $1.3 million in research and development expenses during the three months ended March 31, 2023 compared to $2.4 million during the three months ended March 31, 2022. This decrease was due to lower project spending due to the completion and/or wind-down of certain CMC-related activities and clinical studies evaluating TSC offset by non-recurring severance cost paid during the period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">General and administrative expenses were $3.0 million during the three months ended March 31, 2023 compared to $2.1 million during the three months ended March 31, 2022. The increase was primarily due an increase in professional fees related to ongoing business development activity.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The increase in interest income for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 was primarily as a result of rising interest rates during the first quarter of 2023.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><b>Liquidity and Capital Resources</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Working Capital</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of March&#xa0;31, 2023, we had $14.6 million in cash and cash equivalents, $3.0 million in marketable securities, working capital of $16.4 million and an accumulated deficit of $149.6 million. We expect to continue to incur net losses for the foreseeable future. We intend to use our existing cash, cash equivalents, and marketable securities to fund our working capital and, subject to the completion and outcome of our strategic review process, research and development of our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Cash Flows</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table sets forth our cash flows for the three months ended March&#xa0;31, 2023 and 2022:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended March 31, </b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by (used in):</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating activities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,968,120</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,729,813</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Investing activities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,500,000</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(22,716,415</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#x2014;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,000</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Net increase (decrease) in cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,531,880</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(27,441,228</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Operating Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Net cash used in operating activities of $5.0 million during the three months ended March 31, 2023 was primarily attributable to our net loss of $4.1 million and our net change in operating assets and liabilities of $1.1 million. This amount was offset by $0.1 million in stock-based compensation expense. The net change in our operating assets and liabilities is primarily attributable to a decrease in our accrued expenses and other current liabilities due to the timing of our payments to our vendors and employees as well as an increase in our prepaid expenses, deposits, and other current assets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Net cash used in operating activities of $4.7 million during the three months ended March 31, 2022 was primarily attributable to our net loss of $4.5 million and our net change in operating assets and liabilities of $0.5 million. This amount was offset by $0.3 million in stock-based compensation expense. The net change in our operating assets and liabilities is primarily attributable to an increase in our prepaid expenses, deposits and other current assets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Investing Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">During the three months ended March 31, 2023, $9.5 million in marketable securities matured. During the three months ended March 31, 2022, we purchased $22.7 million in marketable securities with cash.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Financing Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Net cash provided by financing activities was $5,000 during the three months ended March 31, 2022, attributable to proceeds received from the sale of our Series C Convertible Preferred Stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Capital Requirements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Historically, we have incurred substantial expenses and generated significant operating losses pursuing its business strategy of developing TSC. As of the date of this Quarterly Report, most of our cash resources are dedicated to, and its planned expenditures are primarily related to, the Merger.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">While we currently believes we have adequate cash resources to fund our current operations for at least 12 months, we anticipate that, if we complete the Merger, another strategic transaction, or resume development of TSC, we will likely need additional funding in the future to support our research and development activities and other operations which, if available, could be obtained through additional capital raising transactions, entry into strategic partnerships or collaborations, or alternative financing arrangements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In July 2022, we entered into an At-The-Market Sales Agreement, dated July 22, 2022, with BTIG LLC, as agent (the &#x201c;2022 Sales Agreement&#x201d;). The 2022 Sales Agreement is an &#x201c;at-the-market&#x201d; sales agreement pursuant to which we may, from time to time and through BTIG as our agent, sell up to an aggregate of $20.0 million in shares of common stock by any permissible method deemed an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) under the Securities Act. As of the date of this Quarterly Report, however, we have not sold any shares pursuant to the 2022 Sales Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the future, we may seek to raise additional funds through various sources. However, we can give no assurances that we will be able to secure additional sources of funds to support its operations, or if such funds are available to us, that such additional financing will be sufficient or be on acceptable terms. This risk may increase if economic and market conditions continue to be challenging or deteriorate. If we are unable to obtain additional financing when needed, we may need to curtail portions of our operations, terminate, significantly modify, or delay the development of our product candidates, or obtain funds on terms that may require us to relinquish rights to our technologies, product candidates or other assets that we might otherwise seek to develop or commercialize independently or receive superior value. If we are unable to raise adequate additional capital as and when required in the future, we could be forced to cease development activities and terminate our operations, and our stockholders could experience a complete loss of their investment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To the extent that we raise additional capital in the future through the sale of common stock or securities convertible or exchangeable for common stock such as common stock warrants, convertible preferred stock, or convertible debt instruments, or fund acquisitions or other transactions through the issuance of such securities, the interests of our current stockholders may be diluted or otherwise impacted. In particular, specific rights granted to future holders of preferred stock or convertible debt securities may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We do not have any off-balance sheet arrangements, as defined by the rules and regulations of the SEC, that have or are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures, or capital resources. As a result, we are not materially exposed to any financing, liquidity, market, or credit risk that could arise if we had engaged in these arrangements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><b>Critical Accounting Policies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of the date of this Quarterly Report, the Critical Accounting Policies included in our Annual Report have not changed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As a &#x201c;smaller reporting company&#x201d; as defined by Item 10 of Regulation S-K, we are not required to provide the information required by this Item 3.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>CONTROLS AND PROCEDURES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#x2019;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we are required to apply our judgment in evaluating the cost-benefit relationship of possible internal controls. Our management evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this report. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the end of such period to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding disclosure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><b>Change in Internal Control Over Financial Reporting</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">There were no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) promulgated under the Exchange Act) that occurred during the period ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>PART II </b>&#x2013;<b> OTHER INFORMATION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>LEGAL PROCEEDINGS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For this item, please refer to <i>Note 7, Commitments and Contingencies</i> in the notes accompanying the unaudited interim consolidated financial statements included in Part I, Item 1 of this Quarterly Report, which is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 1A.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>RISK FACTORS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of the date of this Quarterly Report, there have been no material changes to our risk factors previously disclosed in our Annual Report except as disclosed under the heading, "<i>Risk Factors</i>" in the Preliminary Merger Proxy Statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b>Unregistered Sales of Equity Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b>Issuer Purchases of Equity Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">None.&#xa0;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>DEFAULTS UPON SENIOR SECURITIES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>MINE SAFETY DISCLOSURES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>OTHER INFORMATION</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>EXHIBITS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">See attached Exhibit Index.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>QUARTERLY REPORT ON FORM 10-Q</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>EXHIBIT INDEX</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-color: black black rgb(0, 0, 0); border-style: solid; border-width: 1px; vertical-align: bottom; width: 12.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>No.</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 56.8%; border-top: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></p>
			</td>
			<td style="border-color: black black rgb(0, 0, 0); border-style: solid; border-width: 1px; vertical-align: bottom; width: 31.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Method of Filing</b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.1</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923008519/ex_494918.htm" style="-sec-extract:exhibit;">Agreement and Plan of Merger, dated as of March 30, 2023, by and among Diffusion Pharmaceuticals Inc., EIP Pharma, Inc. and Dawn Merger Sub Inc. (1)</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 2.1 to the registrant's Current Report on Form 8-K filed on March 30, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923008519/ex_494896.htm" style="-sec-extract:exhibit;">Form of EIP Pharma, Inc. Stockholder Support Agreement, dated as of March 30, 2023</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on March 30, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.2</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923008519/ex_494897.htm" style="-sec-extract:exhibit;">Form of Lock-Up Agreement, dated as of March 30, 2023</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 10.2 to the registrant's Current Report on Form 8-K filed on March 30, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.3</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923008519/ex_494898.htm" style="-sec-extract:exhibit;">Amendment, dated March 29, 2023, to Employment Agreement, dated September 8, 2020, by and between Diffusion Pharmaceuticals Inc. and Robert J. Cobuzzi, Ph.D.</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 10.3 to the registrant's Current Report on Form 8-K filed on March 30, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.4</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923008519/ex_494899.htm" style="-sec-extract:exhibit;">Amendment, dated March 29, 2023, to Employment Agreement, dated September 21, 2018, by and between Diffusion Pharmaceuticals Inc. and William Hornung</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 10.4 to the registrant's Current Report on Form 8-K filed on March 30, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.5</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923008519/ex_494900.htm" style="-sec-extract:exhibit;">Amendment, dated March 29, 2023, to Employment Agreement, dated September 23, 2020, by and between Diffusion Pharmaceuticals Inc. and William Elder</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 10.5 to the registrant's Current Report on Form 8-K filed on March 30, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.6</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923007795/ex_489418.htm" style="-sec-extract:exhibit;">Separation Agreement and General Release, effective as of March 8, 2023, by and between Diffusion Pharmaceuticals and Christopher D. Galloway, M.D.</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 10.14 to the registrant's Annual Report on Form 10-K for the year ended December 31, 2022, filed on March 24, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.7</p>
			</td>
			<td style="vertical-align: top; width: 56.8%; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923007795/ex_489419.htm" style="-sec-extract:exhibit;">Separation Agreement and General Release, effective as of March 8, 2023, by and between Diffusion Pharmaceuticals and Raven Jaeger</a></p>
			</td>
			<td style="vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 10.15 to the registrant's Annual Report on Form 10-K for the year ended December 31, 2022, filed on March 24, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">99.1</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923008519/ex_494901.htm" style="-sec-extract:exhibit;">Form of Diffusion Pharmaceuticals Inc. Stockholder Support Agreement, dated as of March 30, 2023</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 99.1 to the registrant's current report on Form 8-K filed on March 30, 2023</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">31.1</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_518005.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">31.2</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_518006.htm" style="-sec-extract:exhibit;">Certification of principal financial officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">32.1</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_518007.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furnished herewith</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">32.2</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_518008.htm" style="-sec-extract:exhibit;">Certification of principal financial officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furnished herewith</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">101</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following materials from Diffusion&#x2019;s quarterly report on Form 10-Q for the quarter ended March 31, 2023, formatted in XBRL (Extensible Business Reporting Language): (i) the Unaudited Consolidated Balance Sheets, (ii) the Unaudited Consolidated Statements of Operations, (iii) the Unaudited Consolidated Statement of Changes in Stockholders&#x2019;&#xa0;Equity, (iv) the Unaudited Consolidated Statements of Cash Flows, and (v) Notes to Unaudited Consolidated Financial Statements</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 12.2%; border-left: 1px solid black; border-right: 1px solid black; text-align: center;">104</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:56.8%;">Cover Page Interactive Data File (formatted as Inline XBRL and contaminated in Exhibit 101)</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 31.5%; border-left: 1px solid black; border-right: 1px solid black;">&#xa0;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(1) &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Schedules and exhibits have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. Diffusion agrees to furnish on a supplemental basis a copy of any omitted schedule or exhibit to the SEC upon its request; provided, however, that Diffusion may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or exhibit so furnished.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#xa0;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">Date: May 15, 2023</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td colspan="2" style="vertical-align:bottom;width:47.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33.1%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33.1%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33.1%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:33.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p>
			</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33.1%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33.1%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:33.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ William Hornung</p>
			</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">William Hornung</p>
			</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:33.1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>
			</td>
			<td style="vertical-align:bottom;width:14.5%;">&#xa0;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:48.2%;">&#xa0;</td>
			<td style="vertical-align:bottom;width:4.7%;">&#xa0;</td>
			<td colspan="2" style="vertical-align:bottom;width:47.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial and Accounting Officer)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">23</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex_518005.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_518005.htm</title>

	<!-- Generated by ThunderDome Portal - 5/11/2023 8:21:35 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE</b><br>
<b>SARBANES OXLEY ACT OF 2002 AND SEC RULE 13a-14(a)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Robert J. Cobuzzi, Jr., Ph.D., certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this quarterly report on Form 10-Q of Diffusion Pharmaceuticals Inc.;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date:</p>
			</td>
			<td style="vertical-align: bottom; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 15, 2023</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex_518006.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_518006.htm</title>

	<!-- Generated by ThunderDome Portal - 5/11/2023 8:22:03 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE</b><br>
<b>SARBANES OXLEY ACT OF 2002 AND SEC RULE 13a-14(a)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, William K. Hornung, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this quarterly report on Form 10-Q of Diffusion Pharmaceuticals Inc.;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date:</p>
			</td>
			<td style="vertical-align: bottom; width: 45%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 15, 2023</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ William K. Hornung&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">William K. Hornung</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 5%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial and Accounting Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex_518007.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_518007.htm</title>

	<!-- Generated by ThunderDome Portal - 5/11/2023 8:22:24 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Quarterly Report on Form 10-Q of Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) for the quarter ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Robert J. Cobuzzi, Jr., Ph.D, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Robert J. Cobuzzi, Jr., Ph.D</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert J. Cobuzzi, Jr., Ph.D</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 15, 2023</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex_518008.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>ex_518008.htm</title>

	<!-- Generated by ThunderDome Portal - 5/11/2023 8:22:50 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Quarterly Report on Form 10-Q of Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) for the quarter ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, William K. Hornung, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ William K. Hornung</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">William K. Hornung</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer (Principal Financial and Accounting Officer)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 15, 2023</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>dffn-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 01:53PM UTC 2023-05-14--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dffn="http://www.diffusionpharma.com/20230331" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.diffusionpharma.com/20230331">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-unaudited" roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-unaudited-parentheticals" roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-stockholders-equity" roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-" roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-description-of-business" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Organization and Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-cash-cash-equivalents-and-marketable-securities" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-of-financial-instruments" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-accrued-expenses-and-other-current-liabilities" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-common-stock-warrants" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8- Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments-and-contingencies-" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-of-financial-instruments-tables" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 5 - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-accrued-expenses-and-other-current-liabilities-tables" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-common-stock-warrants-tables" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-tables" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 8- Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity-details-textual" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 2 - Liquidity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-details-textual" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 8- Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-stock-option-activity-details" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 8 - Stock-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments-and-contingencies-details-textual" roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dffn_AccruedClinicalStudiesExpensesCurrent" name="AccruedClinicalStudiesExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dffn_BtigLlcMember" name="BtigLlcMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ClassOfWarrantOrRightsExpired" name="ClassOfWarrantOrRightsExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_EquityIncentivePlan2015Member" name="EquityIncentivePlan2015Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_LiquidityDisclosureTextBlock" name="LiquidityDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_MarketableSecuritiesContractualMaturity" name="MarketableSecuritiesContractualMaturity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" name="PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_PrepaidExpensesDepositsAndOtherAssets" name="PrepaidExpensesDepositsAndOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dffn_TheMay2020InvestorWarrantExerciseMember" name="TheMay2020InvestorWarrantExerciseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_TheMay2020OfferingWarrantsMember" name="TheMay2020OfferingWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" name="UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" name="WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" name="WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" name="WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" name="statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" name="statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" name="statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" name="statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" name="statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" name="statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-5-fair-value-of-financial-instruments-tables" name="statement-statement-note-5-fair-value-of-financial-instruments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" name="statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables" name="statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" name="statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" name="statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" name="statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" name="statement-statement-note-8-stockbased-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" name="statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-stockbased-compensation-tables" name="statement-statement-note-8-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>dffn-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 01:53PM UTC 2023-05-14--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business" xlink:href="dffn-20230331.xsd#statement-note-1-organization-and-description-of-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information" xlink:href="dffn-20230331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited" xlink:href="dffn-20230331.xsd#statement-consolidated-balance-sheets-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals" xlink:href="dffn-20230331.xsd#statement-consolidated-balance-sheets-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="dffn-20230331.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:href="dffn-20230331.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-" xlink:href="dffn-20230331.xsd#statement-consolidated-statements-of-cash-flows-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity" xlink:href="dffn-20230331.xsd#statement-note-2-liquidity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_BtigLlcMember" xlink:label="dffn_BtigLlcMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_LiquidityDisclosureTextBlock" xlink:label="dffn_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_BtigLlcMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dffn_LiquidityDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:href="dffn-20230331.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_UnvestedRestrictedStockUnitsMember" xlink:label="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities" xlink:href="dffn-20230331.xsd#statement-note-4-cash-cash-equivalents-and-marketable-securities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_BankTimeDepositsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments" xlink:href="dffn-20230331.xsd#statement-note-5-fair-value-of-financial-instruments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities" xlink:href="dffn-20230331.xsd#statement-note-6-accrued-expenses-and-other-current-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:href="dffn-20230331.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_TheMay2020InvestorWarrantExerciseMember" xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-" xlink:href="dffn-20230331.xsd#statement-note-9-commitments-and-contingencies-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies" xlink:href="dffn-20230331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:href="dffn-20230331.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:href="dffn-20230331.xsd#statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables" xlink:href="dffn-20230331.xsd#statement-note-5-fair-value-of-financial-instruments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:href="dffn-20230331.xsd#statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:href="dffn-20230331.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual" xlink:href="dffn-20230331.xsd#statement-note-2-liquidity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_BtigLlcMember" xlink:label="dffn_BtigLlcMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_BtigLlcMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:href="dffn-20230331.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_UnvestedRestrictedStockUnitsMember" xlink:label="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual" xlink:href="dffn-20230331.xsd#statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_MarketableSecuritiesContractualMaturity" xlink:label="dffn_MarketableSecuritiesContractualMaturity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_MarketableSecuritiesContractualMaturity" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:href="dffn-20230331.xsd#statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_BankTimeDepositsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:href="dffn-20230331.xsd#statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:href="dffn-20230331.xsd#statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20230331.xsd#statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:href="dffn-20230331.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightsExpired" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:href="dffn-20230331.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_TheMay2020InvestorWarrantExerciseMember" xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:href="dffn-20230331.xsd#statement-note-9-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>dffn-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 01:53PM UTC 2023-05-14--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="dffn-20230331.xsd#dffn_DocumentAndEntityInformation" xlink:label="dffn_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="dffn_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DocumentAndEntityInformation" xlink:to="dffn_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="dffn_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="dffn_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-significant-accounting-policies-policies" xlink:label="dffn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-significant-accounting-policies-policies" xlink:to="dffn_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:to="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:label="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:to="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_BtigLlcMember" xlink:label="dffn_BtigLlcMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_BtigLlcMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BTIG, LLC [Member]</link:label>
    <link:label xlink:label="dffn_BtigLlcMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents BTIG, LLC</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BtigLlcMember" xlink:to="dffn_BtigLlcMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-5-fair-value-of-financial-instruments-tables" xlink:label="dffn_statement-statement-note-5-fair-value-of-financial-instruments-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-5-fair-value-of-financial-instruments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-5-fair-value-of-financial-instruments-tables" xlink:to="dffn_statement-statement-note-5-fair-value-of-financial-instruments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:label="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:to="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Common Stock Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:to="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8- Stock-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:to="dffn_statement-statement-note-8-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:to="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:label="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:to="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:label="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:to="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:label="dffn_statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:to="dffn_statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:label="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:to="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_LiquidityDisclosureTextBlock" xlink:label="dffn_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dffn_LiquidityDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity Disclosure [Text Block]</link:label>
    <link:label xlink:label="dffn_LiquidityDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for the liquidity of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_LiquidityDisclosureTextBlock" xlink:to="dffn_LiquidityDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:to="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:to="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:to="dffn_statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NotesToFinancialStatements" xlink:label="dffn_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="dffn_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NotesToFinancialStatements" xlink:to="dffn_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="dffn_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="dffn_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested (1) (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USTreasurySecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1, 2023 (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at March 31, 2023 (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1, 2023 (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at March 31, 2023 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (1) (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at March 31, 2023 (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at March 31, 2023 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at March 31, 2023 (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at March 31, 2023</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at March 31, 2023 (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsFairValueDisclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at March 31, 2023 (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at March 31, 2023</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</link:label>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1, 2022</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at March 31, 2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable at March 31, 2023 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding at March 31, 2023 (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding at March 31, 2023</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestIncomeExpenseNonoperatingNet</link:label>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value: 1,000,000,000 shares authorized: 2,040,025 and 2,039,557 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireMarketableSecurities</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_TheMay2020OfferingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The May 2020 Offering Warrants [Member]</link:label>
    <link:label xlink:label="dffn_TheMay2020OfferingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the May 2020 offering warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_TheMay2020OfferingWarrantsMember" xlink:to="dffn_TheMay2020OfferingWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommercialPaperMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesSubscriptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockSharesSubscriptions</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesSubscriptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Subscriptions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscriptions" xlink:to="us-gaap_CommonStockSharesSubscriptions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other current assets</link:label>
    <link:label xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_TheMay2020InvestorWarrantExerciseMember" xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The May 2020 Investor Warrant Exercise [Member]</link:label>
    <link:label xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the May 2020 Investor Warrant Exercise.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:to="dffn_TheMay2020InvestorWarrantExerciseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedSalariesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and payroll related expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedProfessionalFeesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:label xlink:label="dffn_EquityIncentivePlan2015Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2015 [Member]</link:label>
    <link:label xlink:label="dffn_EquityIncentivePlan2015Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the 2015 equity incentive plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_EquityIncentivePlan2015Member" xlink:to="dffn_EquityIncentivePlan2015Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with May 2019 Public Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to warrants issued in connection with May 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of premium and discount on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:label xlink:label="srt_DirectorMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_UnvestedRestrictedStockUnitsMember" xlink:label="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_UnvestedRestrictedStockUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested Restricted Stock Units [Member]</link:label>
    <link:label xlink:label="dffn_UnvestedRestrictedStockUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents unvested restricted stock units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_UnvestedRestrictedStockUnitsMember" xlink:to="dffn_UnvestedRestrictedStockUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BankTimeDepositsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankTimeDepositsMember" xlink:to="us-gaap_BankTimeDepositsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherSundryLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="locator"/>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</link:label>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis</link:label>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows used in investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Per share information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of series C preferred stock to related parties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_MarketableSecuritiesUnrealizedGainLoss</link:label>
    <link:label xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock warrants issued, exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock warrants issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_AccruedClinicalStudiesExpensesCurrent</link:label>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical studies expenses</link:label>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentQuarterlyReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with the December 2019 Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants issued in connection to the December 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_CityAreaCode</link:label>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityInteractiveDataCurrent</link:label>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1, 2022 (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at March 31, 2022 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired" xlink:type="locator"/>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightsExpired</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Rights, Expired</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants or rights expired.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ClassOfWarrantOrRightsExpired" xlink:to="dffn_ClassOfWarrantOrRightsExpired-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityFileNumber</link:label>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentType</link:label>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityShellCompany</link:label>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCurrentReportingStatus</link:label>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_MarketableSecuritiesContractualMaturity" xlink:label="dffn_MarketableSecuritiesContractualMaturity" xlink:type="locator"/>
    <link:label xlink:label="dffn_MarketableSecuritiesContractualMaturity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_MarketableSecuritiesContractualMaturity</link:label>
    <link:label xlink:label="dffn_MarketableSecuritiesContractualMaturity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities Contractual Maturity (Month)</link:label>
    <link:label xlink:label="dffn_MarketableSecuritiesContractualMaturity-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The contractual maturity of marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_MarketableSecuritiesContractualMaturity" xlink:to="dffn_MarketableSecuritiesContractualMaturity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityRegistrantName</link:label>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCommonStockSharesOutstanding</link:label>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_LocalPhoneNumber</link:label>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense and vesting of restricted stock units (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense and vesting of restricted stock units</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with the November 2019 Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants issued in connection to the November 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows provided by financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of series C preferred stock to related parties (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of series C preferred stock to related parties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriter Warrants in Connection with the February 2021 Common Stock Offering [Member]</link:label>
    <link:label xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to warrants issued to designees of the underwriter in connection with the February 2021 common stock offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>dffn-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 01:53PM UTC 2023-05-14--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business" xlink:href="dffn-20230331.xsd#statement-note-1-organization-and-description-of-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information" xlink:href="dffn-20230331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited" xlink:href="dffn-20230331.xsd#statement-consolidated-balance-sheets-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals" xlink:href="dffn-20230331.xsd#statement-consolidated-balance-sheets-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="dffn-20230331.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-n10" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-n10" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:href="dffn-20230331.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-" xlink:href="dffn-20230331.xsd#statement-consolidated-statements-of-cash-flows-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-n0" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium-n0" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-4" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss-n8" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity" xlink:href="dffn-20230331.xsd#statement-note-2-liquidity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_BtigLlcMember" xlink:label="dffn_BtigLlcMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_LiquidityDisclosureTextBlock" xlink:label="dffn_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dffn_BtigLlcMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dffn_LiquidityDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:href="dffn-20230331.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_UnvestedRestrictedStockUnitsMember" xlink:label="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities" xlink:href="dffn-20230331.xsd#statement-note-4-cash-cash-equivalents-and-marketable-securities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_BankTimeDepositsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments" xlink:href="dffn-20230331.xsd#statement-note-5-fair-value-of-financial-instruments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities" xlink:href="dffn-20230331.xsd#statement-note-6-accrued-expenses-and-other-current-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:href="dffn-20230331.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_TheMay2020InvestorWarrantExerciseMember" xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-" xlink:href="dffn-20230331.xsd#statement-note-9-commitments-and-contingencies-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies" xlink:href="dffn-20230331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-significant-accounting-policies-policies" xlink:label="dffn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:href="dffn-20230331.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:href="dffn-20230331.xsd#statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:label="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables" xlink:href="dffn-20230331.xsd#statement-note-5-fair-value-of-financial-instruments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-5-fair-value-of-financial-instruments-tables" xlink:label="dffn_statement-statement-note-5-fair-value-of-financial-instruments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-5-fair-value-of-financial-instruments-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:href="dffn-20230331.xsd#statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:label="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:href="dffn-20230331.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual" xlink:href="dffn-20230331.xsd#statement-note-2-liquidity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_BtigLlcMember" xlink:label="dffn_BtigLlcMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="us-gaap_CommonStockSharesSubscriptions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dffn_BtigLlcMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscriptions-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:href="dffn-20230331.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_UnvestedRestrictedStockUnitsMember" xlink:label="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual" xlink:href="dffn-20230331.xsd#statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_MarketableSecuritiesContractualMaturity" xlink:label="dffn_MarketableSecuritiesContractualMaturity-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_MarketableSecuritiesContractualMaturity-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:href="dffn-20230331.xsd#statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:label="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_BankTimeDepositsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:href="dffn-20230331.xsd#statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:label="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:href="dffn-20230331.xsd#statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:label="dffn_statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20230331.xsd#statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:label="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:href="dffn-20230331.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightsExpired-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:href="dffn-20230331.xsd#statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_TheMay2020InvestorWarrantExerciseMember" xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:label="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:href="dffn-20230331.xsd#statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:label="dffn_statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:href="dffn-20230331.xsd#statement-note-9-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20230331.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>dffn-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 01:53PM UTC 2023-05-14--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited" xlink:href="dffn-20230331.xsd#statement-consolidated-balance-sheets-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited" xlink:type="extended">
    <link:loc xlink:href="dffn-20230331.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:href="dffn-20230331.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-" xlink:href="dffn-20230331.xsd#statement-consolidated-statements-of-cash-flows-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:href="dffn-20230331.xsd#statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20230331.xsd#statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20230331.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>dffn20230331_10qimg001.jpg
<TEXT>
begin 644 dffn20230331_10qimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R *,# 2(  A$! Q$!_\0
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D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468485599472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">DIFFUSION PHARMACEUTICALS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-0645032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 East Main Street, Suite 201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Charlottesville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">220-0718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DFFN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,040,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468483461168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,645,586<span></span>
</td>
<td class="nump">$ 10,113,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,991,770<span></span>
</td>
<td class="nump">12,408,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dffn_PrepaidExpensesDepositsAndOtherAssets', window );">Prepaid expenses, deposits and other current assets</a></td>
<td class="nump">767,530<span></span>
</td>
<td class="nump">112,406<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">18,404,886<span></span>
</td>
<td class="nump">22,635,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">971,455<span></span>
</td>
<td class="nump">1,127,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,154,475<span></span>
</td>
<td class="nump">1,289,554<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,125,931<span></span>
</td>
<td class="nump">2,417,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 1,000,000,000 shares authorized: 2,040,025 and 2,039,557 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">165,968,961<span></span>
</td>
<td class="nump">165,847,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3,123)<span></span>
</td>
<td class="num">(35,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(149,688,923)<span></span>
</td>
<td class="num">(145,596,539)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">16,278,955<span></span>
</td>
<td class="nump">20,217,716<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 18,404,886<span></span>
</td>
<td class="nump">$ 22,635,052<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PrepaidExpensesDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PrepaidExpensesDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468482290592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding (in shares)</a></td>
<td class="nump">2,040,025<span></span>
</td>
<td class="nump">2,039,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="nump">2,040,025<span></span>
</td>
<td class="nump">2,039,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468483574800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,308,589<span></span>
</td>
<td class="nump">$ 2,425,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,957,691<span></span>
</td>
<td class="nump">2,128,552<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">4,266,281<span></span>
</td>
<td class="nump">4,554,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="num">(173,897)<span></span>
</td>
<td class="num">(27,809)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,092,384)<span></span>
</td>
<td class="num">$ (4,526,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (2.22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">2,039,737<span></span>
</td>
<td class="nump">2,038,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,092,384)<span></span>
</td>
<td class="num">$ (4,526,641)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">32,252<span></span>
</td>
<td class="num">(49,658)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (4,060,132)<span></span>
</td>
<td class="num">$ (4,576,299)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468482626384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at January 1, 2022 (in shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,038,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at January 1, 2022 at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,038<span></span>
</td>
<td class="nump">$ 164,914,540<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (130,005,111)<span></span>
</td>
<td class="nump">$ 34,911,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of series C preferred stock to related parties (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of series C preferred stock to related parties</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock-based compensation expense and vesting of restricted stock units (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock-based compensation expense and vesting of restricted stock units</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">278,131<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">278,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(49,658)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(49,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,526,641)<span></span>
</td>
<td class="num">(4,526,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(49,658)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(49,658)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at March 31, 2022 (in shares) at Mar. 31, 2022</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">2,038,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at March 31, 2022 at Mar. 31, 2022</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 2,038<span></span>
</td>
<td class="nump">165,192,671<span></span>
</td>
<td class="num">(49,658)<span></span>
</td>
<td class="num">(134,531,752)<span></span>
</td>
<td class="nump">30,618,299<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at January 1, 2022 (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,039,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at January 1, 2022 at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,040<span></span>
</td>
<td class="nump">165,847,590<span></span>
</td>
<td class="num">(35,375)<span></span>
</td>
<td class="num">(145,596,539)<span></span>
</td>
<td class="nump">20,217,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Stock-based compensation expense and vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock-based compensation expense and vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">121,371<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">121,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,252<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,092,384)<span></span>
</td>
<td class="num">(4,092,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,252<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,252<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at March 31, 2022 (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,040,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at March 31, 2022 at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,040<span></span>
</td>
<td class="nump">$ 165,968,961<span></span>
</td>
<td class="num">$ (3,123)<span></span>
</td>
<td class="num">$ (149,688,923)<span></span>
</td>
<td class="nump">$ 16,278,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468485460960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,092,384)<span></span>
</td>
<td class="num">$ (4,526,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">121,371<span></span>
</td>
<td class="nump">278,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of premium and discount on marketable securities</a></td>
<td class="nump">50,578<span></span>
</td>
<td class="nump">13,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, deposits and other assets</a></td>
<td class="num">(655,124)<span></span>
</td>
<td class="num">(495,903)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="num">(291,405)<span></span>
</td>
<td class="nump">28,146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,968,120)<span></span>
</td>
<td class="num">(4,729,813)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22,716,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="num">(22,716,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from the sale of series C preferred stock to related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">4,531,880<span></span>
</td>
<td class="num">(27,441,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">10,113,706<span></span>
</td>
<td class="nump">37,313,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">14,645,586<span></span>
</td>
<td class="nump">9,872,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">$ 32,252<span></span>
</td>
<td class="num">$ (49,658)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468485515264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Organization and Description of Business</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Diffusion Pharmaceuticals Inc., a Delaware corporation, is a biopharmaceutical company that has historically focused on developing novel therapies that may enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most. The Company&#8217;s most advanced product candidate, TSC, has been investigated and developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions, including GBM.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468487910480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dffn_LiquidityDisclosureTextBlock', window );">Liquidity Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Liquidity</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has not generated any revenues from product sales and has historically funded operations primarily from the proceeds of public and private offerings of equity, convertible debt, and convertible preferred stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In July 2022, the Company entered into an at-the-market sales agreement (the "2022 Sales Agreement") with BTIG pursuant to which the Company may, from time to time and through BTIG as its agent, sell up to an aggregate of $20.0 million in shares of the Company&#8217;s common stock by any method permitted that is deemed an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act. To date, the Company has <span style="-sec-ix-hidden:c220">not</span> sold any shares pursuant to the 2022 Sales Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On October 25, 2022, the Company announced that its Board authorized a thorough review and evaluation of a range of potential strategic opportunities in the interest of enhancing stockholder value, including transactional opportunities such as a merger, joint venture, licensing, sale, or divestiture of assets.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the first quarter of 2023, in connection with the ongoing strategic review process and efforts to utilize and preserve assets in a manner that maximizes value for its stockholders, the Company committed to a reduction in force that impacted seven of the Company&#8217;s thirteen employees. The reduction was a cash preservation measure and impacted employees primarily in the Company&#8217;s clinical operations function. In connection with the strategic review process and pending its conclusion, the Company has paused significant portions of its TSC development activities, including initiation of the Company&#8217;s previously announced Phase 2 study of TSC in newly diagnosed GBM patients.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On March 30, 2023, the Company entered into the Merger Agreement with EIP and Merger Sub, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into EIP at the effective time of the Merger, with EIP continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of the Company. The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. As of the date of this Quarterly Report, the Merger remains pending and subject to, among other closing conditions, certain approvals by the Company&#8217;s stockholders, &#160;and there is no assurance in the Merger or any other transaction will be consummated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Substantial additional financing will be required by the Company to fund any research and development activities related to the Company's existing or future product candidates, including EIP's product candidates if the Merger is closed. The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties, and other strategic alliances and business transactions. However, as of the date of this Quarterly Report, the Company does not have any commitments to obtain additional funds and no assurance can be given that any such financing will be available in the future &#8212; when needed, in sufficient amounts, on acceptable terms, or at all. If the Company cannot obtain the necessary funding, it may need to, among other things, delay, continue to scale back or eliminate research and development programs, modify its overall development strategy for one or more product candidates (or the Company as a whole) in a manner it would not if sufficient cash resources were available, or cease operations altogether.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Operations of the Company are subject to certain additional risks and uncertainties as well, and any one or more of these factors could materially affect the Company&#8217;s financial condition, future operations and liquidity needs. Many of these risks and uncertainties are outside of the Company&#8217;s control, including the outcome of its ongoing strategic review process and various internal and external factors that may affect the success or failure of the Company's research and development efforts, the length of time and cost of developing and commercializing the Company's current or future product candidates, whether and when any such product candidates become approved drugs, and how significant a drug's market share will be, if approved, among others.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Subject to the outcome and timing of its ongoing strategic review process, and without giving effect to the consummation of the proposed Merger with EIP, the Company currently expect that its existing cash, cash equivalents and marketable securities as of March 31, 2023 are sufficient to fund current operations for at least 12 months following the date of this Quarterly Report.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_LiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidity of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_LiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468487221712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Basis of Presentation and Summary of Significant Accounting Policies</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of the date of this Quarterly Report, the Summary of Significant Accounting Policies included in the Company's Annual Report have not materially changed, except as set forth below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Basis of Presentation</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information as found in the ASC and ASUs of the FASB, and with the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the SEC. In the opinion of management, the accompanying unaudited interim consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March 31, 2023, and its results of operations and cash flows for the three months ended March 31, 2023 and 2022. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The unaudited interim consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2022 filed with the SEC as part of the Annual Report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Use of Estimates</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Fair Value of Financial Instruments</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The carrying amounts of the Company&#8217;s financial instruments, including cash, cash equivalents, and accounts payable approximate fair value due to the short-term nature of those instruments.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Concentration of Credit Risk</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Cash and Cash Equivalents</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company considers any highly-liquid investments, such as money market funds, with an original maturity of three months or less to be cash equivalents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Marketable securities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company classifies its marketable securities as available-for-sale, which include commercial paper and U.S. government debt securities with original maturities of greater than three months from date of purchase. The Company considers its marketable securities as available for use in current operations, and therefore classifies these securities as current assets on the consolidated balance sheet. These securities are carried at fair value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive loss within stockholders&#8217; equity. Gains or losses on marketable securities sold will be based on the specific identification method.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company routinely monitors the difference between cost and the estimated fair value of its investments. Each reporting period, securities with unrealized losses are reviewed to determine whether the decline in fair value requires the recognition of an allowance for credit losses. Factors considered in the review include (i) current market interest rates, (ii) general financial condition of the issuer, (iii) issuer's industry and future business prospects, (iv) issuer's past defaults in principal and interest payments, and (v) the payment structure of the investment and the issuer's ability to make contractual payments on the investment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research and Development</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&#8217;s behalf). Costs incurred for research and development are expensed as incurred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Upfront payments made to third parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Patent Costs</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Stock-based Compensation</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the expected dividend yield and the fair value of the Company&#8217;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For certain stock option grants, the expected term was estimated using the &#8220;simplified method&#8221; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The Company uses the simplified method to estimate the expected term.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For stock price volatility, the Company uses a combination of its own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes no dividend yield because dividends are not expected to be paid in the near future, which is consistent with the Company&#8217;s history of not paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the option. The Company accounts for forfeitures in the periods they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Net Loss Per Common Share</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88,252</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">111,891</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">104,047</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">116,564</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested restricted stock awards</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,910</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,182</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">195,209</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">233,637</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments</i>&#8212;<i>Credit Losses, Measurement of Credit Losses on Financial Instruments</i> (Topic 326). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. The Company adopted the guidance using a modified retrospective approach as of January 1, 2023 which resulted in no cumulative-effect adjustment to retained earnings.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The updated guidance in ASU 2016-13 also amended the previous other-than-temporary impairment (&#8220;OTTI&#8221;) model for available-for-sale fixed income securities by requiring the recognition of impairments relating to credit losses through an allowance account and limits the amount of credit loss to the difference between a security&#8217;s amortized cost basis and its fair value. In addition, the length of time a security has been in an unrealized loss position will no longer impact the determination of whether a credit loss exists. The Company adopted the guidance related to available-for-sale fixed income securities on January 1, 2023 using a prospective transition approach for available-for-sale fixed income securities that were purchased with credit deterioration or had recognized an OTTI write-down prior to the effective date. The effect of the prospective transition approach was to maintain the same amortized cost basis before and after the effective date.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468488891760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Cash, Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents, and Marketable Securities [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>4. </b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Cash, cash equivalents and marketable securities </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following is a summary of the Company's cash and cash equivalents as of the date indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2022</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash in banking institutions</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">631,002</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,586,920</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,014,584</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,526,786</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,645,586</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,113,706</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following is a summary of the Company's marketable securities as of as of the date indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amortized cost</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized gains</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized losses</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fair Value</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"><b>March 31, 2023</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,995,318</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">210</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,437</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,994,091</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">999,575</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,896</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">997,679</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,994,893</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">210</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,333</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,991,770</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">&#160;</td>
			<td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"><b>December 31, 2022</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,445,220</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">263</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21,313</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,424,170</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,999,095</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,325</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,984,770</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,444,315</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">263</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(35,638</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,408,940</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company's marketable securities generally have contractual maturity dates between 7 and 30 months.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of March 31, 2023, $1,991,770 of the marketable securities held were in an unrealized loss position, all of which have been in an unrealized loss position for less than twelve months. The Company determined that unrealized losses on marketable securities were primarily due to market conditions, including changes in the U.S. Federal Reserve interest rate, and not credit losses. The Company does not intend to sell the investments and it is not more likely than not that that the Company will be required to sell the investments before the recovery of the amortized cost basis. No allowance for credit losses related to any of these securities was recorded for the three months ended March 31, 2023.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468488925920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>5. </b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Fair Value of Financial Instruments </b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <i>Fair Value Measurement</i>, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table presents the Company&#8217;s assets that are measured at fair value on a recurring basis (amounts in thousands):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair value measurement at reporting date</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted prices in </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>active markets for </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>identical assets </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level <b>1)</b></b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant other </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>observable inputs</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level <b>2)</b></b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>unobservable inputs </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level <b>3)</b></b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 55%;">March 31, 2023</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Cash equivalents:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money market funds</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,014,584</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,014,584</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Marketable securities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,994,090</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">997,680</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,991,770</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total financial assets</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,014,584</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,991,770</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>December 31, 2022:</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Cash equivalents:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money market funds</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,526,786</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,526,786</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Marketable securities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,424,170</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,984,770</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,408,940</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total financial assets</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,526,786</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,408,940</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair values of the Company&#8217;s Level 2 marketable securities are estimated primarily based on benchmark yields, reported trades, market-based quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications, which represent a market approach. In general, a market approach is utilized if there is readily available and relevant market activity for an individual security. This valuation technique may change from period to period, based on the relevance and availability of market data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468483561792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Accrued Expenses and Other Current Liabilities</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Accrued expenses and other current liabilities consisted of the following as of the dates indicated below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31, </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued payroll and payroll related expenses</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">302,085</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">131,777</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued professional fees</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">734,371</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">552,785</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued clinical studies expenses</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,745</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">475,141</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">101,274</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">129,851</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,154,475</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,289,554</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468487920304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>7.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Stockholders' Equity and Common Stock Warrants</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Common Stock Warrants</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of March 31, 2023, the Company had the following warrants outstanding to acquire shares of its common stock:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Outstanding</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Range of exercise </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price per share</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration dates</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the May 2019 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,648</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">$250.09</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$306.04</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">May and December 2024</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the November 2019 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,269</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$17.51</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">May 2024</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the December 2019 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,264</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">$21.68</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">-</p>
			</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$34.92</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">December 2024 and June 2025</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the May 2020 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,424</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$65.65</td>
			<td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">March 2025</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the May 2020 investor warrant exercise</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,998</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$29.7</td>
			<td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">November 2025</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the February 2021 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,649</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$64.08</td>
			<td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">February 2026</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">88,252</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 18%;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">During the three months ended March 31, 2023, 23,639 warrants expired.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468488941856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8- Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>8.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Stock-Based Compensation</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>2015 Equity Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The 2015 Equity Plan provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to 4.0% of the total shares of the Company&#8217;s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the Company's board of directors. Accordingly, 81,582 shares were added to the reserve as of January 1, 2023, which shares may be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the 2015 Equity Plan. As of March 31, 2023, there were 141,096 shares available for future issuance under the 2015 Equity Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim consolidated statements of operations and comprehensive loss for the periods indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,011</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">58,892</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">109,360</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">219,239</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">121,371</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278,131</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table summarizes the activity related to all stock option grants for the three months ended March 31, 2023:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise price</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>per share</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>contractual life</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>intrinsic </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>value</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 52%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at January 1, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140,040</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">126.75</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cancelled</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(35,993</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20.13</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">104,047</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">163.64</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.99</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">78,533</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">211.21</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.75</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested and expected to vest at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">104,047</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">163.64</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.99</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">There were no options granted during the three months ended March 31, 2023. The total fair value of options vested during the three months ended March 31, 2023 and 2022 was $0.1 million and $0.2 million, respectively. No options were exercised during any of the periods presented. At March 31, 2023, there was $0.4 million of unrecognized compensation expense that will be recognized over a weighted-average period of 1.27 years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Restricted Stock Unit Awards</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company issues restricted stock ("RSU") to newly elected, non-executive members of the board of directors that vest in six, tri-monthly installments beginning 18 months after the respective grant date. The fair value of an RSU is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSU expense is recorded on a straight-line basis over the service period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table summarizes activity related to RSU awards during the period indicated:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Units</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted average grant date fair value</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at January 1, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,652</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36.49</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested (1)</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(742</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33.72</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,910</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38.28</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(1) The RSUs vested during the three months ended March 31, 2023 were settled on a hybrid basis. The Company withheld 274 shares of common stock and, in lieu of delivering such shares, paid the RSU holder an amount in cash equal to the fair market value of such shares on the vesting date, representing the holder's approximate tax liability associated with the vesting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company recognized approximately $14,000 and $16,000 in expense related to these awards during the three months ended March 31, 2023 and March 31, 2022, respectively. At March 31, 2023, there was $48,000 in unrecognized compensation cost that will be recognized over a weighted average period of 1.04 years.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468488923488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>9.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Commitments and Contingencies</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Office Space Lease Commitment</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has a short term agreement to utilize membership-based co-working space in Charlottesville, Virginia and was previously party to a second, similar agreement for co-working space in Philadelphia, Pennsylvania, which was terminated during the year ended December 31, 2022. Rent expense related to the Company's short-term agreements was approximately $1,000 and $9,000 for the three months ended March 31, 2023 and 2022, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Research and Development Arrangements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Prior to the strategic review process and entry into the Merger Agreement with EIP, in the course of normal business operations, the Company entered into agreements with universities and CROs to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of cash.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Defined Contribution Retirement Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has established its 401(k) Plan, which covers all employees who qualify under the terms of the plan. Eligible employees may elect to contribute to the 401(k) Plan up to 90% of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of 4% of the participant&#8217;s compensation. The Company made matching contributions under the 401(k) Plan of approximately $26,000 and $27,000 for the three months ended March 31, 2023 and 2022, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"><i>Legal Proceedings</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company&#8217;s legal predecessor under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#8217; fees and costs. On December 30, 2014, the Company filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to the Company&#8217;s petition to compel arbitration and a motion to stay the action. After a related hearing on April 14, 2015, the court granted the Company&#8217;s petition to compel arbitration and a motion to stay the action. On January 8, 2016, the plaintiff filed an arbitration demand with the American Arbitration Association. On November 19, 2018 at an Order to Show Cause Re Dismissal Hearing, the court found sufficient grounds not to dismiss the case and an arbitration hearing was scheduled, originally for November 2020 but later postponed due to the COVID-19 pandemic and related restrictions on gatherings in the State of California. In addition, following the November 2018 hearing, an automatic stay was placed on the arbitration in connection with the plaintiff filing for personal bankruptcy protection. On October 22, 2021, following a determination by the bankruptcy trustee not to pursue the claims and release them back to the plaintiff, the parties entered into a stipulation to abandon arbitration and return the matter to state court. A case management conference was held on February 23, 2022 at which an initial trial date of May 24, 2023 was set, following which the parties agreed to stipulate to mediation in advance of the trial. On October 20, 2022, the parties filed a joint stipulation to continue the trial and certain deadlines related to the mediation in order to allow plaintiff's counsel to continue to seek treatment for an ongoing medical issue. On November 1, 2022, based on the parties joint stipulation, the court entered an order continuing the trial date to October 25, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company believes the claims in this matter are without merit and is defending itself vigorously. However, at this stage, the Company is unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on the Company&#8217;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&#8217;s consolidated financial position, results of operations and cash flows.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468483526080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><i>Basis of Presentation</i>The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information as found in the ASC and ASUs of the FASB, and with the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the SEC. In the opinion of management, the accompanying unaudited interim consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March 31, 2023, and its results of operations and cash flows for the three months ended March 31, 2023 and 2022. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The unaudited interim consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2022 filed with the SEC as part of the Annual Report.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><i>Use of Estimates</i>The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><i>Fair Value of Financial Instruments</i>The carrying amounts of the Company&#8217;s financial instruments, including cash, cash equivalents, and accounts payable approximate fair value due to the short-term nature of those instruments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><i>Concentration of Credit Risk</i>Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><i>Cash and Cash Equivalents</i>The Company considers any highly-liquid investments, such as money market funds, with an original maturity of three months or less to be cash equivalents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities, Policy [Policy Text Block]</a></td>
<td class="text"><i>Marketable securities</i>The Company classifies its marketable securities as available-for-sale, which include commercial paper and U.S. government debt securities with original maturities of greater than three months from date of purchase. The Company considers its marketable securities as available for use in current operations, and therefore classifies these securities as current assets on the consolidated balance sheet. These securities are carried at fair value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive loss within stockholders&#8217; equity. Gains or losses on marketable securities sold will be based on the specific identification method.The Company routinely monitors the difference between cost and the estimated fair value of its investments. Each reporting period, securities with unrealized losses are reviewed to determine whether the decline in fair value requires the recognition of an allowance for credit losses. Factors considered in the review include (i) current market interest rates, (ii) general financial condition of the issuer, (iii) issuer's industry and future business prospects, (iv) issuer's past defaults in principal and interest payments, and (v) the payment structure of the investment and the issuer's ability to make contractual payments on the investment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><i>Research and Development</i>Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&#8217;s behalf). Costs incurred for research and development are expensed as incurred.Upfront payments made to third parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs, Policy [Policy Text Block]</a></td>
<td class="text"><i>Patent Costs</i>Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><i>Stock-based Compensation</i>The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the expected dividend yield and the fair value of the Company&#8217;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.For certain stock option grants, the expected term was estimated using the &#8220;simplified method&#8221; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The Company uses the simplified method to estimate the expected term.For stock price volatility, the Company uses a combination of its own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes no dividend yield because dividends are not expected to be paid in the near future, which is consistent with the Company&#8217;s history of not paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the option. The Company accounts for forfeitures in the periods they occur.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><i>Net Loss Per Common Share</i>Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88,252</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">111,891</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">104,047</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">116,564</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested restricted stock awards</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,910</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,182</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">195,209</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">233,637</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><b><i>Recently Adopted Accounting Pronouncements</i></b>In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments</i>&#8212;<i>Credit Losses, Measurement of Credit Losses on Financial Instruments</i> (Topic 326). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. The Company adopted the guidance using a modified retrospective approach as of January 1, 2023 which resulted in no cumulative-effect adjustment to retained earnings.
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="width: 100%;">
<div class="hf-row">
<div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;">&#160;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">DIFFUSION PHARMACEUTICALS INC.</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;">&#160;</div>
</div>

<div class="hf-row">
<div class="hf-cell" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div>
</div>
</div>
The updated guidance in ASU 2016-13 also amended the previous other-than-temporary impairment (&#8220;OTTI&#8221;) model for available-for-sale fixed income securities by requiring the recognition of impairments relating to credit losses through an allowance account and limits the amount of credit loss to the difference between a security&#8217;s amortized cost basis and its fair value. In addition, the length of time a security has been in an unrealized loss position will no longer impact the determination of whether a credit loss exists. The Company adopted the guidance related to available-for-sale fixed income securities on January 1, 2023 using a prospective transition approach for available-for-sale fixed income securities that were purchased with credit deterioration or had recognized an OTTI write-down prior to the effective date. The effect of the prospective transition approach was to maintain the same amortized cost basis before and after the effective date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468488886944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88,252</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">111,891</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">104,047</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">116,564</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unvested restricted stock awards</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,910</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,182</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">195,209</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">233,637</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468487894448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Cash, Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 31, 2023</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31, 2022</p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash in banking institutions</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">631,002</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,586,920</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,014,584</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,526,786</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,645,586</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,113,706</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-Sale [Table Text Block]</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Amortized cost</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized gains</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Unrealized losses</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Fair Value</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"><b>March 31, 2023</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,995,318</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">210</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,437</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,994,091</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">999,575</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,896</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">997,679</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,994,893</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">210</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,333</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,991,770</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">&#160;</td>
			<td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;">&#160;</td>
			<td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"><b>December 31, 2022</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 11%;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,445,220</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">263</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(21,313</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,424,170</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">U.S. treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,999,095</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,325</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,984,770</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,444,315</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">263</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(35,638</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,408,940</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468488906544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair value measurement at reporting date</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Quoted prices in </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>active markets for </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>identical assets </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level <b>1)</b></b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant other </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>observable inputs</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level <b>2)</b></b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Significant </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>unobservable inputs </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(Level <b>3)</b></b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 55%;">March 31, 2023</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Cash equivalents:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money market funds</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,014,584</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,014,584</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Marketable securities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,994,090</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">997,680</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,991,770</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total financial assets</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,014,584</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,991,770</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>December 31, 2022:</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Cash equivalents:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money market funds</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,526,786</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,526,786</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
			<td>&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">Marketable securities:</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,424,170</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,984,770</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total marketable securities</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,408,940</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total financial assets</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,526,786</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,408,940</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468488896352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31, </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued payroll and payroll related expenses</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">302,085</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">131,777</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued professional fees</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">734,371</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">552,785</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accrued clinical studies expenses</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,745</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">475,141</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">101,274</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">129,851</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,154,475</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,289,554</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468488861312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Outstanding</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Range of exercise </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>price per share</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration dates</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the May 2019 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,648</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">$250.09</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">-</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$306.04</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">May and December 2024</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the November 2019 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,269</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$17.51</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">May 2024</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the December 2019 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,264</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">$21.68</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;">-</p>
			</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$34.92</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">December 2024 and June 2025</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the May 2020 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,424</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$65.65</td>
			<td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">March 2025</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the May 2020 investor warrant exercise</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,998</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$29.7</td>
			<td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">November 2025</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants issued related to the February 2021 common stock offering</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,649</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">$64.08</td>
			<td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;">February 2026</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 50%;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">88,252</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt; width: 18%;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468482287472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8- Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Three Months Ended </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>March 31,</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2023</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2022</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,011</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">58,892</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">109,360</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">219,239</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">121,371</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">278,131</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise price</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>per share</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>contractual life</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate</b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>intrinsic </b></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>value</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 52%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at January 1, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">140,040</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">126.75</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Cancelled</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(35,993</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">20.13</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">104,047</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">163.64</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.99</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">78,533</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">211.21</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.75</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested and expected to vest at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">104,047</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">163.64</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.99</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom;">
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Units</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted average grant date fair value</b></b></p>
			</td>
			<td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at January 1, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,652</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">36.49</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Vested (1)</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(742</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">33.72</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: Times New Roman; font-size: 10pt;">
			<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at March 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,910</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38.28</td>
			<td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468488831344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity (Details Textual) - BTIG, LLC [Member]<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common Stock, Value, Subscriptions | $</a></td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dffn_BtigLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dffn_BtigLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468482356224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">195,209<span></span>
</td>
<td class="nump">233,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">88,252<span></span>
</td>
<td class="nump">111,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">104,047<span></span>
</td>
<td class="nump">116,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dffn_UnvestedRestrictedStockUnitsMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">2,910<span></span>
</td>
<td class="nump">5,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dffn_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dffn_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468477740208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Cash, Cash Equivalents and Marketable Securities (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position</a></td>
<td class="nump">$ 1,991,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dffn_MarketableSecuritiesContractualMaturity', window );">Marketable Securities Contractual Maturity (Month)</a></td>
<td class="text">7 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dffn_MarketableSecuritiesContractualMaturity', window );">Marketable Securities Contractual Maturity (Month)</a></td>
<td class="text">30 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_MarketableSecuritiesContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contractual maturity of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_MarketableSecuritiesContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468485467040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,645,586<span></span>
</td>
<td class="nump">$ 10,113,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Bank Time Deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">631,002<span></span>
</td>
<td class="nump">1,586,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,014,584<span></span>
</td>
<td class="nump">$ 8,526,786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468478383376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 2,994,893<span></span>
</td>
<td class="nump">$ 12,444,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(3,333)<span></span>
</td>
<td class="num">(35,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,991,770<span></span>
</td>
<td class="nump">12,408,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,991,770<span></span>
</td>
<td class="nump">12,408,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1,995,318<span></span>
</td>
<td class="nump">9,445,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1,437)<span></span>
</td>
<td class="num">(21,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,994,091<span></span>
</td>
<td class="nump">9,424,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,994,091<span></span>
</td>
<td class="nump">9,424,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">999,575<span></span>
</td>
<td class="nump">2,999,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1,896)<span></span>
</td>
<td class="num">(14,325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">997,679<span></span>
</td>
<td class="nump">2,984,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 997,679<span></span>
</td>
<td class="nump">$ 2,984,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468484707472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 2,991,770<span></span>
</td>
<td class="nump">$ 12,408,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,994,091<span></span>
</td>
<td class="nump">9,424,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">997,679<span></span>
</td>
<td class="nump">2,984,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">14,014,584<span></span>
</td>
<td class="nump">8,526,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">14,014,584<span></span>
</td>
<td class="nump">8,526,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,991,770<span></span>
</td>
<td class="nump">12,408,940<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">2,991,770<span></span>
</td>
<td class="nump">12,408,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,994,090<span></span>
</td>
<td class="nump">9,424,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">997,680<span></span>
</td>
<td class="nump">2,984,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">14,014,584<span></span>
</td>
<td class="nump">8,526,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468487662032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and payroll related expenses</a></td>
<td class="nump">$ 302,085<span></span>
</td>
<td class="nump">$ 131,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">734,371<span></span>
</td>
<td class="nump">552,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dffn_AccruedClinicalStudiesExpensesCurrent', window );">Accrued clinical studies expenses</a></td>
<td class="nump">16,745<span></span>
</td>
<td class="nump">475,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">101,274<span></span>
</td>
<td class="nump">129,851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,154,475<span></span>
</td>
<td class="nump">$ 1,289,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_AccruedClinicalStudiesExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_AccruedClinicalStudiesExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468487918496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightsExpired', window );">Class of Warrant or Rights, Expired</a></td>
<td class="nump">23,639<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468482457584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">88,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember', window );">Warrants Issued in Connection with May 2019 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">27,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember', window );">Warrants Issued in Connection with May 2019 Public Offering [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants issued, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember', window );">Warrants Issued in Connection with May 2019 Public Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants issued, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember', window );">Warrants Issued in Connection with the November 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">4,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants issued, exercise price (in dollars per share)</a></td>
<td class="nump">$ 17.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember', window );">Warrants Issued in Connection with the December 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">6,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember', window );">Warrants Issued in Connection with the December 2019 Offering [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants issued, exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember', window );">Warrants Issued in Connection with the December 2019 Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants issued, exercise price (in dollars per share)</a></td>
<td class="nump">$ 34.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember', window );">The May 2020 Offering Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">11,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants issued, exercise price (in dollars per share)</a></td>
<td class="nump">$ 65.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020InvestorWarrantExerciseMember', window );">The May 2020 Investor Warrant Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">4,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants issued, exercise price (in dollars per share)</a></td>
<td class="nump">$ 29.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember', window );">Underwriter Warrants in Connection with the February 2021 Common Stock Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants issued (in shares)</a></td>
<td class="nump">33,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Common stock warrants issued, exercise price (in dollars per share)</a></td>
<td class="nump">$ 64.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020InvestorWarrantExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020InvestorWarrantExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468482402480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8- Stock-based Compensation (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,371<span></span>
</td>
<td class="nump">$ 278,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 16,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dffn_EquityIncentivePlan2015Member', window );">Equity Incentive Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis', window );">Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">81,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dffn_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dffn_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468484677152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 121,371<span></span>
</td>
<td class="nump">$ 278,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">12,011<span></span>
</td>
<td class="nump">58,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 109,360<span></span>
</td>
<td class="nump">$ 219,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468482651680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation - Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance (in shares) | shares</a></td>
<td class="nump">140,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 126.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(35,993)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance (in shares) | shares</a></td>
<td class="nump">104,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 163.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at March 31, 2023 (Year)</a></td>
<td class="text">7 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at March 31, 2023 | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at March 31, 2023 (in shares) | shares</a></td>
<td class="nump">78,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at March 31, 2023 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 211.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at March 31, 2023 (Year)</a></td>
<td class="text">7 years 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at March 31, 2023 | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at March 31, 2023 (in shares) | shares</a></td>
<td class="nump">104,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at March 31, 2023 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 163.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at March 31, 2023 (Year)</a></td>
<td class="text">7 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at March 31, 2023 | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468482400928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance at January 1, 2023 (in shares) | shares</a></td>
<td class="nump">3,652<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at January 1, 2023 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 36.49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (1) (in shares) | shares</a></td>
<td class="num">(742)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (1) (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at March 31, 2023 (in shares) | shares</a></td>
<td class="nump">2,910<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at March 31, 2023 (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 38.28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The RSUs vested during the three months ended March 31, 2023 were settled on a hybrid basis. The Company withheld 274 shares of common stock and, in lieu of delivering such shares, paid the RSU holder an amount in cash equal to the fair market value of such shares on the vesting date, representing the holder's approximate tax liability associated with the vesting.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468485818528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>dffn20230331_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:dffn="http://www.diffusionpharma.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dffn-20230331.xsd" xlink:type="simple"/>
    <context id="d_2023-01-01_2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_PlanNameAxis-EquityIncentivePlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-01-01_PlanNameAxis-EquityIncentivePlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_PlanNameAxis-EquityIncentivePlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020InvestorWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020OfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_CashAndCashEquivalentsAxis-BankTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_CashAndCashEquivalentsAxis-BankTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dffn:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dffn:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_CounterpartyNameAxis-BtigLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dffn:BtigLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_CounterpartyNameAxis-BtigLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dffn:BtigLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2023-05-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2023-05-11</instant>
        </period>
    </context>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="d_2023-01-01_2023-03-31">0001053691</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="d_2023-01-01_2023-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2023-01-01_2023-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="d_2023-01-01_2023-03-31">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2023-01-01_2023-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-01-01_2023-03-31_CounterpartyNameAxis-BtigLlcMember"
      decimals="-3"
      id="c220"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <dei:DocumentType contextRef="d_2023-01-01_2023-03-31" id="c2">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="d_2023-01-01_2023-03-31" id="c3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="d_2023-01-01_2023-03-31" id="c4">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2023-01-01_2023-03-31" id="c5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2023-01-01_2023-03-31" id="c6">001-37942</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="d_2023-01-01_2023-03-31" id="c7">DIFFUSION PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2023-01-01_2023-03-31" id="c8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2023-01-01_2023-03-31" id="c9">30-0645032</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2023-01-01_2023-03-31" id="c10">300 East Main Street, Suite 201</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2023-01-01_2023-03-31" id="c11">Charlottesville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2023-01-01_2023-03-31" id="c12">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2023-01-01_2023-03-31" id="c13">22902</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2023-01-01_2023-03-31" id="c14">434</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2023-01-01_2023-03-31" id="c15">220-0718</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2023-01-01_2023-03-31" id="c16">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2023-01-01_2023-03-31" id="c17">DFFN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2023-01-01_2023-03-31" id="c18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="d_2023-01-01_2023-03-31" id="c19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2023-01-01_2023-03-31" id="c20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2023-01-01_2023-03-31" id="c21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2023-01-01_2023-03-31" id="c22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2023-01-01_2023-03-31" id="c23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2023-01-01_2023-03-31" id="c24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2023-05-11"
      decimals="INF"
      id="c25"
      unitRef="Share">2040025</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-03-31"
      decimals="0"
      id="c30"
      unitRef="USD">14645586</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-12-31"
      decimals="0"
      id="c31"
      unitRef="USD">10113706</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i_2023-03-31"
      decimals="0"
      id="c32"
      unitRef="USD">2991770</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i_2022-12-31"
      decimals="0"
      id="c33"
      unitRef="USD">12408940</us-gaap:MarketableSecuritiesCurrent>
    <dffn:PrepaidExpensesDepositsAndOtherAssets
      contextRef="i_2023-03-31"
      decimals="0"
      id="c34"
      unitRef="USD">767530</dffn:PrepaidExpensesDepositsAndOtherAssets>
    <dffn:PrepaidExpensesDepositsAndOtherAssets
      contextRef="i_2022-12-31"
      decimals="0"
      id="c35"
      unitRef="USD">112406</dffn:PrepaidExpensesDepositsAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="i_2023-03-31"
      decimals="0"
      id="c36"
      unitRef="USD">18404886</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2022-12-31"
      decimals="0"
      id="c37"
      unitRef="USD">22635052</us-gaap:AssetsCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2023-03-31"
      decimals="0"
      id="c40"
      unitRef="USD">971455</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2022-12-31"
      decimals="0"
      id="c41"
      unitRef="USD">1127782</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2023-03-31"
      decimals="0"
      id="c42"
      unitRef="USD">1154475</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="0"
      id="c43"
      unitRef="USD">1289554</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="i_2023-03-31"
      decimals="0"
      id="c44"
      unitRef="USD">2125931</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2022-12-31"
      decimals="0"
      id="c45"
      unitRef="USD">2417336</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2023-03-31"
      id="c47"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2023-03-31"
      id="c48"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2023-03-31"
      decimals="INF"
      id="c50"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c51"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2023-03-31"
      decimals="INF"
      id="c52"
      unitRef="Share">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c53"
      unitRef="Share">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-03-31"
      decimals="INF"
      id="c54"
      unitRef="Share">2040025</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2023-03-31"
      decimals="INF"
      id="c55"
      unitRef="Share">2040025</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c56"
      unitRef="Share">2039557</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c57"
      unitRef="Share">2039557</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i_2023-03-31"
      decimals="0"
      id="c58"
      unitRef="USD">2040</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2022-12-31"
      decimals="0"
      id="c59"
      unitRef="USD">2040</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2023-03-31"
      decimals="0"
      id="c60"
      unitRef="USD">165968961</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2022-12-31"
      decimals="0"
      id="c61"
      unitRef="USD">165847590</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2023-03-31"
      decimals="0"
      id="c62"
      unitRef="USD">-3123</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2022-12-31"
      decimals="0"
      id="c63"
      unitRef="USD">-35375</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-03-31"
      decimals="0"
      id="c64"
      unitRef="USD">-149688923</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2022-12-31"
      decimals="0"
      id="c65"
      unitRef="USD">-145596539</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-03-31"
      decimals="0"
      id="c66"
      unitRef="USD">16278955</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-12-31"
      decimals="0"
      id="c67"
      unitRef="USD">20217716</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2023-03-31"
      decimals="0"
      id="c68"
      unitRef="USD">18404886</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2022-12-31"
      decimals="0"
      id="c69"
      unitRef="USD">22635052</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c73"
      unitRef="USD">1308589</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c74"
      unitRef="USD">2425898</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c75"
      unitRef="USD">2957691</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c76"
      unitRef="USD">2128552</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c77"
      unitRef="USD">-4266281</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c78"
      unitRef="USD">-4554450</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c79"
      unitRef="USD">173897</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c80"
      unitRef="USD">27809</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c81"
      unitRef="USD">-4092384</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c82"
      unitRef="USD">-4526641</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-01-01_2023-03-31"
      decimals="INF"
      id="c84"
      unitRef="USDPerShare">-1.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-01-01_2022-03-31"
      decimals="INF"
      id="c85"
      unitRef="USDPerShare">-2.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-01-01_2023-03-31"
      decimals="INF"
      id="c86"
      unitRef="Share">2039737</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-01-01_2022-03-31"
      decimals="INF"
      id="c87"
      unitRef="Share">2038323</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c89"
      unitRef="USD">-4092384</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c90"
      unitRef="USD">-4526641</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c91"
      unitRef="USD">32252</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c92"
      unitRef="USD">-49658</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c93"
      unitRef="USD">-4060132</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c94"
      unitRef="USD">-4576299</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c97"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c98"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c99"
      unitRef="Share">2038185</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c100"
      unitRef="USD">2038</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c101"
      unitRef="USD">164914540</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c102"
      unitRef="USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c103"
      unitRef="USD">-130005111</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31"
      decimals="0"
      id="c104"
      unitRef="USD">34911467</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c105"
      unitRef="Share">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="0"
      id="c106"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c107"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c108"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c109"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c110"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c111"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c112"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c113"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c114"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c115"
      unitRef="Share">207</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c116"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c117"
      unitRef="USD">278131</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c118"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c119"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c120"
      unitRef="USD">278131</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c122"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c124"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c125"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c126"
      unitRef="USD">-49658</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c127"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c128"
      unitRef="USD">-49658</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="-3"
      id="c130"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c132"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c133"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c134"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c135"
      unitRef="USD">-4526641</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c136"
      unitRef="USD">-4526641</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c137"
      unitRef="Share">10000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="0"
      id="c138"
      unitRef="USD">5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c139"
      unitRef="Share">2038392</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c140"
      unitRef="USD">2038</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c141"
      unitRef="USD">165192671</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c142"
      unitRef="USD">-49658</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c143"
      unitRef="USD">-134531752</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-03-31"
      decimals="0"
      id="c144"
      unitRef="USD">30618299</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c147"
      unitRef="Share">2039557</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c148"
      unitRef="USD">2040</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c149"
      unitRef="USD">165847590</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c150"
      unitRef="USD">-35375</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c151"
      unitRef="USD">-145596539</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2022-12-31"
      decimals="0"
      id="c152"
      unitRef="USD">20217716</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c153"
      unitRef="Share">468</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c154"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c155"
      unitRef="USD">121371</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c156"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c157"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c158"
      unitRef="USD">121371</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c160"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c161"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c162"
      unitRef="USD">32252</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c163"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c164"
      unitRef="USD">32252</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c166"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c167"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c168"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c169"
      unitRef="USD">-4092384</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c170"
      unitRef="USD">-4092384</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c171"
      unitRef="Share">2040025</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c172"
      unitRef="USD">2040</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c173"
      unitRef="USD">165968961</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c174"
      unitRef="USD">-3123</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c175"
      unitRef="USD">-149688923</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2023-03-31"
      decimals="0"
      id="c176"
      unitRef="USD">16278955</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c180"
      unitRef="USD">-4092384</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c181"
      unitRef="USD">-4526641</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c183"
      unitRef="USD">121371</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c184"
      unitRef="USD">278131</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c185"
      unitRef="USD">50578</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c186"
      unitRef="USD">13546</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c188"
      unitRef="USD">655124</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c189"
      unitRef="USD">495903</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c190"
      unitRef="USD">-291405</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c191"
      unitRef="USD">28146</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c192"
      unitRef="USD">-4968120</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c193"
      unitRef="USD">-4729813</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2023-01-01_2023-03-31"
      decimals="-3"
      id="c195"
      unitRef="USD">-0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c196"
      unitRef="USD">22716415</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c197"
      unitRef="USD">9500000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-3"
      id="c198"
      unitRef="USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c199"
      unitRef="USD">9500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c200"
      unitRef="USD">-22716415</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="d_2023-01-01_2023-03-31"
      decimals="-3"
      id="c202"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c203"
      unitRef="USD">5000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2023-01-01_2023-03-31"
      decimals="-3"
      id="c204"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c205"
      unitRef="USD">5000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c206"
      unitRef="USD">4531880</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c207"
      unitRef="USD">-27441228</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2022-12-31"
      decimals="0"
      id="c208"
      unitRef="USD">10113706</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2021-12-31"
      decimals="0"
      id="c209"
      unitRef="USD">37313558</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2023-03-31"
      decimals="0"
      id="c210"
      unitRef="USD">14645586</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2022-03-31"
      decimals="0"
      id="c211"
      unitRef="USD">9872330</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c213"
      unitRef="USD">-32252</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c214"
      unitRef="USD">49658</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NatureOfOperations contextRef="d_2023-01-01_2023-03-31" id="c215">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Organization and Description of Business&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Diffusion Pharmaceuticals Inc., a Delaware corporation, is a biopharmaceutical company that has historically focused on developing novel therapies that may enhance the body&#x2019;s ability to deliver oxygen to areas where it is needed most. The Company&#x2019;s most advanced product candidate, TSC, has been investigated and developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#x2019;s most intractable and difficult-to-treat conditions, including GBM.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:NatureOfOperations>
    <dffn:LiquidityDisclosureTextBlock contextRef="d_2023-01-01_2023-03-31" id="c217">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company has not generated any revenues from product sales and has historically funded operations primarily from the proceeds of public and private offerings of equity, convertible debt, and convertible preferred stock.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;In July 2022, the Company entered into an at-the-market sales agreement (the "2022 Sales Agreement") with BTIG pursuant to which the Company may, from time to time and through BTIG as its agent, sell up to an aggregate of $20.0 million in shares of the Company&#x2019;s common stock by any method permitted that is deemed an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) under the Securities Act. To date, the Company has &lt;span style="-sec-ix-hidden:c220"&gt;not&lt;/span&gt; sold any shares pursuant to the 2022 Sales Agreement.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On October 25, 2022, the Company announced that its Board authorized a thorough review and evaluation of a range of potential strategic opportunities in the interest of enhancing stockholder value, including transactional opportunities such as a merger, joint venture, licensing, sale, or divestiture of assets.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;In the first quarter of 2023, in connection with the ongoing strategic review process and efforts to utilize and preserve assets in a manner that maximizes value for its stockholders, the Company committed to a reduction in force that impacted seven of the Company&#x2019;s thirteen employees. The reduction was a cash preservation measure and impacted employees primarily in the Company&#x2019;s clinical operations function. In connection with the strategic review process and pending its conclusion, the Company has paused significant portions of its TSC development activities, including initiation of the Company&#x2019;s previously announced Phase 2 study of TSC in newly diagnosed GBM patients.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On March 30, 2023, the Company entered into the Merger Agreement with EIP and Merger Sub, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into EIP at the effective time of the Merger, with EIP continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of the Company. The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. As of the date of this Quarterly Report, the Merger remains pending and subject to, among other closing conditions, certain approvals by the Company&#x2019;s stockholders, &#160;and there is no assurance in the Merger or any other transaction will be consummated.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Substantial additional financing will be required by the Company to fund any research and development activities related to the Company's existing or future product candidates, including EIP's product candidates if the Merger is closed. The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third parties, and other strategic alliances and business transactions. However, as of the date of this Quarterly Report, the Company does not have any commitments to obtain additional funds and no assurance can be given that any such financing will be available in the future &#x2014; when needed, in sufficient amounts, on acceptable terms, or at all. If the Company cannot obtain the necessary funding, it may need to, among other things, delay, continue to scale back or eliminate research and development programs, modify its overall development strategy for one or more product candidates (or the Company as a whole) in a manner it would not if sufficient cash resources were available, or cease operations altogether.&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Operations of the Company are subject to certain additional risks and uncertainties as well, and any one or more of these factors could materially affect the Company&#x2019;s financial condition, future operations and liquidity needs. Many of these risks and uncertainties are outside of the Company&#x2019;s control, including the outcome of its ongoing strategic review process and various internal and external factors that may affect the success or failure of the Company's research and development efforts, the length of time and cost of developing and commercializing the Company's current or future product candidates, whether and when any such product candidates become approved drugs, and how significant a drug's market share will be, if approved, among others.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Subject to the outcome and timing of its ongoing strategic review process, and without giving effect to the consummation of the proposed Merger with EIP, the Company currently expect that its existing cash, cash equivalents and marketable securities as of March 31, 2023 are sufficient to fund current operations for at least 12 months following the date of this Quarterly Report.&lt;/p&gt;
</dffn:LiquidityDisclosureTextBlock>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="i_2023-03-31_CounterpartyNameAxis-BtigLlcMember"
      decimals="-7"
      id="c219"
      unitRef="USD">20000000.0</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2023-01-01_2023-03-31" id="c221">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;As of the date of this Quarterly Report, the Summary of Significant Accounting Policies included in the Company's Annual Report have not materially changed, except as set forth below.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information as found in the ASC and ASUs of the FASB, and with the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the SEC. In the opinion of management, the accompanying unaudited interim consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of March 31, 2023, and its results of operations and cash flows for the three months ended March 31, 2023 and 2022. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The unaudited interim consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2022 filed with the SEC as part of the Annual Report.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including cash, cash equivalents, and accounts payable approximate fair value due to the short-term nature of those instruments.&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company considers any highly-liquid investments, such as money market funds, with an original maturity of three months or less to be cash equivalents.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&lt;i&gt;Marketable securities&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company classifies its marketable securities as available-for-sale, which include commercial paper and U.S. government debt securities with original maturities of greater than three months from date of purchase. The Company considers its marketable securities as available for use in current operations, and therefore classifies these securities as current assets on the consolidated balance sheet. These securities are carried at fair value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive loss within stockholders&#x2019; equity. Gains or losses on marketable securities sold will be based on the specific identification method.&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company routinely monitors the difference between cost and the estimated fair value of its investments. Each reporting period, securities with unrealized losses are reviewed to determine whether the decline in fair value requires the recognition of an allowance for credit losses. Factors considered in the review include (i) current market interest rates, (ii) general financial condition of the issuer, (iii) issuer's industry and future business prospects, (iv) issuer's past defaults in principal and interest payments, and (v) the payment structure of the investment and the issuer's ability to make contractual payments on the investment.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&#x2019;s behalf). Costs incurred for research and development are expensed as incurred.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Upfront payments made to third parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the expected dividend yield and the fair value of the Company&#x2019;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;For certain stock option grants, the expected term was estimated using the &#x201c;simplified method&#x201d; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The Company uses the simplified method to estimate the expected term.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;For stock price volatility, the Company uses a combination of its own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes no dividend yield because dividends are not expected to be paid in the near future, which is consistent with the Company&#x2019;s history of not paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the option. The Company accounts for forfeitures in the periods they occur.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;88,252&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;111,891&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;104,047&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;116,564&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested restricted stock awards&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,910&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,182&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;195,209&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;233,637&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments&lt;/i&gt;&#x2014;&lt;i&gt;Credit Losses, Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (Topic 326). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. The Company adopted the guidance using a modified retrospective approach as of January 1, 2023 which resulted in no cumulative-effect adjustment to retained earnings.&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The updated guidance in ASU 2016-13 also amended the previous other-than-temporary impairment (&#x201c;OTTI&#x201d;) model for available-for-sale fixed income securities by requiring the recognition of impairments relating to credit losses through an allowance account and limits the amount of credit loss to the difference between a security&#x2019;s amortized cost basis and its fair value. In addition, the length of time a security has been in an unrealized loss position will no longer impact the determination of whether a credit loss exists. The Company adopted the guidance related to available-for-sale fixed income securities on January 1, 2023 using a prospective transition approach for available-for-sale fixed income securities that were purchased with credit deterioration or had recognized an OTTI write-down prior to the effective date. The effect of the prospective transition approach was to maintain the same amortized cost basis before and after the effective date.&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2023-01-01_2023-03-31" id="c37038561439571">&lt;i&gt;Basis of Presentation&lt;/i&gt;The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information as found in the ASC and ASUs of the FASB, and with the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the SEC. In the opinion of management, the accompanying unaudited interim consolidated financial statements of the Company include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited interim consolidated financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of March 31, 2023, and its results of operations and cash flows for the three months ended March 31, 2023 and 2022. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The unaudited interim consolidated financial statements presented herein do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December 31, 2022 filed with the SEC as part of the Annual Report.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2023-01-01_2023-03-31" id="c260953453310560">&lt;i&gt;Use of Estimates&lt;/i&gt;The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2023-01-01_2023-03-31" id="c496653349819554">&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;The carrying amounts of the Company&#x2019;s financial instruments, including cash, cash equivalents, and accounts payable approximate fair value due to the short-term nature of those instruments.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2023-01-01_2023-03-31" id="c1451237916133946">&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2023-01-01_2023-03-31" id="c127951372828067">&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;The Company considers any highly-liquid investments, such as money market funds, with an original maturity of three months or less to be cash equivalents.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="d_2023-01-01_2023-03-31" id="c1163347336978062">&lt;i&gt;Marketable securities&lt;/i&gt;The Company classifies its marketable securities as available-for-sale, which include commercial paper and U.S. government debt securities with original maturities of greater than three months from date of purchase. The Company considers its marketable securities as available for use in current operations, and therefore classifies these securities as current assets on the consolidated balance sheet. These securities are carried at fair value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive loss within stockholders&#x2019; equity. Gains or losses on marketable securities sold will be based on the specific identification method.The Company routinely monitors the difference between cost and the estimated fair value of its investments. Each reporting period, securities with unrealized losses are reviewed to determine whether the decline in fair value requires the recognition of an allowance for credit losses. Factors considered in the review include (i) current market interest rates, (ii) general financial condition of the issuer, (iii) issuer's industry and future business prospects, (iv) issuer's past defaults in principal and interest payments, and (v) the payment structure of the investment and the issuer's ability to make contractual payments on the investment.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2023-01-01_2023-03-31" id="c227282049721951">&lt;i&gt;Research and Development&lt;/i&gt;Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&#x2019;s behalf). Costs incurred for research and development are expensed as incurred.Upfront payments made to third parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LegalCostsPolicyTextBlock contextRef="d_2023-01-01_2023-03-31" id="c816531795414716">&lt;i&gt;Patent Costs&lt;/i&gt;Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations and comprehensive loss.</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2023-01-01_2023-03-31" id="c1032028848819100">&lt;i&gt;Stock-based Compensation&lt;/i&gt;The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the expected dividend yield and the fair value of the Company&#x2019;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.For certain stock option grants, the expected term was estimated using the &#x201c;simplified method&#x201d; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. The Company uses the simplified method to estimate the expected term.For stock price volatility, the Company uses a combination of its own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes no dividend yield because dividends are not expected to be paid in the near future, which is consistent with the Company&#x2019;s history of not paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the option. The Company accounts for forfeitures in the periods they occur.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2023-01-01_2023-03-31" id="c713833990570218">&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;88,252&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;111,891&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;104,047&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;116,564&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested restricted stock awards&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,910&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,182&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;195,209&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;233,637&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2023-01-01_2023-03-31" id="c263">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;88,252&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;111,891&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;104,047&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;116,564&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Unvested restricted stock awards&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,910&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,182&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;195,209&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;233,637&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c265"
      unitRef="Share">88252</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c266"
      unitRef="Share">111891</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c267"
      unitRef="Share">104047</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c268"
      unitRef="Share">116564</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember"
      decimals="INF"
      id="c269"
      unitRef="Share">2910</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember"
      decimals="INF"
      id="c270"
      unitRef="Share">5182</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2023-01-01_2023-03-31"
      decimals="INF"
      id="c271"
      unitRef="Share">195209</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2022-01-01_2022-03-31"
      decimals="INF"
      id="c272"
      unitRef="Share">233637</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2023-01-01_2023-03-31" id="c1331704437450428">&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial Instruments&lt;/i&gt;&#x2014;&lt;i&gt;Credit Losses, Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (Topic 326). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will no longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. The Company adopted the guidance using a modified retrospective approach as of January 1, 2023 which resulted in no cumulative-effect adjustment to retained earnings.
&lt;div class="PGFTR" style="text-align: center; width: 100%"&gt;
&lt;div class="hf-row"&gt;
&lt;div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;"&gt;8&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;

&lt;hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/&gt;
&lt;div class="PGHDR" style="width: 100%;"&gt;
&lt;div class="hf-row"&gt;
&lt;div class="hf-cell TOCLink" style="text-align: left; margin: 0pt; width: 99.9%; display: inline-block;"&gt;&#160;&lt;/div&gt;
&lt;/div&gt;

&lt;div class="hf-row"&gt;
&lt;div class="hf-cell" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;"&gt;DIFFUSION PHARMACEUTICALS INC.&lt;/div&gt;
&lt;/div&gt;

&lt;div class="hf-row"&gt;
&lt;div class="hf-cell" style="margin: 0pt; width: 99.9%; display: inline-block;"&gt;&#160;&lt;/div&gt;
&lt;/div&gt;

&lt;div class="hf-row"&gt;
&lt;div class="hf-cell" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center; font-weight: bold; margin: 0pt; width: 99.9%; display: inline-block;"&gt;NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
The updated guidance in ASU 2016-13 also amended the previous other-than-temporary impairment (&#x201c;OTTI&#x201d;) model for available-for-sale fixed income securities by requiring the recognition of impairments relating to credit losses through an allowance account and limits the amount of credit loss to the difference between a security&#x2019;s amortized cost basis and its fair value. In addition, the length of time a security has been in an unrealized loss position will no longer impact the determination of whether a credit loss exists. The Company adopted the guidance related to available-for-sale fixed income securities on January 1, 2023 using a prospective transition approach for available-for-sale fixed income securities that were purchased with credit deterioration or had recognized an OTTI write-down prior to the effective date. The effect of the prospective transition approach was to maintain the same amortized cost basis before and after the effective date.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="d_2023-01-01_2023-03-31" id="c273">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;4. &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Cash, cash equivalents and marketable securities &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The following is a summary of the Company's cash and cash equivalents as of the date indicated:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;March 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;December 31, 2022&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash in banking institutions&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;631,002&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,586,920&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money market funds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,014,584&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,526,786&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,645,586&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10,113,706&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The following is a summary of the Company's marketable securities as of as of the date indicated:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Amortized cost&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Unrealized gains&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Unrealized losses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Fair Value&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,995,318&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;210&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,437&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,994,091&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;999,575&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,896&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;997,679&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,994,893&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;210&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,333&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,991,770&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,445,220&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;263&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(21,313&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,424,170&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,999,095&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(14,325&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,984,770&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,444,315&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;263&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(35,638&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,408,940&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company's marketable securities generally have contractual maturity dates between 7 and 30 months.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;As of March 31, 2023, $1,991,770 of the marketable securities held were in an unrealized loss position, all of which have been in an unrealized loss position for less than twelve months. The Company determined that unrealized losses on marketable securities were primarily due to market conditions, including changes in the U.S. Federal Reserve interest rate, and not credit losses. The Company does not intend to sell the investments and it is not more likely than not that that the Company will be required to sell the investments before the recovery of the amortized cost basis. No allowance for credit losses related to any of these securities was recorded for the three months ended March 31, 2023.&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="d_2023-01-01_2023-03-31" id="c316">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;March 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;December 31, 2022&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash in banking institutions&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;631,002&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,586,920&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Money market funds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,014,584&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,526,786&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,645,586&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;10,113,706&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-BankTimeDepositsMember"
      decimals="0"
      id="c318"
      unitRef="USD">631002</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-BankTimeDepositsMember"
      decimals="0"
      id="c319"
      unitRef="USD">1586920</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember"
      decimals="0"
      id="c320"
      unitRef="USD">14014584</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember"
      decimals="0"
      id="c321"
      unitRef="USD">8526786</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2023-03-31"
      decimals="0"
      id="c322"
      unitRef="USD">14645586</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2022-12-31"
      decimals="0"
      id="c323"
      unitRef="USD">10113706</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="d_2023-01-01_2023-03-31" id="c324">
&lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Amortized cost&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Unrealized gains&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Unrealized losses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;Fair Value&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;&lt;b&gt;March 31, 2023&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,995,318&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;210&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,437&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,994,091&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;999,575&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,896&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;997,679&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,994,893&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;210&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,333&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,991,770&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;&lt;b&gt;December 31, 2022&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 11%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,445,220&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;263&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(21,313&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,424,170&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;U.S. treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,999,095&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(14,325&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,984,770&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 44%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,444,315&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;263&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(35,638&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 11%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,408,940&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2023-03-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c327"
      unitRef="USD">1995318</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2023-03-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c328"
      unitRef="USD">210</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2023-03-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c329"
      unitRef="USD">1437</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-03-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c330"
      unitRef="USD">1994091</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2023-03-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c331"
      unitRef="USD">999575</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2023-03-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c332"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2023-03-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c333"
      unitRef="USD">1896</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-03-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c334"
      unitRef="USD">997679</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2023-03-31"
      decimals="0"
      id="c335"
      unitRef="USD">2994893</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2023-03-31"
      decimals="0"
      id="c336"
      unitRef="USD">210</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2023-03-31"
      decimals="0"
      id="c337"
      unitRef="USD">3333</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-03-31"
      decimals="0"
      id="c338"
      unitRef="USD">2991770</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c340"
      unitRef="USD">9445220</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c341"
      unitRef="USD">263</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c342"
      unitRef="USD">21313</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c343"
      unitRef="USD">9424170</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c344"
      unitRef="USD">2999095</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c345"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c346"
      unitRef="USD">14325</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c347"
      unitRef="USD">2984770</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2022-12-31"
      decimals="0"
      id="c348"
      unitRef="USD">12444315</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2022-12-31"
      decimals="0"
      id="c349"
      unitRef="USD">263</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2022-12-31"
      decimals="0"
      id="c350"
      unitRef="USD">35638</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31"
      decimals="0"
      id="c351"
      unitRef="USD">12408940</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <dffn:MarketableSecuritiesContractualMaturity
      contextRef="d_2023-01-01_2023-03-31_RangeAxis-MinimumMember"
      id="c307">P7M</dffn:MarketableSecuritiesContractualMaturity>
    <dffn:MarketableSecuritiesContractualMaturity
      contextRef="d_2023-01-01_2023-03-31_RangeAxis-MaximumMember"
      id="c308">P30M</dffn:MarketableSecuritiesContractualMaturity>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i_2023-03-31"
      decimals="0"
      id="c311"
      unitRef="USD">1991770</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2023-01-01_2023-03-31" id="c352">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;5. &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;Fair Value of Financial Instruments &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;

		&lt;tbody&gt;&lt;tr&gt;
			&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align:top;width:18pt;"&gt;
			&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align:top;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;

		&lt;tbody&gt;&lt;tr&gt;
			&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align:top;width:18pt;"&gt;
			&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align:top;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;"&gt;

		&lt;tbody&gt;&lt;tr&gt;
			&lt;td style="width:18pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align:top;width:18pt;"&gt;
			&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#x2022;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align:top;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The following table presents the Company&#x2019;s assets that are measured at fair value on a recurring basis (amounts in thousands):&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair value measurement at reporting date&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Quoted prices in &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;active markets for &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;identical assets &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level &lt;b&gt;1)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant other &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;observable inputs&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level &lt;b&gt;2)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;unobservable inputs &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level &lt;b&gt;3)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt;March 31, 2023&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;Cash equivalents:&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Money market funds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;14,014,584&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total cash and cash equivalents&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,014,584&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;Marketable securities:&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,994,090&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US treasury&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;997,680&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total marketable securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,991,770&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total financial assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,014,584&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,991,770&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;December 31, 2022:&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;Cash equivalents:&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Money market funds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8,526,786&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total cash and cash equivalents&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,526,786&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;Marketable securities:&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,424,170&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US treasury&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,984,770&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total marketable securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,408,940&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total financial assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,526,786&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,408,940&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The fair values of the Company&#x2019;s Level 2 marketable securities are estimated primarily based on benchmark yields, reported trades, market-based quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications, which represent a market approach. In general, a market approach is utilized if there is readily available and relevant market activity for an individual security. This valuation technique may change from period to period, based on the relevance and availability of market data.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="d_2023-01-01_2023-03-31" id="c402">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair value measurement at reporting date&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Quoted prices in &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;active markets for &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;identical assets &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level &lt;b&gt;1)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant other &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;observable inputs&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level &lt;b&gt;2)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Significant &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;unobservable inputs &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(Level &lt;b&gt;3)&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"&gt;March 31, 2023&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;Cash equivalents:&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Money market funds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;14,014,584&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total cash and cash equivalents&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;14,014,584&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;Marketable securities:&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,994,090&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US treasury&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;997,680&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total marketable securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,991,770&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total financial assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,014,584&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,991,770&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;December 31, 2022:&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;Cash equivalents:&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Money market funds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8,526,786&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total cash and cash equivalents&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,526,786&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;Marketable securities:&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,424,170&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US treasury&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,984,770&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total marketable securities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,408,940&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total financial assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,526,786&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,408,940&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c406"
      unitRef="USD">14014584</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c407"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c409"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-03-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c410"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c412"
      unitRef="USD">14014584</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c413"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c416"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c417"
      unitRef="USD">1994090</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c419"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c420"
      unitRef="USD">997680</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c422"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c423"
      unitRef="USD">2991770</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c425"
      unitRef="USD">14014584</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c426"
      unitRef="USD">2991770</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c430"
      unitRef="USD">8526786</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c431"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c433"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c434"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c436"
      unitRef="USD">8526786</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c437"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c440"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c441"
      unitRef="USD">9424170</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c443"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c444"
      unitRef="USD">2984770</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c446"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c447"
      unitRef="USD">12408940</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c449"
      unitRef="USD">8526786</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2022-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c450"
      unitRef="USD">12408940</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="d_2023-01-01_2023-03-31" id="c452">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Accrued Expenses and Other Current Liabilities&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;"&gt;Accrued expenses and other current liabilities consisted of the following as of the dates indicated below:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;March 31, &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued payroll and payroll related expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;302,085&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;131,777&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued professional fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;734,371&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;552,785&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued clinical studies expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16,745&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;475,141&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;101,274&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;129,851&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,154,475&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,289,554&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="d_2023-01-01_2023-03-31" id="c464">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;March 31, &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued payroll and payroll related expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;302,085&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;131,777&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued professional fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;734,371&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;552,785&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accrued clinical studies expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16,745&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;475,141&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;101,274&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;129,851&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,154,475&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,289,554&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i_2023-03-31"
      decimals="0"
      id="c466"
      unitRef="USD">302085</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i_2022-12-31"
      decimals="0"
      id="c467"
      unitRef="USD">131777</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2023-03-31"
      decimals="0"
      id="c468"
      unitRef="USD">734371</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2022-12-31"
      decimals="0"
      id="c469"
      unitRef="USD">552785</us-gaap:AccruedProfessionalFeesCurrent>
    <dffn:AccruedClinicalStudiesExpensesCurrent
      contextRef="i_2023-03-31"
      decimals="0"
      id="c470"
      unitRef="USD">16745</dffn:AccruedClinicalStudiesExpensesCurrent>
    <dffn:AccruedClinicalStudiesExpensesCurrent
      contextRef="i_2022-12-31"
      decimals="0"
      id="c471"
      unitRef="USD">475141</dffn:AccruedClinicalStudiesExpensesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i_2023-03-31"
      decimals="0"
      id="c472"
      unitRef="USD">101274</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="0"
      id="c473"
      unitRef="USD">129851</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2023-03-31"
      decimals="0"
      id="c474"
      unitRef="USD">1154475</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2022-12-31"
      decimals="0"
      id="c475"
      unitRef="USD">1289554</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2023-01-01_2023-03-31" id="c476">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Stockholders' Equity and Common Stock Warrants&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;As of March 31, 2023, the Company had the following warrants outstanding to acquire shares of its common stock:&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Range of exercise &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;price per share&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Expiration dates&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the May 2019 common stock offering&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27,648&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$250.09&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$306.04&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;May and December 2024&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the November 2019 common stock offering&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,269&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;$17.51&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;May 2024&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the December 2019 common stock offering&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,264&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$21.68&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$34.92&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;December 2024 and June 2025&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the May 2020 common stock offering&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,424&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;$65.65&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;March 2025&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the May 2020 investor warrant exercise&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,998&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;$29.7&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;November 2025&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the February 2021 common stock offering&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;33,649&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;$64.08&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;February 2026&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;88,252&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 18%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;During the three months ended March 31, 2023, 23,639 warrants expired.&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2023-01-01_2023-03-31" id="c503">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Range of exercise &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;price per share&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;Expiration dates&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the May 2019 common stock offering&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;27,648&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$250.09&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$306.04&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;May and December 2024&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the November 2019 common stock offering&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,269&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;$17.51&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;May 2024&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the December 2019 common stock offering&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,264&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$21.68&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;-&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$34.92&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;December 2024 and June 2025&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the May 2020 common stock offering&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11,424&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;$65.65&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;March 2025&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the May 2020 investor warrant exercise&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;4,998&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;$29.7&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;November 2025&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants issued related to the February 2021 common stock offering&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;33,649&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;$64.08&lt;/td&gt;
			&lt;td style="width: 5%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;February 2026&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 50%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;88,252&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 5%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 18%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember"
      decimals="INF"
      id="c505"
      unitRef="Share">27648</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c506"
      unitRef="USDPerShare">250.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c508"
      unitRef="USDPerShare">306.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember"
      decimals="INF"
      id="c510"
      unitRef="Share">4269</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember"
      decimals="INF"
      id="c511"
      unitRef="USDPerShare">17.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember"
      decimals="INF"
      id="c513"
      unitRef="Share">6264</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c514"
      unitRef="USDPerShare">21.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c516"
      unitRef="USDPerShare">34.92</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember"
      decimals="INF"
      id="c518"
      unitRef="Share">11424</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember"
      decimals="INF"
      id="c519"
      unitRef="USDPerShare">65.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember"
      decimals="INF"
      id="c521"
      unitRef="Share">4998</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember"
      decimals="INF"
      id="c522"
      unitRef="USDPerShare">29.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember"
      decimals="INF"
      id="c524"
      unitRef="Share">33649</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-03-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember"
      decimals="INF"
      id="c525"
      unitRef="USDPerShare">64.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-03-31"
      decimals="INF"
      id="c527"
      unitRef="Share">88252</us-gaap:ClassOfWarrantOrRightOutstanding>
    <dffn:ClassOfWarrantOrRightsExpired
      contextRef="d_2023-01-01_2023-03-31"
      decimals="INF"
      id="c501"
      unitRef="Share">23639</dffn:ClassOfWarrantOrRightsExpired>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2023-01-01_2023-03-31" id="c528">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&lt;i&gt;2015 Equity Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The 2015 Equity Plan provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to 4.0% of the total shares of the Company&#x2019;s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the Company's board of directors. Accordingly, 81,582 shares were added to the reserve as of January 1, 2023, which shares may be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the 2015 Equity Plan. As of March 31, 2023, there were 141,096 shares available for future issuance under the 2015 Equity Plan.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim consolidated statements of operations and comprehensive loss for the periods indicated:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Three Months Ended &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12,011&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;58,892&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;109,360&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;219,239&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;121,371&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278,131&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The following table summarizes the activity related to all stock option grants for the three months ended March 31, 2023:&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;per share&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;contractual life&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;intrinsic &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at January 1, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;140,040&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;126.75&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cancelled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(35,993&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;20.13&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at March 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;104,047&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;163.64&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable at March 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;78,533&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;211.21&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.75&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested and expected to vest at March 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;104,047&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;163.64&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;There were no options granted during the three months ended March 31, 2023. The total fair value of options vested during the three months ended March 31, 2023 and 2022 was $0.1 million and $0.2 million, respectively. No options were exercised during any of the periods presented. At March 31, 2023, there was $0.4 million of unrecognized compensation expense that will be recognized over a weighted-average period of 1.27 years.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Restricted Stock Unit Awards&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company issues restricted stock ("RSU") to newly elected, non-executive members of the board of directors that vest in six, tri-monthly installments beginning 18 months after the respective grant date. The fair value of an RSU is equal to the fair market value price of the Company&#x2019;s common stock on the date of grant. RSU expense is recorded on a straight-line basis over the service period.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The following table summarizes activity related to RSU awards during the period indicated:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of Units&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted average grant date fair value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at January 1, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,652&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;36.49&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested (1)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(742&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;33.72&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at March 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,910&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;38.28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;(1) The RSUs vested during the three months ended March 31, 2023 were settled on a hybrid basis. The Company withheld 274 shares of common stock and, in lieu of delivering such shares, paid the RSU holder an amount in cash equal to the fair market value of such shares on the vesting date, representing the holder's approximate tax liability associated with the vesting.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company recognized approximately $14,000 and $16,000 in expense related to these awards during the three months ended March 31, 2023 and March 31, 2022, respectively. At March 31, 2023, there was $48,000 in unrecognized compensation cost that will be recognized over a weighted average period of 1.04 years.&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis
      contextRef="d_2023-01-01_2023-03-31_PlanNameAxis-EquityIncentivePlan2015Member"
      decimals="2"
      id="c530"
      unitRef="Pure">0.040</dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2023-01-01_2023-01-01_PlanNameAxis-EquityIncentivePlan2015Member"
      decimals="INF"
      id="c531"
      unitRef="Share">81582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2023-03-31_PlanNameAxis-EquityIncentivePlan2015Member"
      decimals="INF"
      id="c532"
      unitRef="Share">141096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2023-01-01_2023-03-31" id="c573">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Three Months Ended &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;March 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12,011&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;58,892&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;109,360&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;219,239&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;121,371&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;278,131&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="c575"
      unitRef="USD">12011</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="c576"
      unitRef="USD">58892</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="c577"
      unitRef="USD">109360</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="c578"
      unitRef="USD">219239</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c579"
      unitRef="USD">121371</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c580"
      unitRef="USD">278131</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2023-01-01_2023-03-31" id="c581">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;per share&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;contractual life&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;intrinsic &lt;/b&gt;&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at January 1, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;140,040&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;126.75&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cancelled&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(35,993&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;20.13&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at March 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;104,047&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;163.64&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable at March 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;78,533&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;211.21&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.75&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested and expected to vest at March 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;104,047&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;163.64&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;7.99&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c583"
      unitRef="Share">140040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-12-31"
      decimals="INF"
      id="c584"
      unitRef="USDPerShare">126.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-01-01_2023-03-31"
      decimals="-3"
      id="c585"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-01-01_2023-03-31"
      decimals="-3"
      id="c586"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2023-01-01_2023-03-31"
      decimals="INF"
      id="c587"
      unitRef="Share">35993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-01-01_2023-03-31"
      decimals="INF"
      id="c588"
      unitRef="USDPerShare">20.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-03-31"
      decimals="INF"
      id="c589"
      unitRef="Share">104047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-03-31"
      decimals="INF"
      id="c590"
      unitRef="USDPerShare">163.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2023-01-01_2023-03-31" id="c591">P7Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2023-03-31"
      decimals="-3"
      id="c592"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2023-03-31"
      decimals="INF"
      id="c593"
      unitRef="Share">78533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2023-03-31"
      decimals="INF"
      id="c594"
      unitRef="USDPerShare">211.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2023-01-01_2023-03-31" id="c595">P7Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i_2023-03-31"
      decimals="-3"
      id="c596"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2023-03-31"
      decimals="INF"
      id="c597"
      unitRef="Share">104047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-03-31"
      decimals="INF"
      id="c598"
      unitRef="USDPerShare">163.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2023-01-01_2023-03-31" id="c599">P7Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i_2023-03-31"
      decimals="-3"
      id="c600"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2023-01-01_2023-03-31"
      decimals="-5"
      id="c557"
      unitRef="USD">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2022-01-01_2022-03-31"
      decimals="-5"
      id="c558"
      unitRef="USD">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2023-03-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c559"
      unitRef="USD">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c560">P1Y3M7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      id="c561">P18M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="d_2023-01-01_2023-03-31" id="c601">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of Units&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted average grant date fair value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at January 1, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,652&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;36.49&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Vested (1)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(742&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;33.72&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;
			&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at March 31, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,910&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;38.28&lt;/td&gt;
			&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c603"
      unitRef="Share">3652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c604"
      unitRef="USDPerShare">36.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c605"
      unitRef="Share">742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c606"
      unitRef="USDPerShare">33.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c607"
      unitRef="Share">2910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c608"
      unitRef="USDPerShare">38.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="d_2022-01-01_2022-03-31"
      decimals="INF"
      id="c568"
      unitRef="Share">274</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      decimals="0"
      id="c569"
      unitRef="USD">14000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-01-01_2022-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      decimals="0"
      id="c570"
      unitRef="USD">16000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      decimals="-9"
      id="c571"
      unitRef="USD">48000000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2023-01-01_2023-03-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      id="c572">P1Y14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2023-01-01_2023-03-31" id="c609">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 36pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&lt;i&gt;Office Space Lease Commitment&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company has a short term agreement to utilize membership-based co-working space in Charlottesville, Virginia and was previously party to a second, similar agreement for co-working space in Philadelphia, Pennsylvania, which was terminated during the year ended December 31, 2022. Rent expense related to the Company's short-term agreements was approximately $1,000 and $9,000 for the three months ended March 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&lt;i&gt;Research and Development Arrangements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Prior to the strategic review process and entry into the Merger Agreement with EIP, in the course of normal business operations, the Company entered into agreements with universities and CROs to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of cash.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&lt;i&gt;Defined Contribution Retirement Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company has established its 401(k) Plan, which covers all employees who qualify under the terms of the plan. Eligible employees may elect to contribute to the 401(k) Plan up to 90% of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of 4% of the participant&#x2019;s compensation. The Company made matching contributions under the 401(k) Plan of approximately $26,000 and $27,000 for the three months ended March 31, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;"&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company&#x2019;s legal predecessor under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp;amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#x2019; fees and costs. On December 30, 2014, the Company filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to the Company&#x2019;s petition to compel arbitration and a motion to stay the action. After a related hearing on April 14, 2015, the court granted the Company&#x2019;s petition to compel arbitration and a motion to stay the action. On January 8, 2016, the plaintiff filed an arbitration demand with the American Arbitration Association. On November 19, 2018 at an Order to Show Cause Re Dismissal Hearing, the court found sufficient grounds not to dismiss the case and an arbitration hearing was scheduled, originally for November 2020 but later postponed due to the COVID-19 pandemic and related restrictions on gatherings in the State of California. In addition, following the November 2018 hearing, an automatic stay was placed on the arbitration in connection with the plaintiff filing for personal bankruptcy protection. On October 22, 2021, following a determination by the bankruptcy trustee not to pursue the claims and release them back to the plaintiff, the parties entered into a stipulation to abandon arbitration and return the matter to state court. A case management conference was held on February 23, 2022 at which an initial trial date of May 24, 2023 was set, following which the parties agreed to stipulate to mediation in advance of the trial. On October 20, 2022, the parties filed a joint stipulation to continue the trial and certain deadlines related to the mediation in order to allow plaintiff's counsel to continue to seek treatment for an ongoing medical issue. On November 1, 2022, based on the parties joint stipulation, the court entered an order continuing the trial date to October 25, 2023.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company believes the claims in this matter are without merit and is defending itself vigorously. However, at this stage, the Company is unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on the Company&#x2019;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&#x2019;s consolidated financial position, results of operations and cash flows.&lt;/p&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c611"
      unitRef="USD">1000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c612"
      unitRef="USD">9000</us-gaap:OperatingLeaseExpense>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="d_2023-01-01_2023-03-31"
      decimals="1"
      id="c613"
      unitRef="Pure">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="d_2023-01-01_2023-03-31"
      decimals="2"
      id="c614"
      unitRef="Pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2023-01-01_2023-03-31"
      decimals="0"
      id="c615"
      unitRef="USD">26000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2022-01-01_2022-03-31"
      decimals="0"
      id="c616"
      unitRef="USD">27000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc xlink:href="#c605" xlink:label="c605" xlink:type="locator"/>
        <link:loc xlink:href="#c606" xlink:label="c606" xlink:type="locator"/>
        <link:footnote id="fe94240fc-b4f2-44ab-a6ef-b62420724a17" xlink:label="fe94240fc-b4f2-44ab-a6ef-b62420724a17" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">The RSUs vested during the three months ended March 31, 2023 were settled on a hybrid basis. The Company withheld 274 shares of common stock and, in lieu of delivering such shares, paid the RSU holder an amount in cash equal to the fair market value of such shares on the vesting date, representing the holder's approximate tax liability associated with the vesting.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c605"
          xlink:to="fe94240fc-b4f2-44ab-a6ef-b62420724a17"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c606"
          xlink:to="fe94240fc-b4f2-44ab-a6ef-b62420724a17"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M^"A<&BEL]S]9F^W#FKD:S"[0=MM&K&/8)ESZ)FPW.W?<AWR-YSRQ^8H](H3
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M_-*44![G^ZBG%T7?1-W10<!O3(Y(%'XB-*"1@\_\_>ET@$[4CW%D\:(+>-U
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MOIE5C;WR] X.MPJF-M69GT:5\*Y/C=J[[;GB776:=G+_'M\LZ]/!SDU]6/E
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M0Q<VL+VPW /VD^!@>!27/P%02P,$%     @ RD*O5GH>@L:("0  )Q<  !@
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MQCOP1:DI00=4 "P^"4?V"#T%+D6+LD#.3L=+S"V]D91B=0\"I4%%&N3<2JX
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MYVL63Y.,W,';5OW([(4B8D5P/;*B7Y AT068^)KR9U+0W(Y7HL1;@/$UV>S
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MD6T/; =:U+;O+(7&+F8?"_S; -($X/N5P!NW&QB!_H_(_#=02P,$%     @
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M)N#Y2N,5OKDA!]TGK,N_ %!+ P04    " #*0J]6^4BB?"@*  #T%P  &0
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M8INF,",T)*1HMVQA(#G)!UX27KI&P+KP7B,!DBU7WK"F9'B('O:L#5(+^(.
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M^0#^7C@$J7M@!<.'_O/_ %!+ P04    " #*0J]6;"#0=#X$  #<#0  &0
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MK;+4\.VRI F+VCF0O5#T^OJ-NV"8V:O?4$L#!!0    ( ,I"KU:"!/D5@P,
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MF7JY1RI8\:XVG^7^(QSB<01+66OW)?O^;)IYI.RTD<T!C P:T?;__/F0AQ-
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M@/*;D,911MX>5)CQ(AP]CA=C8M"/[M0+64I;C*(H:)(EY/6KG(7LG07F18K
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M-#J>'-JJ<>*VZG?3$\5^$H[]2?)+^=G7=L@3#MUBP5[7(9$;UULUI+(6IFE
MW6K7OL^:KO5DWO1^VKT-%QH*7)-K>#H:>*":?MI,C*Q<#UM)0QW1#7/Z!$%E
M#>C]6M*-TTYL@.ZC9O$O4$L#!!0    ( ,I"KU8CSF#1J@(  ,P%   9
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MUUARW9<U5K2SDJKDAJ8J#W2MD&=.J2P"%H9)4')1>?.I6[M5\ZG<F$)4>*M
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MNU?(57/Y_B?>/&'(=TYM 06N2#4D*GF@FF=!,S&R=E?Q4AJZV-UP32\I5%:
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MNVB5!6\HTZ>>HM _08$7A /PR7[X%/(>'NS"79VC/E%!GZC \D5O\/5F<S.
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M0F\X0PQ?WQ]/0H<Q%$VQO-\$&&W ?K\^VNCFS@HQ_PI\G2L#?@5>,1?R,HE
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MQT]*5)VLFBA>FF:PX I;BQDFV/Q!Z #<7W)L"/5$OZ#Y.Q'^ U!+ P04
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MA0,4E#7 ^X7$IEIM[ /U2([_ %!+ P04    " #*0J]61V\2=2X#   *$P
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MOYYG7U!+ 0(4 Q0    ( ,I"KU8'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ RD*O5A+E&97N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ RD*O5IE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " #*0J]68[;6/O8%   7'P  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ RD*O5H9C.\*N!   T!   !@              ("!.0X  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,I"KU8/@J+-:P(  ((&
M   8              " @1T3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    " #*0J]6NEG,\!H$  #_#0  &               @(&^%0
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ RD*O5HC(YYU*
M!@  &28  !@              ("!#AH  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( ,I"KU8 Q4K39 4  )$5   8              "
M@8X@  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #*0J]6
M9!I]ZEP#   @!P  &               @($H)@  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ RD*O5GH>@L:("0  )Q<  !@
M     ("!NBD  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M ,I"KU8_//E?$@\  .LI   8              " @7@S  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    " #*0J]6]0-B"M\$  !+"P  &0
M            @(' 0@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( ,I"KU8?D6!4X 8  '<1   9              " @=9'  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ RD*O5FXZ/JS[ @
MH@8  !D              ("![4X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    " #*0J]6CVG:=V@#  "4"   &0              @($?
M4@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,I"KU8K
MOVW7GP<  ,X2   9              " @;Y5  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ RD*O5OE(HGPH"@  ]!<  !D
M     ("!E%T  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,I"KU8CSF#1J@(  ,P%   9              "
M@;9V  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ RD*O
M5D8)FZ,K P  W <  !D              ("!EWD  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    " #*0J]6*3N7IN,#  "G"0  &0
M        @('Y?   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( ,I"KU;<;DK.8P(  .@$   9              " @1.!  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ RD*O5M'?24T? P  '0H
M !D              ("!K8,  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    " #*0J]6CDL$9Y\"  #C!@  &0              @($#AP
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,I"KU:N@PTP
MD@(  (L'   9              " @=F)  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ RD*O5M_D[#/# P  %P\  !D
M ("!HHP  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #*
M0J]67QB!2]($   7'0  &0              @(&<D   >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,I"KU9*+O71D (  -P&   9
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M970S,RYX;6Q02P$"% ,4    " #*0J]6:"86$J #  "]#@  &0
M    @('7IP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M ,I"KU;H(9X&O ,  #4*   9              " @:ZK  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ RD*O5I!'.%_3 @  G@<  !D
M             ("!H:\  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    " #*0J]61V\2=2X#   *$P  #0              @ &KL@  >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,I"KU:7BKL<P    !,"   +
M      "  02V  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,I"KU8+!QK:>0,
M /08   /              "  >VV  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " #*0J]6UOKYL7@!   #%@  &@              @ &3N@  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #*0J]6ZXBZY94!  ""
M%@  $P              @ %#O   6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    +  L .L+   )O@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>97</ContextCount>
  <ElementCount>154</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business</Role>
      <ShortName>Note 1 - Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity</Role>
      <ShortName>Note 2 - Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities</Role>
      <ShortName>Note 4 - Cash, Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments</Role>
      <ShortName>Note 5 - Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities</Role>
      <ShortName>Note 6 - Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants</Role>
      <ShortName>Note 7 - Stockholders' Equity and Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8- Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation</Role>
      <ShortName>Note 8- Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-</Role>
      <ShortName>Note 9 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables</Role>
      <ShortName>Note 4 - Cash, Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 5 - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables</Role>
      <ShortName>Note 5 - Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables</Role>
      <ShortName>Note 6 - Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables</Role>
      <ShortName>Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 8- Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables</Role>
      <ShortName>Note 8- Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 2 - Liquidity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual</Role>
      <ShortName>Note 2 - Liquidity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual</Role>
      <ShortName>Note 4 - Cash, Cash Equivalents and Marketable Securities (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details</Role>
      <ShortName>Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details</Role>
      <ShortName>Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details</Role>
      <ShortName>Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details</Role>
      <ShortName>Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual</Role>
      <ShortName>Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details</Role>
      <ShortName>Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 8- Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual</Role>
      <ShortName>Note 8- Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details</Role>
      <ShortName>Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 8 - Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details</Role>
      <ShortName>Note 8 - Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details</Role>
      <ShortName>Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dffn20230331_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 9 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:StockIssuedDuringPeriodSharesNewIssues -  dffn20230331_10q.htm 13</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="dffn20230331_10q.htm">dffn20230331_10q.htm</File>
    <File>dffn-20230331.xsd</File>
    <File>dffn-20230331_cal.xml</File>
    <File>dffn-20230331_def.xml</File>
    <File>dffn-20230331_lab.xml</File>
    <File>dffn-20230331_pre.xml</File>
    <File>ex_518005.htm</File>
    <File>ex_518006.htm</File>
    <File>ex_518007.htm</File>
    <File>ex_518008.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>dffn20230331_10qimg001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="324">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>55
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dffn20230331_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 324,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "contextCount": 97,
   "dts": {
    "calculationLink": {
     "local": [
      "dffn-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dffn-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "dffn20230331_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dffn-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dffn-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dffn-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    }
   },
   "elementCount": 254,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 1,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 6
   },
   "keyCustom": 6,
   "keyStandard": 148,
   "memberCustom": 9,
   "memberStandard": 21,
   "nsprefix": "dffn",
   "nsuri": "http://www.diffusionpharma.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
     "shortName": "Note 4 - Cash, Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 5 - Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
     "shortName": "Note 5 - Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
     "shortName": "Note 6 - Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
     "shortName": "Note 7 - Stockholders' Equity and Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 8- Stock-based Compensation",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
     "shortName": "Note 8- Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 9 - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-",
     "shortName": "Note 9 - Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "16",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
     "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
     "shortName": "Note 4 - Cash, Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 5 - Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables",
     "shortName": "Note 5 - Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets (Unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
     "shortName": "Note 6 - Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
     "shortName": "Note 7 - Stockholders' Equity and Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 8- Stock-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables",
     "shortName": "Note 8- Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "dffn:LiquidityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31_CounterpartyNameAxis-BtigLlcMember",
      "decimals": "-7",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesSubscriptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 2 - Liquidity (Details Textual)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual",
     "shortName": "Note 2 - Liquidity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "dffn:LiquidityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31_CounterpartyNameAxis-BtigLlcMember",
      "decimals": "-7",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesSubscriptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
     "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities (Details Textual)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
     "shortName": "Note 4 - Cash, Cash Equivalents and Marketable Securities (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
     "shortName": "Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31_CashAndCashEquivalentsAxis-BankTimeDepositsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
     "shortName": "Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
     "shortName": "Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
     "shortName": "Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "dffn:ClassOfWarrantOrRightsExpired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
     "shortName": "Note 7 - Stockholders' Equity and Common Stock Warrants (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "dffn:ClassOfWarrantOrRightsExpired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
     "shortName": "Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2023-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 8- Stock-based Compensation (Details Textual)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual",
     "shortName": "Note 8- Stock-based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
     "shortName": "Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 8 - Stock-based Compensation - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details",
     "shortName": "Note 8 - Stock-based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2022-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
     "shortName": "Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual",
     "shortName": "Note 9 - Commitments and Contingencies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Note 1 - Organization and Description of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business",
     "shortName": "Note 1 - Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dffn:LiquidityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 2 - Liquidity",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity",
     "shortName": "Note 2 - Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dffn:LiquidityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
     "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20230331_10q.htm",
      "contextRef": "d_2023-01-01_2023-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 31,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "dei_CityAreaCode",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "dei_DocumentType",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "dei_EntityCommonStockSharesOutstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "dei_EntityCurrentReportingStatus",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information",
      "http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-",
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "dei_EntityFileNumber",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "dei_EntityInteractiveDataCurrent",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "dei_EntityRegistrantName",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "dei_EntityShellCompany",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information",
      "http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-",
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "dei_LocalPhoneNumber",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dffn_AccruedClinicalStudiesExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.",
        "label": "dffn_AccruedClinicalStudiesExpensesCurrent",
        "terseLabel": "Accrued clinical studies expenses"
       }
      }
     },
     "localname": "AccruedClinicalStudiesExpensesCurrent",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_BtigLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents BTIG, LLC",
        "label": "BTIG, LLC [Member]"
       }
      }
     },
     "localname": "BtigLlcMember",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_ClassOfWarrantOrRightsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights expired.",
        "label": "dffn_ClassOfWarrantOrRightsExpired",
        "terseLabel": "Class of Warrant or Rights, Expired"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsExpired",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "dffn_EquityIncentivePlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the 2015 equity incentive plan.",
        "label": "Equity Incentive Plan 2015 [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2015Member",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_LiquidityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the liquidity of the company.",
        "label": "Liquidity Disclosure [Text Block]"
       }
      }
     },
     "localname": "LiquidityDisclosureTextBlock",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dffn_MarketableSecuritiesContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contractual maturity of marketable securities.",
        "label": "dffn_MarketableSecuritiesContractualMaturity",
        "terseLabel": "Marketable Securities Contractual Maturity (Month)"
       }
      }
     },
     "localname": "MarketableSecuritiesContractualMaturity",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "dffn_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.",
        "label": "dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis",
        "terseLabel": "Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis"
       }
      }
     },
     "localname": "PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "dffn_PrepaidExpensesDepositsAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses, deposits and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesDepositsAndOtherAssets",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_TheMay2020InvestorWarrantExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the May 2020 Investor Warrant Exercise.",
        "label": "The May 2020 Investor Warrant Exercise [Member]"
       }
      }
     },
     "localname": "TheMay2020InvestorWarrantExerciseMember",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_TheMay2020OfferingWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the May 2020 offering warrants.",
        "label": "The May 2020 Offering Warrants [Member]"
       }
      }
     },
     "localname": "TheMay2020OfferingWarrantsMember",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants issued to designees of the underwriter in connection with the February 2021 common stock offering.",
        "label": "Underwriter Warrants in Connection with the February 2021 Common Stock Offering [Member]"
       }
      }
     },
     "localname": "UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_UnvestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents unvested restricted stock units.",
        "label": "Unvested Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "UnvestedRestrictedStockUnitsMember",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to warrants issued in connection with May 2019 public offering.",
        "label": "Warrants Issued in Connection with May 2019 Public Offering [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedInConnectionWithMay2019PublicOfferingMember",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the warrants issued in connection to the December 2019 public offering.",
        "label": "Warrants Issued in Connection with the December 2019 Offering [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedInConnectionWithTheDecember2019OfferingMember",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the warrants issued in connection to the November 2019 public offering.",
        "label": "Warrants Issued in Connection with the November 2019 Offering [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedInConnectionWithTheNovember2019OfferingMember",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Cash, Cash Equivalents and Marketable Securities - Cash and Cah Equivalents (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Cash, Cash Equivalents and Marketable Securities - Marketable Securities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Cash, Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "statement-statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-5-fair-value-of-financial-instruments-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "statement-statement-note-5-fair-value-of-financial-instruments-tables",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)"
       }
      }
     },
     "localname": "statement-statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "statement-statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Common Stock Warrants"
       }
      }
     },
     "localname": "statement-statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-8-stockbased-compensation-stock-option-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stock-based Compensation - Stock Option Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockbased-compensation-stock-option-activity-details",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-8-stockbased-compensation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8- Stock-based Compensation"
       }
      }
     },
     "localname": "statement-statement-note-8-stockbased-compensation-tables",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.diffusionpharma.com/20230331",
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r97",
      "r98",
      "r187",
      "r192",
      "r291",
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r466",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r213",
      "r322",
      "r337",
      "r350",
      "r351",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r411",
      "r412",
      "r422",
      "r426",
      "r430",
      "r433",
      "r490",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r213",
      "r322",
      "r337",
      "r350",
      "r351",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r411",
      "r412",
      "r422",
      "r426",
      "r430",
      "r433",
      "r490",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r206",
      "r213",
      "r241",
      "r242",
      "r243",
      "r298",
      "r322",
      "r337",
      "r350",
      "r351",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r411",
      "r412",
      "r422",
      "r426",
      "r430",
      "r433",
      "r436",
      "r486",
      "r490",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r176",
      "r206",
      "r213",
      "r241",
      "r242",
      "r243",
      "r298",
      "r322",
      "r337",
      "r350",
      "r351",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r411",
      "r412",
      "r422",
      "r426",
      "r430",
      "r433",
      "r436",
      "r486",
      "r490",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r187",
      "r192",
      "r291",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r466",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r432"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "us-gaap_AccruedProfessionalFeesCurrent",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r12",
      "r414"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "us-gaap_AccruedSalariesCurrent",
        "terseLabel": "Accrued payroll and payroll related expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r15",
      "r16",
      "r46",
      "r79",
      "r330",
      "r342",
      "r343"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r1",
      "r5",
      "r16",
      "r267",
      "r270",
      "r290",
      "r338",
      "r339",
      "r459",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r41",
      "r432",
      "r535"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r348",
      "r463",
      "r464",
      "r465",
      "r518",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r245",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r77",
      "r80",
      "r96",
      "r156",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r262",
      "r264",
      "r283",
      "r432",
      "r488",
      "r489",
      "r523"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsFairValueDisclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
        "negatedLabel": "Unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r126",
      "r164",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r127",
      "r164",
      "r324",
      "r468"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Fair value",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r18",
      "r78",
      "r413"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r18",
      "r52",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r0",
      "r52"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Common stock warrants issued, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Common stock warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r58",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r491",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r13",
      "r35",
      "r328",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r57",
      "r171",
      "r172",
      "r410",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r463",
      "r464",
      "r518",
      "r533",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r40",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r40",
      "r360",
      "r377",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "auth_ref": [
      "r26",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "us-gaap_CommonStockSharesSubscriptions",
        "terseLabel": "Common Stock, Value, Subscriptions"
       }
      }
     },
     "localname": "CommonStockSharesSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40",
      "r329",
      "r432"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value: 1,000,000,000 shares authorized: 2,040,025 and 2,039,557 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r17",
      "r84",
      "r86",
      "r90",
      "r325",
      "r335"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r37",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r66",
      "r166",
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount",
        "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent",
        "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r214",
      "r215",
      "r246",
      "r247",
      "r249",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share information:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r91",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r112",
      "r113",
      "r115",
      "r116",
      "r117",
      "r119",
      "r275",
      "r276",
      "r326",
      "r336",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share of common stock, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r20",
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r6",
      "r74",
      "r87",
      "r88",
      "r89",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r120",
      "r157",
      "r158",
      "r205",
      "r250",
      "r251",
      "r252",
      "r260",
      "r261",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r338",
      "r339",
      "r340",
      "r348",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r34",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r188",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r279",
      "r295",
      "r296",
      "r297",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r278",
      "r279",
      "r280",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r188",
      "r207",
      "r212",
      "r279",
      "r295",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r188",
      "r207",
      "r212",
      "r279",
      "r296",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r188",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r295",
      "r296",
      "r297",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r277",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r4",
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r165",
      "r167",
      "r168",
      "r189",
      "r202",
      "r272",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r334",
      "r423",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r481",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r50",
      "r381"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r170",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable, accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses, deposits and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "us-gaap_InterestIncomeExpenseNonoperatingNet",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Amortization of premium and discount on marketable securities"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r96",
      "r156",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r263",
      "r264",
      "r265",
      "r283",
      "r358",
      "r420",
      "r444",
      "r488",
      "r523",
      "r524"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r45",
      "r63",
      "r332",
      "r432",
      "r462",
      "r485",
      "r520"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r458"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "us-gaap_MarketableSecuritiesUnrealizedGainLoss",
        "negatedLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r67",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r47",
      "r54",
      "r64",
      "r76",
      "r83",
      "r85",
      "r89",
      "r96",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r110",
      "r111",
      "r114",
      "r121",
      "r122",
      "r123",
      "r124",
      "r156",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r276",
      "r283",
      "r333",
      "r379",
      "r395",
      "r396",
      "r421",
      "r442",
      "r488"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r421"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "negatedTotalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r521"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r81",
      "r82",
      "r155"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Unrealized gain (loss) on marketable securities",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r25"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "us-gaap_OtherSundryLiabilitiesCurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "us-gaap_PaymentsToAcquireMarketableSecurities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441",
      "r533",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r2"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from the sale of series C preferred stock to related parties"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r38",
      "r259",
      "r531"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r42",
      "r60",
      "r331",
      "r341",
      "r343",
      "r346",
      "r361",
      "r432"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r74",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r157",
      "r158",
      "r250",
      "r251",
      "r252",
      "r260",
      "r261",
      "r266",
      "r268",
      "r269",
      "r271",
      "r274",
      "r338",
      "r340",
      "r348",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r7",
      "r8",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodEndLabel": "Outstanding at March 31, 2023 (in shares)",
        "periodStartLabel": "Balance at January 1, 2023 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodEndLabel": "Outstanding at March 31, 2023 (in dollars per share)",
        "periodStartLabel": "Balance at January 1, 2023 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "negatedLabel": "Vested (1) (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Vested (1) (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Exercisable at March 31, 2023 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Exercisable at March 31, 2023 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Outstanding at March 31, 2023"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Balance (in dollars per share)",
        "periodStartLabel": "Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest at March 31, 2023"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest at March 31, 2023 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest at March 31, 2023 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r214",
      "r219",
      "r238",
      "r239",
      "r240",
      "r241",
      "r244",
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Exercisable at March 31, 2023"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Exercisable at March 31, 2023 (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Outstanding at March 31, 2023 (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest at March 31, 2023 (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balance at March 31, 2022 (in shares)",
        "periodStartLabel": "Balance at January 1, 2022 (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation",
        "terseLabel": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r55",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r6",
      "r14",
      "r74",
      "r87",
      "r88",
      "r89",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r111",
      "r120",
      "r157",
      "r158",
      "r205",
      "r250",
      "r251",
      "r252",
      "r260",
      "r261",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r338",
      "r339",
      "r340",
      "r348",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r120",
      "r323",
      "r344",
      "r349",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-",
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r120",
      "r323",
      "r344",
      "r349",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r360",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r380",
      "r381",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r397",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited-parentheticals",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited",
      "http://www.diffusionpharma.com/20230331/role/statement-note-1-organization-and-description-of-business",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-cash-and-cah-equivalents-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-rsu-stockbased-payment-awards-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stock-option-activity-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-",
      "http://www.diffusionpharma.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual",
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r39",
      "r40",
      "r60",
      "r345",
      "r397",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Sale of series C preferred stock to related parties (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity",
      "http://www.diffusionpharma.com/20230331/role/statement-note-2-liquidity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r6",
      "r39",
      "r40",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock-based compensation expense and vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r39",
      "r40",
      "r60",
      "r348",
      "r397",
      "r407",
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Sale of series C preferred stock to related parties"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r6",
      "r39",
      "r40",
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock-based compensation expense and vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r43",
      "r44",
      "r56",
      "r362",
      "r377",
      "r398",
      "r399",
      "r432",
      "r444",
      "r462",
      "r485",
      "r520",
      "r536"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-balance-sheets-unaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r74",
      "r75",
      "r88",
      "r99",
      "r100",
      "r101",
      "r103",
      "r109",
      "r157",
      "r158",
      "r205",
      "r250",
      "r251",
      "r252",
      "r260",
      "r261",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r274",
      "r284",
      "r285",
      "r289",
      "r290",
      "r339",
      "r340",
      "r347",
      "r362",
      "r377",
      "r398",
      "r399",
      "r408",
      "r443",
      "r462",
      "r485",
      "r520",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.",
        "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
        "periodEndLabel": "Balance at March 31, 2022",
        "periodStartLabel": "Balance at January 1, 2022"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-changes-in-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r95",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r205",
      "r273",
      "r400",
      "r401",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-7-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20230331/role/statement-note-8-stockbased-compensation-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r189",
      "r202",
      "r272",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r334",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r481",
      "r482",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r418",
      "r427",
      "r429",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities",
      "http://www.diffusionpharma.com/20230331/role/statement-note-4-cash-cash-equivalents-and-marketable-securities-marketable-securities-details",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20230331/role/statement-note-5-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r68",
      "r69",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r434",
      "r435",
      "r438",
      "r439",
      "r440",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20230331/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r112",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average shares outstanding, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.diffusionpharma.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(4)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r445": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r446": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r447": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r448": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r449": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r451": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org//320/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>56
<FILENAME>0001437749-23-014359-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-23-014359-xbrl.zip
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MMZ.;6;$2A_=@SXJS584!WH0UJI]F/-\@2XSQPVQBWW^S?X(=?OX?4$L#!!0
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M_IG,BMW@%<M>UZ^S7&'/L8@#9!G@*7[ ,5U*1U-O[4!]/#)Y '7UOV,RFXM
M8O0@9OIL?:3:>/HJ9M:M[;7&\/BKQU\]_NKQUSV6@)Z2<R5LU7336LNK<Y_1
MB%&CJ,DY)-V(U4I7V3D@W8@]\X#1.5S=B%]-C.F<G@(K@D'0D7.&M9)L#8LE
M#J=S]M2$OP:.MG/6!YSE,H-MG?N^)ASL;S'I'()PSI35E!8X3^%40K0X.IH'
M0B9\IP0YP"]JD!OE0&&O<"/M:4)KC4QG1R>(?7^AS>9GA[WL[\*I87J.('WZ
MJKO44JYLU\-Y2E(/:"(4OS21#6H[+*I;R\4?<$[)YSAJR^Y:#(,9PU&U&= U
M[?7D(RW5^L9V,QO XG;'*MKWS!(OJ=,QZN.S7P>0_<IM0%$XN6O+"M6]PH_Y
M([6L33J[P]<-%H$4"=.U"1P](E98[W/*IIBD&:O'LLFX+D@C+^JN^9'+^SK#
M5=FG^,;4WD^CL7H^!TZX+7$FUY=K>5$134:I(/<^R\\!FM KFLADG8A"XQR;
M+U!LG1A:&[RO#'<+B>$:*Z%[P+$V>J(F'J%EWO1I<+-O\^I($%!@YAR*"OZ8
M%5&^<X GF#$#X,4YK!_.9#V\S+E4(YAA2%S76Q%.27U4N\:G72OK2W.ZS<6U
M=)>9:UQUX/,Y9X -1&$8T#IG>ANQJ@OK@)S:.^:HA8]J'K(#I=#]G7[M?6]@
M@ ODO/O;_@P+*ETJ).C^KD SX8"JO%RH%$!\'DQC^LB#=LH"7H_G2 V BC"_
MM=EO;=:6,OQ?QHOC7"?T!@L-"TF,7TSO"96GH%\S^D"$'AVO[H3]N4B>BT)'
M\AKPPNA5W._5X:OL%DX(&O<.AM\NA>N#XU_^L--2(9Q6QAR.%(HE47QXL99R
M?(J+_W\.(,Z>BIJF&V'BSJ93K-Z=W@L1UN5\+@R[C)_$GQ?)@^!'3H8D.B<)
M$I-H=V*<$BX]A*QR0WQ;PUK>N+W_K?8.39<;)EX=+ZZ00+/!>N;[V2:NX<R*
MKVT^0,_\K:]L.%UG&-8[#[27P;8SF&6^Y:PK;J]>U]Z.%A(\^6=^C,UX*N>=
M5$E!JV!B0;*%DNG:(UGEN.RJD6U$M0FE%$R:=;9=*E?FNI284@5OY@,XRE^%
M):H_D O\;I?)FM]3,X"C_-7[GH"!7."W)+0PXU,S@*/\U?N>KL5@PRA-%H[D
M.MX=A2+N8+AL!5-0;]37<M$P#3&.^#FC"PD-R_/EQ].7U2"%FR%^P.)A_HN*
MS4:#]<;W+<KC@^\HE5]B-9Z:?-FZX]@O5SX6_G,D07#A,.>.I((E?6-?\NN/
MXGY.(?BC8/Q1,+[>I./D7",7SKF*U 8,'?3)%-UG5)Q3A4Y9WJ_9JG!HG#,/
MMH33&&P<:)U7713=N5E4@Q&M&,P!=N?F3MLB,<\E.;<(-1-)7<!LH(6137%0
MYVQ$ X9H(Q3+.=/0DB2:H3[.68=VI%(W33+0HN*FV:^A6 D(0XJY41<$'HK9
M,!1-W;SP4.R%H3CZ+/AR+FIQ0*2U).3:)H=V:^&<L]&ML;<CLCJE./9W!B0T
MQ<&G("9"82.CHP%5/2U6^^M)\'7]AUS7_UHUY2]_'*=D=AF'I2=>J1NT\.++
MC1)NK<-$:.!Q_#JQ#V[?/,O*6;J3817_VGXI\8\_3B0 @]D2L71UA1:XY'-5
M->N<QAN\S)AP.S@>S1C.)_X^/:43H%;?P^"FUR,12_2YHJ *T,/71QQ8?41;
MCBE8=RS[G(=2_Z%GI')QH(WL\.!*76"+I3/A3[U/0ZL]*:<J>EI74A<.MO)U
M61W692DY.K2Z+'NK.62=IL:A44]XR>?@'G&2GRJP9)B+W_.JCOQ*=9XM%HBM
MY#-.9@F9DA")?JA(=I-D%BQI3,(=-!H(M;3[4MLH31?4>X#G#0(\=SDVBZ.]
MHW7NA,Z6GW-NV,ONV1)"0A&),WEQW18E/GN2Z18<R5R?K*W+TG71V*M+J%;E
M V@.(+?P1@<DJ(113+L= B\>#6IV08E8(ND*%PGU\5+."^U]"I7M[6)#VP5U
M]+R>7J^74Q5 7:^SQ^@.X-J"WQ%CXG-K-;RTC4<2/9+8PNF_-OP36M</&!P>
M:=WK<PYW ']@"K)O3D%BCLX9%^#1CC0#Z-LY5UEHPFNM>-F#WQ[\]N!W0_"[
M2=C5$Q+^8W&L;OX?O*UYS6'=Q7,!9,!?;=D @MZUQ[>-;S<DU$/9APQEUZH4
M^XZ>R");E$;BRN?=4R4FCY:JLN?=5]7)30F*XL57S^Q0HY10R5-W*.H5*SY&
MR9\3X0B=XB7EJG0.K+'U\X='R?Z^#TT2IKI#W^=4YULO7^]?J *,&XQDEV.Z
M6(@(@L@;ST0H<4738HL3CGXGZ;S\\U3> -]L0)^5,>)@O2T'Q1>)H"*3CIAF
MPE6TMGN^+TWPJI@2YUD2Z?5*W]@JW:]VO.VI<XU9T\:0;UD&O:[6/@/7#9T3
MAA(^Q4RNG+>8/1"Y^7 \+3%A?"+HXN6/M!4#7;S"RTC]BE[GZ=WM1&[BSMAJ
MZWUI+5)U!Y_K];G>AKM&7D?EM"(\=HD#J%]);=A<%P4#B'!I%W[@8#/T4$C
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M'N,I97B"GA3Q7ZMC#T(J,F_2E51*QW9)*@O*4DFH/-0VO_B[G@"4P_3*ZY;
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M%(.>OC[&U\<H =->\Q6@0A"(':6U3-9@BR; 2XLS^2>SKT,;V#FGLA==Z/!
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M_)QC^VQGYME+74U!)"3QAB(T).5$^^D/#9 4)?$% /%"IZ8FMB4 _4.CT6@
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MNN+T3*%CKNR$9G'J,A<Z>/E\-J,?^36GSWVH.@)?6U!YI+8U!D?RG>T]->3
MY+93=W '^LW<I62-H[ (Y<K.R1J2-($?\FV^)*EX@:?)>4:IHHX'C10!VX)>
M@.#OFP&*"0H+'")&"I H/:7DKJ-Z?C5G.$VWW+MW13>\3Q"+ BXVL^(N-EL2
MDJ.0&7/P#9N9611R/U>VRG)>,9V PR=>%EXB#^#A9-8"SM%:.,@B\*&EJRA
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M$"*.SC(>!%3__HQF^0W-_TER>/9YD71X_UBGISDEK.%R==9NK0,Z!^\CXN;
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M:ZY3LF0X&"#0CBMR0_+;^2/^UI/Z3J&F?DAG'P4'KI$[" CBU?UDPU-A-AW
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M?:539J@J\]R='_-T,/UI<UK+Z9X*'[;GZA[EB+#.[8D!]&N21C1\R'&:JTV
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MK\:5]E6EL:Z.!\P'GK 0MEO41@MA]_\K,UC'4S'TA%9R<7D_%BA=E/9;NZ4
M=W.B7-&%T#LO>^->E_13K7*'QST6V7,%<VI)]]0;Z&A!4A=0,BG5;Z@/_=VM
MF#6_:$$#_?JB!0+6^Z(*#?6AOP4^EUX_"QKHUQ?5=V#K-]3O78A=[08#JS49
M, JY*T)AT6)6(K]2W:Z6/:X@(801NZ1D(>):XL;#\?1U.F)N=_ ?('^8_5+6
MTT:-==;O!Y#Y##<@$1]C-9[J?-RZ[=C?L';*;>I(A$FX$9U9EB5=*BX<G'0C
M^7 W?6T\==E4K5+%A2U> T_EKOHZ1Y+S[P^IK<R-](?4]B ]M(\)"DV-<7-H
M=9 RU ",TM,CZ^8!#66<56J7^5BE.?U[AO2)V-9 HX =ILY(#6E7E-46JFW0
MY<>5-%XWB&1@V'=YF',-&"I!K!6=<F6TMPVF?@C7W!CNX*C,9G#6I[6/:V](
MTS"'8Q-B SCVMZ[7HK==F0=;PK 9B^S45-@.HO5CM\>U&ZQI+-\5(J<!#B7C
MN&X S-S,V)_!K EK_=2:8Y@9-<'L-OG6G,'9V>[W'GR6VIOBM=>PCK9D]0'C
MNOO>G-CXW&[:N6..5&O@[ %>,UNVB_V#F"0P^!3$B ^62.NBB[*:5O<$5@OA
M=_^UL_OOK1J(7_X\3=#L.@X+3RHO+]#"BZ\WGWLW'"?\6Y_&;]/;E,NW(-8M
M5T8V(>MI \3;V;DLBTBS5O-$(D:3O20B_J^=,O%__'DF:%Q(^:29K&[! A9H
ME*R8<1GOX3*EW%)E<#2C, /J4)["L5FKKM74K0+EE&2?*=08;@\ZRA8>;-+B
M,2?\Z4ZDG>?\]?:X'XT!.73Z\*@S(J7K.&FT9 X='GFVI)HA-/10F8J:R$S]
MH6-@,WEX*#E+1Y\\K&)Z$VWWLS,&Z'/P!!C*SE+:?V4 <!2P=+$ ="6>,33#
M:(I"P.N!/.M'G"JV)#$*]R+;BN11NR^USSN9D-]35D8IJSY1-"4B/F8,--P+
M9F2!YD>,DN)+ 35KV3WVBW_$",5I@I[WN/"+%Q%SA)$(M8OTZC19I_]NSJZ_
M@S1/P%X5-U!Q]YV%-_8 P5*:2[?:</FAX?>@(X;K@J^09 7S_)7Q4HR#RLM&
MI>7M\EV[U72T74SOUFMI612@7F7/.SIPE^0?@%+^N2LUO+",9T<].^K9T>-D
M1VT:DZ2NT>8*R')2R9I-[PI5:5EO*]9/5YA/RX@JVMRN; &SA&XMIL25.<&'
M+WSX0C=\T<1O[BR6\7-^'43V!]S+ 1>T_&*;F1NP-QOR%,,6M=NW'Z%H**H/
M1AQ-,*)6+N8->$&+=%'(K90^-R\5PM52%3TWG[<J]E:5)-2^>69'FE*$"IY:
MY>Q. ?YK@KC7"Y>$E86]U I;OS9BA \W'U4$J^05NKY@)-O-_G8WBXQH;]"2
MW1Z3Q0)2,8W>@26D?&[-]T/"Z ^4S(L_3Z4V-F]PN/&LX?>@HXC<=BV_PER.
M5"SF%9.&I+3=2R4(AJM\6%^F.*H>&]6%K<K]9NOHP9"L,?+;:-)''!V(.$XH
MP(Q[_F+%>X#T&8DMI.-IP;!E$RX7*WY4F=UAXA56,7I\F(C3!U*ZVED"E:-+
M7L'':WV\]A .'Z_=YWC=C=<6.]%$XLT.O=>J!B&QL7"X J:"2TY,&'VNX">/
ML:B2'JX$WO0T2H7.<B4>IX>,BOOHBL[(1Y$2"^ *'!HK7%L$G"MC3 ,Z51_+
M%6BJ-_>6!&6&/J0J3>6*T-C0/WIUO\L#E:ZD6-E(_QG*J;H^_4<O_:=Q-*^S
M7* OP10@&G"A4RCVXDXWJV& =N[L1E;%_!^M-NWG_-00S^?Y''F>SS'E.+SV
M#W2"^5UFEO@\!9^GT'V> E]8_B'6E=/5]J]_1Y#RY7V^NH;/,*Y*6]"JW%6_
M;C('.)MG+RG\9PIQ6+1@U*C938]V2B3-V5*JTTTOKO R35BF)">5TYI"C<Y[
M\$F[!Y_ZT(,B_:Y,4M"HV7F/V-LI2;MOTC:Z[^6]<-0HPC,U%52HZO/D?)Z<
MSY/S>7(^3\X(1CY/SN?)^3RY5I7FF//D?,:8"3#UB W2BA?A"G@^W:XUY9,2
M4!+-J_3-7<'+IR?Z)+P6D_!J<-JNH-/"LB<C:8>><U1+D=3B" YJ4=/UJYJB
M=$67VAUVA9$%5Z#26]D4@OWNYP+Z['*?73Z4[/+!9INVEW [E.NI?<*M7L*M
M1BI&9ZFUOXC+;#A<40!?EA SF!\K1Y(YI($PQ$3)&($G%-<Y9:]N\_83;IM)
MZG-O?>ZM:C1P??8FNP,K,:&.<K6[WJD6-S[&0NWV?MK-(&>Y*LK2P,R\9+BY
MEL/O@;])V=^D[&/J/J;N8^I#]_=Z3J1X?Z^FOV?2YNK,0?PU8.)BA3F)^1=C
MV?GCR2ISC7C5!<'YX^!'?GF(KG]8LW7[[F$C0;UW>#3>88F(DSF\ 2O^^\>K
M[.(20M>W[5R\""*:%9_B7:=JJ\*.IWQN1GBV?F/%S;6J=5H0[Y$/)?J#(FXS
M;MYQA<\(QC 4PUY0^%R:2_A$4T"%2"=GV1#-;^%92U=U!V_KS;?0Z:THC/$U
MY5"@#/J3;W?I4XQ">1<;-V:\0QSA<QAF[Q2R-.V24G,V.G5+GMOLE+PY?WN$
MOSUBD+='G,6 L?%T/03&]![-YE7[Q*3ENY>^<I.+0HWA<I?#[X%G7YW:M?:P
MY\Q=9+Z<< <*OG]I%S3K>V[9<\N>6SY.;OFXSS67&V:DAA7D"CH*.UG4#%M7
MH@]*ZM(FB^$*</X<W,,^^W-PG>MWV[.$!H?FRK:!%J%3Y51=2097ATXO'.)*
MIG@=?#2"6LHP_>(*3,9B4:ZL S;2=7H^G_MTG9KI.C4YO,XR<;[F.29/@(,H
MLD[$+H7LI1OY%'-NI.W8SZY1%,GGT1C-H\D'P14.^7=!S_ N!IA;=E_*X]-*
M%1Q+\*D5:CU'E*_8I/B<\O("QN6:H"2&X^D5CM SBE)0=/*SM)Q]*87=<P_C
M;(9@<[2<D(I!W* %N]N"?@ :B<.W*H+<A64Z"JJ.IV=[$W4&)HS."$O8 Y_U
MX:F8R^_ *C]33!).:ZG5X8:7A]^#C@+D%]Q((2L(<X]G*92F\F1-:7FKTG^'
M&%(^F^)H%"T01@)*L9)>Y%M0*WNB5==JK[A!0!9PYW6(MPI'HGQ>4ZC1AQY4
M)O HU;':"V&/W8)%U8)25*03&2NA+2YD^PAM* [GX</M7!RY0Y;B(ZN,4XV:
M'1T*GLV%CQ@E[/[A4?'4[XHZ=A-YME;!OMTP$ES9+#?V3U=O+(?,C-K94CA2
MTD*3K_))97Y+KT^[\FE7/NVJ?:U0,2Y)+3O.%82*:05B<^ES!<I"@YJHF;)#
MQT#.%)(6Z+BAHZ0>MRMWSH:>MB4;+;K1!5?PD.N$,E/B"B2:J[>VM^U*)H0F
M3C780U>0D@^RBC"+*\-*:O(I$N6N*(44#PWJR_W,(L68\- 'B[)!6Q6^=R7Y
MU9^$[%/MZJ;:M1K?[RP![UMVUA-*,N'69S]QC<<SB$,$6; 14S$/3[4Y^^EX
M>I+YK+RC.=VJ^;D8.[T25RSL:Y7ZYOMZC0PWM6;X/?"G9_A IP]T^D"G#W0.
MW4/KJ:?N/;2&'EH3FZH+AXRA&493% +^=Y"?N\P%#I8D1IF+LOF+ND^FVZ)5
MMZR><-XS,^J9[7V>VA]JWV=KH[TN;K+A MVMQ9"X"/(*5N4_!0RQ\?1 JE7^
MI\P+U:MLU\LNO,%0K5M:=2US!UDJ ,V90\3^.N,K+TK$WTJ) FD-NYM5 ,5<
M4=@=I!G;J?9%%&M9[<GV:KOQM.#RR+6ZE/1'JZ[57F5+149&JWT9:7FKTN?W
MN0N[=W<U9^6'D%>P*O\M_+$WF5*"^5]#N*<3:A^E;C-VM[V\ED&R;$I*#T_R
MCOC RN2@RJ&B4;,'VU_R= TNZZODN>K)H$%+GM-UX$3D1\;7XPN6H 47I0S3
MXD*.<<^MN&&>E2YCI167A*'S<)Z1]HRT9Z1?)?M+K-BW-^E)>2)7H%'H+VG&
M/+DRG/20JK)7G,E<UD*D!OGB2CJS'E#*W*$K^;V:\.C3Q*YD >L!I4JR*:/3
M\\-M]=#1YE648?K5)9@4B69E<+ZZ!$YCYDH9MF\NP:855E(W'YVRM)O%$CK;
MJ/ Y>!(N0D"FP?XKLTQ^EBX6@*[$,QFIE:U:NC=Z&WFW_2T0!KOALW*L9^68
M^Z2R_!W3RF0KBA'.892*C9 C+E2$XE2LJ#N+]N(EC%.NTY=\LA6K<)KWD#O?
M!ZN,]&)%8R_R42H'HE39FV4Z5%RH[W*JQ<2'Q6]V,2WZR%M9Y*U:WX;.I?N
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M]F4;Y]T%(@LG5>7RGEUU@%U=;P6HU(3",HXQI7U;/3T5ZSX5:W/5)'57)U=
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M/%>@+'0/B9IC-G0,Y&PL:8'R'#I*ZK'T<JK!E4AQV6C1#5&Y@H=<)RJX:%=
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M_SA!UL"]D>X%XRL80??9\G>_!M;#=]NXY,,>!SX>.I9XR!VP5!Z-5/*)H[O
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MG5V2&DCY@G?0#O?A!YC<OT6W.!^C\@-\.K(.W1Z3L/>8V#H]/L"!R3FD%8B
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M?>/QD6Z9J2I')A^Y/O882,);C8SQNQ;N_6J?Z/)O6M1%N37:77B$^23>>JV
M,/M]YT@"X4SBX%2B )2S:\2 < PN0^D'^P=:N[EQ,M\@H!1TBX)N^[72:;W0
MK9.4VK@%L:%CA&J:%3+#[=[%M-5M"*;FVJC[16J"5S/3#=&8FB"G;3@#%A]=
M/K'O+VO("()>1?D\!+)N:8>;=SEM$$T*MVO"[<&R)M3*N&TTM/UF6ZNU&Z7$
M;>DLJ2^]X^^6*),0M9:Y2_5NB_JR,70]!F-U>%N"![[[Q2N=7A>=?-L)):GC
M;_6D-W#\_3]_AF[P>6*0XL,Y^I00BL)[A@G2(6;SC?0QND:52_KU+NG6TD?2
MT>K?B,5?0;'J'-2U5KN];5>T@LTK8+/TF7-QL*EK]<:!=G"X<75\N\Z@0O@F
M9?9E^AIGSQI2ZH;RUI;26]M:^B1:N&4%!E(&VFJ4V&YIK8.-LW!US%!!X"Y]
M"+X.X#8..UJ[W2HE<$OGT=G&(4-&$JG I:45ME>?2T=4EZ*TY0*5ZHVVUFG6
MMZVE*;2\ BVO/@HN#"VM^H'6;*JXT2E'H#L<6H&L_07Z^HF+A88?N&.@<_T#
ME:GI?"RS>VEER9.+U+SSH,5"ZI,%Q1CH]'*FD?OL6T>.9?^V@]50@%PF<3E+
M(+V%5=_$_AV^R?W+81^;4='FG+#EGALH2;A.=4%I)>59I K*_(W&(B,_!:[L
M(P/1V'_G<NOVPJ<%-]R[&^@>S^/:KD-<ZD;WKKT[K-)H4J)1\I57ZHT75^<S
M]-CVPF[JC8^WME>KY=E$$Q^PD>ZQ1WS=$<N?XF)^P)<F1]?];A@,7 ] 9!:Y
M"8LY?#8SPKI6J]6BOPLLOT]OQ;XC\K6SMF$Q^WJQ25Z' 55%!H6FR'W(,^J6
M'>*%[X?+[D%#J[5@_1MY[N+)]4=3)W\V>0&,RZ)J30N^6*S:1A:\B6[.@\4!
M;]'K9%?6>'&PVG.V/@_=,57<14M5N[3'RF^WO">FO9)])!&T=!XO4>JV73$*
M+J^ 2V?I7/"W I?W>FHBS_9-T94)^[KJEKEK.<P07<84%UZ>K/:7CY**]^,&
MMN/"D2W?ECJLW&]KG?U#^*O.4JJ$G>5#I8K%SF'K0&MWW@!_KK*7I6L8X3 4
M'?ADR)4[''E\P!T?RZG;KJ_.N1>#U8=\<ELZ+BJU-11I<I+>F L']HE_A]VY
MXL%U_UY_7H(,J370;SN[.\=-K8ZU33=-B;GG@PI2+T%JZ8BEC4*JK34W'X&7
MPM0[5[Q3C-WD?>RIHTIUE"40<09=+QT3=<M%][$SW7.PG6AJ\T_%WJ]$RO56
M1]L_!$U_\S)B!KR*%1P*P\5A>.E(K;5CN W6QK[6;G;*AN'W;8&(L%H_%2?R
M*Q5[#=;CIU>T7E3@_/[2)3O204$B%F@Y'X+6. "AM/E,/97F44&T+EVHHQBT
M-FI:HWZ@'=2W7V5&Y7;DIG.(KH-;DT.J(D\Q%7GVESZA3N4*=!VS("&EBDLI
M*"\-Y:5/S]<!Y6K4FYIN&CB_46#Y.T$OTDGOCG.F&WATHSM8*1_;YG)J-![W
MUZ/&W9XUI%:Z<4O ON7HCF&1!1;U)Y_;,G?]<\FLIVJI6U<==5_HJ)NO)4X1
MMB865\/FU%9_)M])=QE/3:4<=%[!IJ-W,5_!WN/7(^[I*#.BK,'T8?-W.FPN
MP03RNY*6A!^JSJ<;R2R,>V3NO]<>F?<##]2*2_CZP&=GL-%F$FQ=^G:9%0'7
MNVW JIKIOJF]5/USQ9@S_7/7[L.4VA38>U'MM*/BUK^<F?OJ2=M]TOL^K+[E
M/B<5"(T7DS]RVQVA;5.=$-F2-X\\F(AM-*7WO@Y_7A$.)7:IZYBGR1[)CC#+
MU65KU@ZU]N'&0T>JD^A0=ERU<G#52'#5V JN&EJKT=8..X?;QE7)U*@-<_5O
MW $]RB:FKIM#R['\ /6J1ZY"D$H=U''0+D!:R-T'HNYF]GXENNZT#[3]SL83
MXU1D4@5!O%^ :%H+B.L-4'I*<-RK.MY-%:/%HQ+6]]PA<^,3E>H8(>7+BCTX
M*$"2Q.Z8))5JI9CUEM;8W]<:ARJ_NDI(.BR G1>/I#96Q&^_@6SK2AD:\((+
M])IS/V 6;:6R*,JBC.4G,!UT"A $T9X+ZI4ZV)7KN!%97_'E^@,<-+7#3E[9
M+)6$IS <8_BP5H (6A>&&P?:84WEX&U=+L'VK:^ZAPH)7WUT,VB[7H!\@KTO
M3+&L=1I:\W#['6N:FY!)"L9%P;A1@(@J$L;MQKZVW]J^P[99M%RJFKUTPSU1
M]!4,)K&/L TJK$4]286UK$7_8Z.8X-P^5G]+5=WOZ;YEB%@7RPX#;BIEL5I2
M-B_JX25E<5;K@:@P2W3]*X)CJ0+@J:HL>YWM5V]0FF.E,)UWYO^2YKA)3#?V
M&ML_,GWW:N0_*;\16P; 1/4''C422'4/>(/R;6':*HUK\Y4I\8=YP1)S)5HN
MW4?HZ IP7(78+N*Z/]5]8WE^()M<'#2W[ZU_"X4?WCZP\P(0YHJU;0+[4&N6
MH!;DG#(0[\B0.YDJV*V\)>I))?>65$J=G @77^O)V1M/SIAATQ41=/$&#K4J
M41&_[&#J%!']\ :.EMYO=,-DL/0/Q^,PS?]PDSWHEL,^(/?^R  P\*6?7%13
M\;D1>E0Q387HE26\*9^^BXB F-7^(H'*[ZZ-^_4- (,\X-JYBP'2]2P?+IW"
MK\[##?<LUURA9<9QLZ$U2IIEH:!?KLB^3A%A$R7"?DI,=K3]]L;S8-<?%E@I
M0R?7FU!UG_@[.Q_K%%%!(8<[%$/E6FV_IM6;VY=VZM"W4J NHGS#^D#=/MC7
M&IWM![7GG_JJDLCK+8E<\'JIDL<-5?*XA"6/\=69L:DJR,M60;[+=!DYDUU&
M2C#F>25?&<C9.@7+)+4[59WFE^O6.Z%M[ZBBS1LYW51%F^^ T\.#3QBP']I"
M!-V-Q_O<\X@/ ><IOE:KVM8U;^N)B,NO^/:MMT+R-O:E"^P;33W=SNS*Y@=R
MHULF,':%C1)A(]6"FWSN$^TNU%Z5<J_4MI1G6ZA)XY8Y:\986S\X%C]RJH@J
M_@[;(HAP:]76HJK[UQVZX?RB[FK_RKQ_DG%+*E1-9M[";D8TJ79SU> G="?H
M(RO6K-0*+K&"2:]"M7Q++-\I[UN&%3"UA$LO8?K8:",+6+)@N.B@M7&XD5Y;
M7W5;=PS.](#]K^Z$NC=FXDRLL4R W/_\&;K!YXF1B0^+2>,H^@7["P0&O>J=
M"Q=4[ASD=$&OBR[H?\3GJH(:T,'F.GC,VGVV_-WXW(-L^$N.R; O9=!.I<K.
MB@WZ#_=<4_<'Z;"@W28M9:-6;WU>*1IHY:6L2@'OUV83+8+#I5Z:C[W#=6$O
M)SXM[6@2C[QP##M$#-ZX'@ZJ&P2>U0OI)/G>O7(=')OGVC95"A?U6K<"UZ56
MO"H0+8@[%HC*SM*H%.>(ZV"'BQ0-J!]NO-I3=6!6;DY8K]76 KJ-\\'Y+6\
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M8D]@YNSBAJ AKX)RHDUK94(W]L/>OP%ND2CU8=W]OE2D@"J?=.&,$?N<N!2
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M"<D235]$8)@43_\8&ZO1<V,3M\>E]H]+*U\V!BN6R7/64W@<!@/&+Q+'7,N
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M(U'XX.6Z^"-NH"(%D$:MM1^5S!.E;LKD8NM4CR%,D+OG@@KM<%"6@90LF1W
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M0W/G^)QJ(HI:4AG:(#8P"37"*-;]3LXO1.X*WA6U2? M;-/4QX,V<>(4=TC
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M3@ZV<ZCV"1?J>Z ( 1*+,R>ONJGW1(8L44!D)]!M8EL6%^@N.-48$> K<3]
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MCDB^EQ<^;RDD>>3A4-!>&:8Q8S5BGTK#U$&?AC30]6<=Q*XXC9B%ZO 13G-
MGDDW+">![HZI+9?=SV%C:%#?B>R+.-/I'<&"]"0>:4L&=#D)WR03%VECWBP%
MMQK_K%03:Q.^]Y2]:IZRE\&4O6TKE!C GZ-CVG'_N)0[PDV <BBL**1L=70-
M]GI\+)0%E5D)A#N%AP-3C#!AQ.6B7"R==N,5NVBAG;N&  FE!5/_/4_.1,]*
M_D:8=]1&#[\S>8>)''57W"AT>D,QM["T\PM6DA$)Y%K0V\, :P,],)JT]#$
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M?=%#'5U#(/LQY.J&B2:  W%L+#M$Z2/ 8S-;GM/U^Z5K@9THKQ1AL2:R%=T
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M3^ LTBULG)TB+M?4Q!=;HB%+-_2QX0$'/'#7]IT>5CG=?865-#;"N/BG[?Q
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M1'A@O&-I%07AR59N-J1Q0V] 5Y&#E>=TUT94.E'N,R!X,04,HX$21+H%\QQ
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M5_F%A<Z@5*&!(;R\KM\=@6&</#5,9<"*]@Y%&&4M4TY%44>8C/5?_+OP4N#
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MU&5<O! "VJLR,3RL7* !7$&/Z4E^>@)N$PC#SXX>5W"O05F$=K7^8W:K3]3
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M.0[S>%?'39K!O#K]68;L%^\.Z8H*/D"&WZP+U[*WLMF<,&I5A?5+M[7&N5A
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MK1\&*#[PR-N8WN9N(-!B1HWD2MZJ9W(<]?Z*'['_QAN@T%5;+BB;U>1R'PD
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M7GG@@EETU.L6_/M<O3;Z&U!+ P04    " #*0J]6O+KN*:D$  #>$P  #0
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M:>)^*L:7U>CC"Z3J29&]_G0^' Q[WGPX'L%X )/I<-0;3KQ+& Q''M[BW7B
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M(XM"2\F[IT*SX\+D8G1]=1\-+<SWKX]<,(NZ^1[6[=3S[WI_ E!+ 0(4 Q0
M   ( ,I"KU:+(K<:[ L  /.(   1              "  0    !D9F9N+3(P
M,C,P,S,Q+GAS9%!+ 0(4 Q0    ( ,I"KU8\W,;#(0<  !Y,   5
M      "  1L,  !D9F9N+3(P,C,P,S,Q7V-A;"YX;6Q02P$"% ,4    " #*
M0J]6+BMR%$8J  "BJ , %0              @ %O$P  9&9F;BTR,#(S,#,S
M,5]D968N>&UL4$L! A0#%     @ RD*O5KLV> $T.   UQH# !4
M     ( !Z#T  &1F9FXM,C R,S S,S%?;&%B+GAM;%!+ 0(4 Q0    ( ,I"
MKU8^D5%[[2P  &'Z P 5              "  4]V  !D9F9N+3(P,C,P,S,Q
M7W!R92YX;6Q02P$"% ,4    " #*0J]6/,DUZF?"  #34@D %
M    @ %OHP  9&9F;C(P,C,P,S,Q7S$P<2YH=&U02P$"% ,4    " #*0J]6
M$[P.=MT-  ".#@  &@              @ $(9@$ 9&9F;C(P,C,P,S,Q7S$P
M<6EM9S P,2YJ<&=02P$"% ,4    " #*0J]6??I]X,<'  #T(@  #0
M        @ $== $ 97A?-3$X,# U+FAT;5!+ 0(4 Q0    ( ,I"KU:/Q5N
MI@<  '8B   -              "  0]\ 0!E>%\U,3@P,#8N:'1M4$L! A0#
M%     @ RD*O5DO5D^N*!   /1(   T              ( !X(,! &5X7S4Q
M.# P-RYH=&U02P$"% ,4    " #*0J]6O+KN*:D$  #>$P  #0
L    @ &5B $ 97A?-3$X,# X+FAT;5!+!08     "P + ,$"  !IC0$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
